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Abstract 
 
 The mammalian neocortex contains diverse neuronal and glial cell types. Among them 
lies an important subclass, the subcerebral projection neurons (SCPN) that project to distant 
targets like the spinal cord. Aiming at identifiying molecular controls over the postnatal 
development of SCPN, I focus my investigations on the role of Ppargc1α because its function 
remains relatively unknown in the brain while it is important for metabolism and survival in 
other tissue systems.  
 Ppargc1α function in neuronal survival has been studied within the context of acute 
cellular stress but its developmental function remains unexplored. Work presented in this 
dissertation began by studying whether Ppargc1α is required for neuronal survival, either in the 
native cellular state without acute stress, or in the context of aging. Focusing on the neocortex, I 
found that absence of Ppargc1α does not cause cortical abnormalities or enhanced cell death. 
Moreover, I found lesions in the internal capsule (IC) within the axonal path of SCPN and 
myelin-positive vacuoles in the Ppargc1α null neocortex. Analysis of newly generated 
conditional null mutants for Ppargc1α in the dorsal telencephalon revealed that conditional loss 
of Ppargc1α generates myelin-positive neocortical vacuoles but not IC-localized lesions. Thus, 
Ppargc1α is required for myelin-positive neocortical vacuoles but not for neuronal survival and 
IC-localized lesion formation. 
  iv
 Considering the role of Ppargc1α in metabolism, I discovered that neuron-specific 
Ppargc1α is required for proper neocortical myelination. I found that Ppargc1α is restricted to 
neurons and is excluded from oligodendrocytes in the neocortex. Interestingly, the absence of 
Ppargc1α in neurons or in the dorsal forebrain caused hypomyelination across all cortical layers. 
Aging studies of mutants at 18 months further revealed that these hypomyelination defects are 
not due to a delay in myelination because they persist with age. Overexpression of Ppargc1α did 
not result in ectopic myelination. Therefore, neuron-specific Ppargc1α is required but not 
sufficient for neocortical myelination. Moreover, loss of Ppargc1α leads to decreased neuronal 
metabolism, suggesting that secreted metabolites can act as mediators for neuron-specific 
Ppargc1α to interact with oligodendrocytes to control myelination. Together, these data support 
a novel function for Ppargc1α in myelination and implicate it in neuron-to-glia communications.  
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Chapter 1: 
Introduction 
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1.1. Overview. 
 The mammalian neocortex is a complex yet highly organized brain structure involved in 
higher-order functions like cognition, motor behavior and sensory perception (1-3). Comprising 
six radially organized layers, it contains a diversity of neuronal and glial cell types (1). Cortical 
neurons can be broadly categorized into two classes, namely inhibitory GABAergic interneurons 
(IN) that make local connections and the excitatory glutamatergic projection neurons (PN) that 
connect to distant intracortical, subcortical and subcerebral targets (1, 4). Cortical PN are 
classified into different subtypes based on their birthdates, laminar positions, axonal targets as 
well as molecular identities (1). Among the cortical PN, subcerebral projection neurons (SCPN) 
connect layer Vb to targets in the pons, superior colliculus and the spinal cord (1). SCPN in layer 
V, together with PN projecting to subcortical targets such as corticothalamic PN (CThPN) in 
layer VI, are collectively referred to as corticofugal PN (CfuPN) (1). 
 The molecular signals that govern SCPN development are not fully elucidated, with 
regard to their fate specification during early embryonic development as well as their maturation 
and maintenance of cell identity at later stages of differentiation during postnatal ages through to 
adulthood. To address this, a series of neuronal subtype-specific genes that mark SCPN in vivo 
has been identified (5). Notably, it was discovered that the transcription factor Forebrain 
Embryonic Zinc Finger 2 (Fezf2) is necessary for the birth and early differentiation of all SCPN 
(6-9). It is also sufficient to “fate-switch” cortical progenitors fated to form upper layer callosal 
PN (CPN) to generate deep layer CfuPN, including CSMN (6-9). Moreover, our laboratory has 
recently demonstrated in two distinct studies that Fezf2 is sufficient not only to direct the 
differentiation of non-cortical striatal progenitors to CfuPN in vivo (10), but also to instruct 
upper layer CPN to postmitotically lineage reprogram into deep layer CfuPN and change their 
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axonal connectivity from interhemispheric, intracortical projections to corticofugal projections 
directed below the cortex (11). Given the central role played by Fezf2 in SCPN-specification and 
differentiation, our laboratory has investigated the molecular mechanisms mediating Fezf2 
function and has identified a second array of SCPN-specific genes that are acutely triggered or 
repressed by Fezf2 (Lodato et al., unpublished).  
 Here, I follow the hypothesis that mining the previously described dataset of SCPN-
specific genes (5) and the newly defined database of Fezf2 target genes (Lodato et al., 
unpublished) will allow me to select molecules that are expressed exclusively in SCPN and are 
downstream targets mediating Fezf2 action. Identifying and studying these molecular signals is 
critical to enriching our current understanding of SCPN/CSMN development, particularly for 
survival during later stages of differentiation from postnatal ages to adulthood where much 
remains unknown. Building on this prior work, I chose to broadly investigate the functional role 
of transcriptional co-activator Peroxisome Proliferative-Activated Receptor Gamma, Co-
activator 1 Alpha (Ppargc1α) in the postnatal differentiation of SCPN and to specifically answer 
the following questions:  
(1) Is Ppargc1α cell-intrinsically important in SCPN to act as a novel regulator that control 
subtype-selective survival during postnatal development? Initial studies in the context of 
neurodegenerative diseases and acute cellular stress have implicated Ppargc1α in neuronal 
survival. Yet, it is unclear if the developmental function of Ppargc1α in the nervous system, 
particularly in SCPN, maintains cell survival in the absence of acute cellular stress or in 
conjunction with chronic stress caused by aging. In Chapter 2, I studied whether Ppargc1α is 
cell-autonomously necessary in SCPN to govern their survival in vivo.  
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In addition, is Ppargc1α cell-intrinsically critical in SCPN to prevent the formation of 
spongiform-like lesions in the striatum? Previous studies have shown that the global loss of 
Ppargc1α leads to spongiform-like lesions in the white matter of the striatum. Since 
SCPN/CSMN project through the internal capsule of the striatum, in chapter 2, I elucidated if 
Ppargc1α is cell-autonomously required in SCPN to govern the development of these lesions. 
Knowing the cellular origins of these spongiform-like lesions will allow us to better understand 
the disease mechanisms behind their formation.  
(2) Is Ppargc1α cell-intrinsically crucial in SCPN to establish a proper neocortical myelination 
pattern? In Chapter 3, I investigated whether Ppargc1α is cell-autonomously necessary in SCPN 
to establish a correct myelination pattern in the neocortex and whether it is sufficient to induce 
ectopic myelination. This study is significant because it purports a novel function for Ppargc1α 
in SCPN by implicating it in neocortical myelination and broadly in neuron-to-glia interactions. 
It is especially interesting because it questions whether and how a transcriptional co-activator 
restricted to neurons can regulate a process like myelination that is exclusively executed by 
another cell type – the oligodendrocytes. 
 Besides the role of Ppargc1α in the postnatal differentiation of SCPN, I have also 
dedicated a component of my thesis to test the extent to which cell-intrinsic developmental 
signals that direct SCPN-specification and development in the embryo can be utilized to 
selectively generate deep layer CfuPN, including SCPN/CSMN, from pluripotent mouse 
embryonic stem cells (mESC) and mouse induced pluripotent stem cells (miPSC) in vitro. Since 
the main focus of my dissertation is the role of Ppargc1α in the postnatal differentiation of 
SCPN, I have included this work in the Appendix (Chapter 6). There, I elucidated if Fezf2 
overexpression in mESC-derived dorsal telencephalic progenitors (DTP) and cortical-like 
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neurons (CLN) can preferentially instruct them to differentiate into CfuPN, including SCPN, in 
vitro. If successful, it will be the first study in vitro demonstrating that a single transcription 
factor Fezf2 can direct mESC-derived cells to resemble CfuPN or even SCPN, in terms of their 
molecular identities as well as axonal connectivity. Achieving this is important for future 
applications like chemical screens as well as disease modeling, among others.  
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1.2. Molecular development of SCPN in the mammalian neocortex. 
 1.2.1. Neocortical progenitors generate the six-layer mammalian neocortex in an 
“inside-out” manner. 
 The mammalian telencephalon, originates from the evagination of the two cerebral 
hemispheres at the anterior aspect of the neural tube that encompasses the lateral ventricles (1, 2, 
12). The mammalian cerebral cortex is formed from the dorsal side of the rostral telencephalon 
during early stages of embryonic development (1, 2, 12). Being the major part of the cerebral 
cortex, the mammalian neocortex is a six-layered structure that first comprises the ventricular 
zone (VZ), a thin proliferative neuroepithelium that lies immediately adjacent to the dorsal wall 
of the lateral ventricles (1, 2, 12). As neurogenesis progresses, the subventricular zone (SVZ), 
another propagating layer, forms above or superficial to the VZ (1, 2, 12). Neocortical 
progenitors located in the VZ and SVZ produce diverse postmitotic PN populations, which 
migrate radially to occupy different neocortical layers, in a temporal order that is tightly 
governed from embryonic day (E) 11.5 to E17.5 in the mouse (1, 13-15). The earliest born 
postmitotic neurons are generated around E10.5 in the mouse and they migrate to form a layer 
above the VZ, known as the preplate (PP) at E11.5 (1). A day later at E12.5, the PP is split into 
the more superficial marginal zone (MZ) and the more deeply located subplate (SP) by the 
expanding cortical plate (CP) from which the multilayered neocortex arises (1). The CP consists 
of postmitotic neurons from VZ and SVZ that migrate in such a manner that later born neurons 
arriving at the CP migrate past earlier born neurons to occupy a more superficial position, thus 
gradually establishing the six-layer formation of the mature cortex in an “inside-out” fashion (1, 
13, 15). The distinct classes of PN are born in sequential and overlapping temporal waves where 
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the peak birth of deep layer V SCPN and upper layers II/III CPN occurs at E13.5 and E15.5 
respectively (1, 16).  
 
 1.2.2. The mammalian neocortex is populated by distinct subtypes of PN, including 
CSMN and other SCPN.  
 The excitatory glutamatergic PN of the neocortex connect to diverse ipsilateral or 
contralateral cortical, subcortical or subcerebral targets (1, 17-21). Among these, CPN project 
their axons to targets within the cortex while CfuPN project their axons to targets away from the 
cortex (1, 17-21). CPN belong to a larger class of commissural PN that extend their axonal 
projections within the cortex to the opposite hemisphere via either the corpus callosum or 
anterior commissure (1, 17-21). CfuPN can be further divided into subcortical PN that connect to 
targets below the cortex like CThPN that project to the thalamus (Th), and SCPN that connect to 
targets below the brain (1, 17-21). SCPN include various subpopulations classified based on their 
final projection targets. Among others, these include the corticopontine PN which project to the 
pons, the corticotectal PN (CTPN) which project to the superior colliculus, and the CSMN which 
project to the spinal cord (SC) (1, 17-21). Diverse PN subtypes are born at different times from 
neural progenitors of the dorsal telencephalon and occupy distinct laminar positions in the 
neocortex. CfuPN are located in the deep cortical layers V/VI while CPN mainly reside in the 
superficial layers II/III, with smaller numbers in layer Va and VI (2, 13-15, 22-24). 
 
 1.2.3. The molecular pathways that control CSMN and other SCPN development 
are beginning to be understood. 
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 As opposed to molecular signals that broadly control neuronal development in the cortex 
(25-32), the mechanisms that govern the development of individual classes of PN are only 
beginning to be elucidated for some populations (1, 5-9, 33-35). My P.I., Professor Paola Arlotta, 
together with Dr. Bradley J. Molyneaux, identified neuronal subtype-specific genes that label 
with different degrees of specificity SCPN/CSMN (5) during her postdoctoral work in Professor 
Jeffrey Macklis’s laboratory. Among these genes, selected ones regulate specific aspects of 
CSMN development in vivo (5). In the Arlotta and Molyneaux’s study, they compared the gene 
expression profile by microarray of purified CSMN to that of two other cortical PN populations, 
the CPN and the CTPN (5). Purification of these distinct PN populations enabled them not only 
to overcome the cellular heterogeneity that often confounds gene expression profiling within the 
central nervous system (CNS), but also to determine differential gene expression between the 
diverse populations without contamination by other cell types. Through this study, they 
identified genes that are expressed with various degrees of specificity in CSMN at early (e.g., 
Ctip2 and Clim1), intermediate (e.g., Crim1 and Mu-crystallin), late (e.g., Encephalopsin and 
Cadherin 22), or through all stages (e.g., Fezf2 and Cadherin 13) of development (5). They also 
distinguished markers that were exclusively expressed in CSMN but not in CTPN (e.g., Diap3 
and S100a10), as well as genes that were selectively expressed in other PN subtypes but not in 
CSMN (e.g., Lmo4) (5, 36). A more recent study by Molyneaux and Arlotta et al. identified 
additional, novel genes that are preferentially expressed in CPN but not in SCPN (36).  
 
 1.2.4. Fezf2 is a critical transcription factor that is necessary and partly sufficient 
for the specification and differentiation of SCPN/CSMN. 
  The screen, described above in section 1.2.4., enabled the identification of many 
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SCPN/CSMN-specific genes that had not previously been functionally characterized in the CNS. 
To verify that the screen revealed true SCPN/CSMN genes, the functional roles of COUP-TF-
interacting protein 2 (Ctip2) (5), Forebrain Embryonic Zinc Finger 2 (Fezf2) (6) and SRY-box 5 
(Sox5) (33) in CSMN development were characterized.  
 Most importantly, Fezf2, which encodes a 455 amino acid transcription factor that 
contains six C2H2 zinc fingers and an engrailed homology repressor domain, was discovered to 
be necessary for the birth and early differentiation of SCPN/CSMN from cortical progenitors (6-
9). Fezf2-/- mice display a complete absence of CSMN as well as other SCPN, and lacked the 
corticospinal tract as well as all subcerebral projections (6). Absence of SCPN/CSMN is 
accompanied by the specification of additional CPN (8). Gain-of-function analysis also showed 
that Fezf2 overexpression in cortical progenitors fated to form the upper layer CPN “fate-
switched” them to become neurons that not only express CfuPN-specific genes like Ctip2, Sox5, 
Tle4 and Tbr1, but also extend axons subcortically (i.e., to the thalamus) and subcerebrally (i.e., 
to the cerebral peduncle) (6, 37) (refer to the Appendix/Chapter 6 for more details). Together, 
these loss and gain-of-function experiments indicate that Fezf2 plays a central role in controlling 
various aspects of SCPN/CSMN-specification and differentiation. Understanding how Fezf2 
mediates its function via downstream effectors is crucial for enhancing our knowledge of SCPN 
development and differentiation.  
 
 1.2.5. Fezf2 controls the expression of a cascade of genes that mark SCPN/CSMN 
during embryonic and postnatal stages of development.  
 Although the first screen by Arlotta and Molyneaux et al. provided important information 
on the combinatorial code of genes that define the CSMN subtype during development, CSMN 
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could not be purified based on their projection target nor could it be profiled earlier than E18.5, 
when their fate specification has most likely already occurred. Since Fezf2 is critical for 
SCPN/CSMN early differentiation (i.e., Fezf2-/- mice do not have SCPN as early as E14.5, one 
day after peak SCPN birth in vivo) (6-9), and overexpression of Fezf2 is sufficient to fate-switch 
neural progenitors as well as early postmitotic CPN to acquire a deep layer CfuPN identity, it is 
likely that Fezf2 acutely regulates genes acting early during SCPN/CSMN differentiation. In 
addition, Fezf2, expressed throughout all stages of development, is potentially crucial to maintain 
SCPN/CSMN identity by initiating a cascade of gene expression that ultimately leads to 
induction of genes acting at late stages of SCPN/CSMN development. Therefore, to identify 
genes crucial for early CSMN fate specification as well as to expand the pool of genes expressed 
at late stages of CSMN development, Dr. Simona Lodato and Alyssa Meleski in our laboratory 
have recently completed a new microarray screen to identify molecular pathways that act 
downstream of Fezf2 (Lodato et al., unpublished). They overexpressed Fezf2 in E14.5 cortical 
progenitors (i.e., destined to generate upper layer CPN) via in utero ultrasound-guided 
microinjection and electroporation of a Fezf2GFP vector (Lodato et al., unpublished). This 
initiates precise molecular changes that direct SCPN/CSMN differentiation. The same procedure 
was repeated with an empty control CtlGFP vector (Lodato et al., unpublished). Fezf2+/GFP+ and 
control GFP+ cells were isolated at 24 hours and 48 hours after electroporation and purified by 
FACS for subsequent expression profiling by microarray analysis (Lodato et al., unpublished). 
Using this approach, they successfully identified a new repertoire of promising candidate genes 
that were differentially up or downregulated by Fezf2. In situ hybridization (ISH) on the 
developing neocortex for a selected set of Fezf2-triggered genes verifies their restricted 
expression in the developing SCPN/CSMN (Lodato et al., unpublished). Significantly, this 
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screen revealed not only some of the earliest SCPN/CSMN-specific markers, which may play 
critical roles during early SCPN/CSMN fate specification, but also notably SCPN/CSMN-
specific markers that may be important during later, more mature stages of differentiation 
(Lodato et al., unpublished). Particularly, I am interested in identifying molecular controls that 
govern the survival of SCPN. Understanding how distinct subtypes regulate and maintain their 
survival will shed light on disease mechanisms that leads to subtype-specific degeneration and 
inform the development of potential therapeutic strategies. Thus, I have identified Ppargc1α to 
be an ideal candidate to study neuronal survival in the neocortex because it has been shown to be 
a key regulator in energy metabolism and has been implicated in neuronal survival upon acute 
cellular stress.  
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1.3. Ppargc1α function. 
 1.3.1. Ppargc1α is a transcriptional co-activator.  
 Numerous intricate biological programs are governed at the level of genetic regulation by 
DNA-binding, sequence-specific transcription factors. While most studies investigating gene 
transcription are centered on the amount or activity of transcription factors as a key mode of 
genetic control, there is an increasing focus on transcriptional co-activators as important, if not 
primary, players of transcriptional regulation (38). 
 Transcriptional co-activators are increasingly found to be crucial determinants of genetic 
control because they are often tissue-specific, sensitive to extracellular cues, capable of binding 
to various transcription factors, and can be principal targets of signal transduction pathways as 
well as hormone signaling (39). Notably, the Peroxisome Proliferative-Activated Receptor 
Gamma, Co-activator 1 (PGC-1) family of co-activators has developed into exemplars of 
transcriptional co-activators as they emerge to be versatile multifunctional components that act 
as “molecular switches” to integrate environmental cues with internal signaling mechanisms to 
control cellular and systemic metabolism (38, 40). They are also sequence conserved in many 
chordate species such as amphibians, birds, rodents and primates (38, 40), with the drosophila 
PGC-1 homolog Spargel being recently identified (40, 41). 
 Ppargc1α or PGC-1α is the first member of the PGC-1 family to be identified (38, 42) 
and it shares more sequence identity with homolog PGC-1β than with its other family member 
PRC (38, 43-45). It functions as a critical transcriptional co-activator with powerful 
transcriptional activity when activated by associating with DNA sequences, either through 
transcription factor docking or linkage with a heterologous DNA binding domain (46, 47). It can 
also interact with distinct nuclear hormone receptors like Peroxisome Proliferative-Activated 
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Receptor Gamma (PPARγ) (38, 42, 42, 48-50) and Thyroid Hormone Receptor Beta (TRβ) (38, 
42, 51-53), as well as Nuclear Respiratory Factors like NRF-1 and NRF-2 (38, 54, 55).  
 Ppargc1α encodes for a 797 amino acid protein that contains (i) a potent activation 
domain at its N terminus which interacts with components of the histone acetyltransferase (HAT) 
complex consisting of CBP/p300 and SRC-1 (46), (ii) a repression domain that contains several 
p38 MAPK phosphorylation sites (56), (iii) LXXLL motifs present in the activation and 
repression domains which bind to the ligand binding domains of nuclear receptors (42, 57), (iv) 
RNA processing motifs which consists of a arginine/serine-rich RS domain and a RNA binding 
domain which have been shown to interact with the C-terminal domain of RNA polymerase II 
via the Thyroid Hormone Receptor-Associated Proteins (TRAP) / Vitamin D Receptor 
Interacting Protein (DRIP) / Mediator complex (42, 58). Therefore, Ppargc1α enhances 
transcriptional activity by (i) mediating chromatin remodeling via bound HAT-containing 
proteins (46), (ii) recruiting the mediator complex and RNA polymerase to facilitate transcription 
(58), and (iii) displacing repressor proteins such as histone deacetylase and small heterodimer 
partner (59, 60). In all, Ppargc1α is a key transcriptional co-activator whose function is well 
characterized in tissue with high metabolic demand like brown fat and skeletal muscle, but 
remains relatively unknown in the brain and CNS, particularly in SCPN/CSMN.  
 
 1.3.2. Ppargc1α is important for energy metabolism in several tissues. 
  1.3.2.A. Ppargc1α is crucial for adaptive thermogenesis in brown adipose 
tissue.  
 Ppargc1α was first discovered to be a molecular switch that can turn on significant 
regulators of adaptive thermogenesis in brown adipose tissue (BAT) (42, 61). BAT functions to 
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dissipate energy primarily in the form of heat, while white adipose tissue functions to store 
energy (40). Adaptive thermogenesis dispels heat by inducing fuel intake, increasing 
mitochondrial fatty acid oxidation and enhancing heat production via the expression of 
Uncoupling Protein-1 (UCP1), which dissipates the mitochondrial proton gradient and 
uncouples oxidative phosphorylation from ATP production (38, 40, 42). Upon exposure to cold, 
Ppargc1α mRNA expression in BAT is quickly and highly stimulated and “kick starts” adaptive 
thermogenesis (38, 40, 42). Loss-of-function analysis showed that Ppargc1α null mice are 
remarkably sensitive to cold exposure due to defective thermogenesis (62, 63). Gain-of-function 
analysis demonstrated that Ppargc1α is sufficient to specify brown adipocytes from white 
preadipocytes by stimulating UCP1 expression in mouse cells (42), and more recently in human 
cells (64). Thus, Ppargc1α is a cold-inducible regulator crucial for adaptive thermogenesis in 
BAT.  
  1.3.2.B. Ppargc1α is critical for mitochondrial biogenesis and fat metabolism 
in skeletal muscle.   
 Ppargc1α is an exercise-inducible co-activator important for mitochondrial biogenesis 
(51, 54, 61) as well as fatty acid metabolism in skeletal muscle (40, 65). For mitochondrial 
biogenesis, Ppargc1α induces the expression of and coactivates transcription factors NRF-1 and 
NRF-2, which in turn stimulates the expression of many nuclear-encoded mitochondrial genes, 
notably mitochondrial transcription factor A (Tfam) (38, 54, 61). Tfam is a key mitochondrial 
transcriptional activator essential for the replication and transcription of mitochondrial DNA (66, 
67). Regarding fat metabolism, Ppargc1α promotes the transcription of enzymes critical for fat 
metabolism such as Fatty Acid Translocase (FAT) or CD36, Carnitine Palmitoyltransferase 1 
(CPT 1) and Medium-chain acyl-Coenzyme A Dehydrogenase (MCAD) (40, 65). Loss-of-
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function analysis of Ppargc1α null and muscle-specific conditional null mice showed that these 
mice are intolerant of exercise and are particularly sensitive to contraction-induced fatigue (40, 
62). The studies also demonstrated that these null mice have reduced amounts of mitochondrial 
respiratory chain proteins and ATP synthase (40, 62). Remarkably, gain-of-function analysis 
revealed that transgenic expression of Ppargc1α in white glycolytic fast-twitch skeletal muscle 
can “fate-switch” them to display genetic and physiological features characteristic of red 
oxidative slow-twitch skeletal muscle, such as the expression of contractile proteins like 
Troponin I, and greater resistance to electrically stimulated fatigue (38, 68). Hence, Ppargc1α 
plays a critical role in mitochondrial biogenesis and fat metabolism in skeletal muscle. 
  1.3.2.C. Ppargc1α is essential for oxidative metabolism in the heart.  
 Ppargc1α is a key regulator for mitochondrial biogenesis as well as fatty acid β-oxidation, 
and acts as a molecular switch to transform cardiac muscle from a glycolytic state to an oxidative 
phosphorylated state (38, 40, 69). Loss-of-function analysis demonstrated that Ppargc1α null 
mice display lower cardiac reserves after electrical or chemical stimulation, decreased treadmill-
running capacity and reduced cardiac functions such as atypical heart rate and defective left 
ventricular function after exercise (38, 40, 62, 70). These null mice also showed early symptoms 
of cardiac failure by expressing cardiac genes reminiscent of an early embryonic stage and 
stimulating the production of circulated atrial natriuretic peptide which is used as an indicator of 
cardiac dysfunction (38, 40, 70). Gain-of-function analysis revealed that Ppargc1α 
overexpression in vivo and in cultured neonatal cardiomyocytes in vitro can induce 
mitochondrial biogenesis and gene expression (38, 40, 69, 71). Therefore, Ppargc1α is essential 
for oxidative mitochondrial metabolism in the heart.  
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 1.3.3. Ppargc1α function in the CNS remains relatively unknown. 
 Despite its well-studied function in many tissues and its involvement in 
neurodegenerative diseases, the cell-autonomous role of Ppargc1α in the neocortex is relatively 
unknown, especially its function in the differentiation of SCPN, including CSMN. 
 For neurodegenerative diseases, three studies have implicated Ppargc1α in repressing the 
neurodegeneration of striatal neurons in a mouse model of HD by suppressing reactive oxygen 
species (ROS) and protecting against mitochondrial dysfunction, thereby enhancing neuronal 
survival against oxidative insults (72-74). In these studies, it was revealed that ectopic expression 
of Ppargc1α in the striatum of transgenic HD mice protects them against atrophy and leads to an 
increase in mean neuronal volume (73). In the context of Parkinson’s disease (PD), previous 
work has shown that when exposed to the neurotoxin MPTP, Ppargc1α-/- mice show greater 
dopaminergic cell death, similar to what is observed in mice with PD (72). In this case, enhanced 
cell death is caused by excessive oxidative damage to the dopaminergic neurons present in the 
substantia nigra, as evident by an increase in nitrosylated proteins – a marker for ROS-induced 
cell damage (72). The association of Ppargc1α with PD is also supported by a genome-wide 
expression study showing that mitochondrial genes responsive to Ppargc1α are underexpressed 
in patients with PD (75), as well as another recent study showing that PARIS, a parkin 
interacting molecule that contributes to neurodegeneration in PD, transcriptionally represses 
Ppargc1α (76). In addition, there is preliminary work linking Ppargc1α to ALS (77-79), multiple 
sclerosis (80), Alzheimer’s disease (81), bipolar disorder and schizophrenia (82). Interestingly, it 
has been suggested that Ppargc1α enhances neuronal recovery from hypoxia (83) and protects 
neurons against reperfusion injury, ischemia as well as stroke (84-87). Although these studies 
support a role for Ppargc1α in controlling neuronal survival, possibly by regulating mitochondria 
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function and biogenesis, it is important to note that they were performed in the context of acute 
cellular stress caused by either the administration of toxic substances or by ongoing 
neurodegeneration with selective cell loss. Therefore, it remains unknown whether cell-intrinsic 
loss of Ppargc1α, either in the absence of acute cellular stress or in combination with chronic 
stress caused by aging, can induce cell death. This question motivated me to investigate whether 
Ppargc1α in SCPN is important for neuronal survival, as described in Chapter 2.  
 In addition, gross examination of the Ppargc1α null brain revealed spongiform-like 
lesions in the striatum (63). Since SCPN project through the internal capsule in the striatum, I 
was prompted to study whether Ppargc1α in SCPN contributes to the generation of these lesions, 
as detailed in Chapter 2.  
 In the process of elucidating Ppargc1α’s function in SCPN with regard to neuronal 
survival and lesion development, I discovered a novel function for Ppargc1α in SCPN. In 
Chapter 3, I investigated whether SCPN-specific Ppargc1α is involved in the regulation of 
neocortical myelination, a process exclusively governed by oligodendrocytes. This is the first 
study implicating Ppargc1α to be important for neuron-to-glia interactions, a role that has not 
previously been described. Interestingly, a recent report has also suggested that the spongiform 
lesions reflect a myelination deficit in the striatum of Ppargc1α null mutants (88).  
 In the context of nervous system development, early in vitro studies implicate Ppargc1α 
in the differentiation of neurons or Schwann cells (89-91), as well as the regulation of 
mitochondrial density in primary cortical neurons (92). Few in vivo studies point to a role in 
governing the expression of Parvalbumin in GABAergic interneurons (93, 94), the formation and 
maintenance of neuronal dendritic spines (95) but not in the maintenance of medium spiny 
neurons in the striatum (96). In the study by Cowell and her group focusing on Parvalbumin and 
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GABAergic dysfunction in Ppargc1α null mutants, they found that Ppargc1α is required for 
Parvalbumin expression throughout the cortex, hippocampus, striatum and cerebellum (97). 
However, analysis of other GABAergic markers such as GAD67, GAD65, KV3.1, Calbindin, 
Calretinin, Cholecystokinin and Somatostatin showed that these markers are unaffected in the 
Ppargc1α null mutants (97). Hence, in line with a prior study looking at the rat brain, Ppargc1α 
null mutants do not suffer from a loss of Parvalbumin expressing interneurons but from a loss of 
Parvalbumin expression (94, 97). Consistent with this result, electrophysiological tests showed 
that spontaneous synaptic inhibition was not altered in the Ppargc1α null mutants though evoked 
synaptic responses showed decreased paired-pulse depression and dramatic facilitation in 
response to repetitive stimulation at the gamma frequency (97). In addition, Lucas et al. showed 
that overexpression of Ppargc1α can induce the mRNA expression of Parvalbumin in cultured 
neuroblastoma cells (97). Therefore, Ppargc1α is required for Parvalbumin expression in the 
brain.   
 In spite of these initial studies, the cell-autonomous function of Ppargc1α in neocortical 
development, particularly in SCPN/CSMN differentiation, remains unknown. Hence, in Chapters 
2 and 3, I chose to investigate the functional role of transcriptional co-activator Ppargc1α in the 
postnatal differentiation of SCPN, including CSMN, in relation to neuronal survival, spongiform 
lesion formation and neocortical myelination.  
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1.4. Neuronal survival  
 Neurons in the central nervous system can be induced to die by apoptosis (98, 99). 
Extrinsic apoptotic pathways operate through the stimulation of death receptors by extracellular 
ligands to induce downstream JNK (c-Jun-N-terminal kinase) pathways that activate effector 
caspases (99). They can also combine with intrinsic apoptotic pathways at the mitochondria (99). 
Intrinsic apoptotic pathways cause the mitochondria to release cytochrome c that results in the 
assembly of the apoptosome complex, which further stimulates effector caspases to kill the cell 
(99). Translocation of apoptotic factors like BH3 proteins to the mitochondrial membrane to 
cause the release of cytochrome c from the mitochondria highlights the key role played by this 
organelle (99).  
 Many neuronal survival factors promote survival by inhibiting apoptotic pathways at 
distinct sites of action: upstream of the mitochondria, at the mitochondria to prevent the release 
of pro-apoptotic factors, or downstream of the mitochondria (99). Upstream of the mitochondria, 
there are decoy proteins that prevent apoptosis by competing with pro-apoptotic ligands for 
binding with death receptors such as cFLIP/cFLAR (100, 101), or by sequestering the ligands 
like DCR3 (102). Downstream of the mitochondria, survival factors can either act as decoys or 
they can associate with and prevent cytochrome c from forming the apoptosome (103, 104).  At 
the mitochondria, neuronal survival factors typically prevent the permeabilization of 
mitochondrial membranes and the release of apoptotic factors. Many well-known factors include 
the anti-apoptotic BCL2-like family members (105) and the uncoupling proteins from the UCP 
family that reduce reactive oxygen species (ROS) (106). Interestingly, Ppargc1α is known to be 
important for mitochondrial biogenesis in skeletal muscle (51, 54, 61) and has been shown to be 
able to induce UCP-1 expression in brown fat (42). Hence, Ppargc1α is purported to be 
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important for cellular survival, acting potentially by inhibiting apoptosis at the mitochondria to 
prevent the release of pro-apoptotic factors.  
 Previous studies have reported that Ppargc1α-/- mice develop striking lesions 
predominantly in the striatum that are reminiscent of those in HD mice (63). Spongiform-like 
lesions are found in a variety of diseases that range from prion diseases like transmissible 
spongiform encephalopathies (107), white matter disorders such as leukodystrophies (108, 109) 
and multiple sclerosis (110), to neurodegenerative diseases like HD (111). Lesions are typically 
characterized based on commonly used histological stainings such as hematoxylin and eosin, as 
well as their location of occurance. The inability to define lesions with specific markers that are 
yet to be identified limits current research into lesion characterization and generation across 
various disorders. Hence, it remains unknown how lesions are formed and whether they differ or 
are similar across distinct diseases. More importantly, it remains unknown how genetic factors 
causes lesions and whether different molecular signals can converge into a common pathway that 
is shared across the different disorders.  
 In Chapter 2, I elucidate whether Ppargc1α is cell-intrinsically necessary in SCPN to 
govern neuronal survival in vivo, either in the native cellular context without acute external stress 
or neurodegeneration, or in the context of chronic stress caused by aging. Initial studies in the 
context of neurodegenerative diseases and acute cellular stress have implicated Ppargc1α in 
neuronal survival. Yet, it is unclear if the developmental function of Ppargc1α in the nervous 
system is to maintain cell survival. Focusing on the neocortex, I found that Ppargc1α is not 
required for neuronal survival, especially in the native cellular context where there is no acute 
external stress or concurrent neurodegeneration. These findings motivated another study to 
investigate whether Ppargc1α is important for neuronal survival in the context of chronic stress 
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caused by aging. Remarkably, examination of 18-month-old Ppargc1α null and conditional null 
mutants in the dorsal telencephalon revealed similar results where there are neither gross cortical, 
neuronal or PN subtype-specific anomalies, nor enhanced cell death. Thus, Ppargc1α is not cell-
intrinsically required in SCPN to control neuronal survival, either in the native cellular context 
without external stress or neurodegeneration or in the context of chronic stress caused by aging. 
These results show that Ppargc1α is not important for SCPN birth, migration, laminar 
positioning nor survival. They further augment my new data in Chapter 3 by showing that the 
hypomyelination defects are not caused by neuronal loss.  
 In addition, in Chapter 2, I also study whether Ppargc1α is cell-autonomously required in 
SCPN to govern the development of spongiform-like lesions in the striatum. This was motivated 
by the fact that SCPN/CSMN project through the internal capsule of the striatum where these 
lesions are localized in Ppargc1α null mutants. Understanding the contribution of Ppargc1α in 
SCPN to these lesions will allow us not only to identify the cellular origins of these lesions, but, 
more importantly, to understand if these lesions affect the SCPN axonal efferents. First, I 
determine the expression profile of Ppargc1α and study the exact localization and temporal 
profile of these lesions. I find that Ppargc1α is highly expressed in SCPN predominantly during 
postnatal ages. I also elucidate that these lesions are closely associated with, or exactly localized 
to, the internal capsule through which SCPN project. By generating conditional null mutants for 
Ppargc1α in the dorsal telencephalon, I discover that conditional loss of Ppargc1α in the dorsal 
forebrain do not cause lesion formation, even in 18-month-old mutants. These data indicate that 
Ppargc1α in SCPN is not required for lesion formation. They further suggest that other neuronal 
regions may be responsible for the lesions and, more importantly, that SCPN axonal efferents are 
normal and not affected by these lesions. These data further support my novel findings in 
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Chapter 3 by showing that the hypomyelination defects are not caused by abnormal SCPN 
axonal projections.  
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1.5. Myelination by oligodendrocytes in the central nervous system 
 1.5.1. Myelin 
 The myelin sheath is an important development in the vertebrate nervous system during 
evolution (112, 113). By providing neurons with electrical insulation, it greatly increases the 
conduction velocity of action potentials and hence allows for efficient saltatory propagation of 
nerve impulses over long distances (112, 113). It is generated by oligodendrocytes in the central 
nervous system (CNS) or by Schwann cells in the peripheral nervous system (PNS), and is made 
by consecutive wrapping and subsequent compaction of stacked glial plasma membrane bilayers 
over the neuronal axon (112, 113). Essentially, myelin is a lipid-rich membrane that is replete 
with glycosphingolipids as well as cholesterol, and contains a myriad of proteins including the 
two major CNS myelin proteins – myelin basic proteins (MBP) and proteolipid proteins 
(PLP/DM20) (112, 113).  
 
 1.5.2. Oligodendrocyte origins in the dorsal telencephalon 
 During embryonic development, oligodendrocyte precursors are produced by cells that 
reside in the ventricular zone that lies adjacent to the ventricles in both the spinal cord and in the 
brain (114-116). In the telencephalon, oligodendrocyte precursors first originate from ventral 
regions (114, 115, 117). As early as E11.5 to E12.5, oligodendrocyte progenitors from the most 
ventrally located medial ganglionic eminence (MGE) and anterior entopeduncular area (AEP) 
begin to be produced and they migrate in a ventral to dorsal fashion to occupy both the ventral 
and dorsal telencephalon (115, 117-119). At around E16.5, these progenitors are joined by a 
second group of progenitors from the lateral and/or caudal ganglionic eminence (LGE and CGE 
respectively) (115, 117). In contrast, oligodendrocyte progenitors from dorsal regions within the 
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cortex only start to be produced postnatally after birth (115, 117). These precursors will generate 
committed oligodendrocyte progenitors that will proliferate and migrate laterally and dorsally 
over long distances to generate white matter over all parts of the telencephalon (112, 116). In the 
cerebral cortex, the MGE and/or AEP derived Nkx2.1 positive oligodendrocyte population is the 
first to arrive at the neocortex as early as E16.5 and they populate the entire cortex by E18.5 (115, 
117). At the same time around E18.5, the second population of ventrally derived 
oligodendrocytes precursors - the Gsh2 positive population from the LGE - arrives at the cortex 
(115, 117). Hence by E18.5, all of the oligodendrocyte populations in the neocortex are ventral 
in origin (115, 117). After E18.5 and by birth, the third wave of dorsally derived Emx1 positive 
oligodendrocyte populates the cortex (115, 117). This population migrates and stays within the 
dorsal forebrain and do not migrate to ventral regions (115, 117). Hence, depending on the 
developmental age, distinct populations of oligodendrocyte precursors from both dorsal and 
ventral regions inhabit the cerebral cortex.  
 During postnatal development, oligodendrocyte precursors are located in the 
subventricular zone near the tips of the lateral ventricles (115, 116, 120-122). This postnatal 
germinal zone, which is derived primarily from the LGE and the lateral cortex, remains active 
and continues to generate oligodendrocytes postnatally and through adulthood (115-117). Hence, 
the ventral-most MGE- and AEP-derived Nkx2.1 positive oligodendrocyte precursors do not 
contribute to the postnatal subventricular zone and thus do not contribute to resident 
oligodendrocyte populations in the postnatal brain (115-117). This is further supported by prior 
work showing that at P10, the earliest population of ventrally derived Nkx2.1 positive 
oligodendrocytes is eliminated from the cortex as well as from all other parts of the brain (117). 
Hence, the cortex is predominantly occupied by Gsh2 and Emx1 positive oligodendrocyte 
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progenitors as well as differentiated oligodendrocytes from P10 to adulthood (117). This study 
has also shown that targeted ablation of any one of the three abovementioned populations by 
diphtheria toxin results in functional compensation by the remaining populations where mutant 
mice display not only have a normal complement of myelin and oligodendrocytes but also 
normal behavior (117). Therefore, these distinct populations of oligodendrocyte progenitors are 
functionally redundant and have been proposed to compete for space in the developing brain.  
 
 1.5.3. Cell-intrinsic control of oligodendrocyte development and myelination 
 In the CNS, the formation of the myelin sheath by oligodendrocytes is temporally and 
spatially regulated and is critically dependent on a multitude of cell-autonomous as well as non-
cell-autonomous factors (112).  
 Cell-intrinsic factors that control oligodendrocyte development include factors that affect 
transcriptional regulation. Some well-studied transcription factors that are expressed throughout 
oligodendrocyte development include the basic helix – loop – helix transcription factors Olig1 
and Olig2 (118, 123-128), homeodomain transcription factor Nkx2.2 (129, 130) and HMG 
transcription regulator Sox10 (131, 132). These factors are expressed in oligodendrocyte 
progenitors as well as postmitotic differentiated oligodendrocytes and thus may play different 
roles at distinct stages of oligodendrocyte development that is likely dependent on other 
regulators that are differentially expressed. Some transcription factors that are predominantly 
expressed in oligodendrocyte progenitors like Id2, Id4, Hes5 and Sox6 have been shown to be 
active inhibitors of oligodendrocyte differentiation (114). Other determinants that are mainly 
expressed in differentiated oligodendrocyte include MRF that has been shown to be important to 
induce expression of myelin genes (133).  
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 Besides transcriptional regulation, oligodendrocyte development is also controlled by 
posttranscriptional changes mediated by microRNAs. It has been shown that conditional loss of 
Dicer in oligodendrocyte lineage results in dysmyelination where selective loss of Dicer in 
mature oligodendrocytes causes dysfunction in lipid homeostasis (134-136). In addition, 
microRNA profiling has also revealed important microRNAs like mir-219 (134) and mir-338 
(135) that have been shown to be important to inhibit oligodendrocyte differentiation by 
targeting progenitor genes like PDGFRα, Hes5 and Sox6.  
 Epigenetic regulation via chromatin remodeling mediated by histone deacytalases 
(HDAC) have also been shown to be important for oligodendrocyte differentiation. Loss of 
function analyses with conditional null mutants for HDAC1 and HDAC2 revealed a loss of 
oligodendrocyte progenitors as well as differentiated oligodendrocytes, suggesting that HDAC 
are important for various stages of oligodendrocyte development (137). HDAC can promote 
differentiation of oligodendrocytes by inhibiting genes that maintain oligodendrocyte precursors 
in an undifferentiated state. For instance, HDAC can interact with transcription factor YY1 to 
inhibit the expression of Id4 (138).  
 In all, cell-intrinsic determinants can control oligodendrocyte birth, specification and 
differentiation at various levels, ranging from transcriptional and posttranscriptional control to 
epigenetic regulation. 
 
 1.5.4. Cell-extrinsic control of oligodendrocyte development and myelination 
 Besides cell-intrinsic determinants that affect oligodendrocyte birth, specification and 
differentiation, cell extrinsic determinants that include hormones like thyroid hormone, growth 
and trophic factors such as fibroblast growth factor 2 (FGF-2) and insulin-like growth factor 1 
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(IGF-1) are also crucial in affecting oligodendrocyte development and subsequent myelin 
biogenesis (112, 113, 139).  
 Notably, the increasing importance of neuron-derived factors for myelination highlights 
the fact that reciprocal neuron and glia communication is imperative for oligodendrocyte 
development as well as proper myelination. This is supported by increasing evidence showing 
that neurons can regulate oligodendrocyte development by affecting their proliferation, 
differentiation and survival so as to ensure the right ratio of oligodendrocytes to axonal surface 
for myelination (113, 139), and the fact that myelination of neuronal axons must occur at the 
right time during development and not before the neurons are equipped to be myelinated (113, 
140). Conversely, oligodendrocytes need to communicate with neurons to organize protein 
complexes at the nodes of Ranvier (113, 141-144) and have been shown to affect axonal 
cytoskeleton and transport (113, 145, 146). Thus, complementary interactions between neurons 
and oligodendrocytes are important for oligodendrocyte development and myelination.  
 Many studies have shown that neuron-derived molecules, whether secreted or not, are 
involved at various stages of oligodendrocyte development from proliferation to differentiation. 
Some known secreted signals include platelet-derived growth factor subunit A (PDGF-A), 
neurotrophin 3 (NT-3), ciliary neurotrophic factor (CNTF), FGF-2 and IGF-1 (113, 147-149). 
PDGF-A is a soluble factor released by both neurons and astrocytes. While loss-of-function 
experiments have demonstrated that it controls the proliferation and survival of oligodendrocyte 
progenitors (113, 150-152), gain-of-function analyses have shown that PDGF-A induction leads 
to an increase in the number of oligodendrocytes (153). Besides secreted factors, non-secreted 
molecules that can act as cell surface receptors such as Jagged 1 (154) and contactin (155) are 
also implicated in neuron glia signaling. Jagged 1 is a cell surface ligand located on neuronal 
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axons that can interact with the Notch 1 receptor found on oligodendrocytes, thus activating 
Notch signaling in oligodendrocytes to inhibit their differentiation (154). The decrease in Jagged 
1 expression in neurons with age coincides with the onset and promotion of myelination (113, 
154). Therefore, Jagged 1 has been proposed to be a way neurons regulate the timing of 
oligodendrocyte differentiation to affect myelination.  
 In addition to affecting oligodendrocyte development, other studies have shown that 
neuron-derived signals can affect myelination itself. For instance, electrical activity of neurons 
has been shown to be necessary to trigger myelination (156). It has been suggested that electrical 
activity in axons after target innervation not only leads to the secretion of promyelinating 
molecules like adenosine (157), but also induces changes in axonal protein expression (158) such 
as decreasing the amount of polysialated adhesion molecule NCAM on the cell membrane to 
enable myelination (159). 
 In Chapter 3, I investigate whether Ppargc1α is cell-autonomously necessary in SCPN to 
establish a correct myelination pattern in the neocortex and whether it is sufficient to induce 
ectopic myelination. I discovered that neuron-specific Ppargc1α is necessary for proper 
neocortical myelination but not sufficient to induce ectopic myelination. Employing various 
genetic null and newly generated conditional null mutants for Ppargc1α, I demonstrate that 
global or conditional loss of Ppargc1α in either neurons or the dorsal forebrain causes 
hypomyelination across all cortical layers in the neocortex. Aging studies of these null and 
conditional null mutants at 18 months further revealed that these hypomyelination defects are not 
due to a delay in myelination because they persist with age. However, overexpression of 
Ppargc1α did not result in ectopic myelination. Initial results of research into the mechanistic 
action of Ppargc1α show that the loss of Ppargc1α leads to decreased neuronal metabolism, 
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suggesting that secreted metabolites can act as mediators for neuron-specific Ppargc1α to 
interact with oligodendrocytes to control myelination. This study is significant because it 
purports a novel function for Ppargc1α in SCPN by implicating it, for the first time, in 
neocortical myelination and broadly in neuron-to-glia interactions. It is especially interesting 
because it suggests that a transcriptional co-activator restricted to neurons can control a process 
like myelination that is exclusively executed by another cell type–the oligodendrocytes.  
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1.6. Neuron-to-glia metabolism 
 1.6.1. Neuron-to-astrocyte metabolic interactions 
 Neurons can interact with glial cells via secreted metabolites, such as glutamate and 
glutamine for astrocytes as well as N-acetyl-aspartate (NAA) for oligodendrocytes (160). The 
metabolic interactions between neurons and astrocytes have been extensively studied over the 
past few decades with particular focus on the glutamate-glutamine-GABA shuttle (161). 
Excitatory glutamatergic neurons release neurotransmitter glutamate in the synapses. Excess 
glutamate is taken up predominantly by astrocytes via specific high-affinity glutamate 
transporters or by pre-synaptic reuptake (162, 163). This reabsorption of glutamate is important 
to prevent neuronal excitotoxicity. Within the astrocytes, glutamine synthetase, an enzyme that is 
found exclusively in astrocytes but not in neurons, convert glutamate to glutamine (164, 165). 
The resultant glutamine is then transferred back to neurons where it is converted back to 
glutamate, thus closing the glutamate-glutamine cycle (160). It has also been shown that 
glutamine released by astrocytes can also be converted to GABA via glutamate in inhibitory 
neurons (166, 167). Therefore, the metabolic interactions between neurons and astrocytes have 
been extended to be the glutamate-glutamine-GABA cycle.  
 
 1.6.2. Neuron-to-oligodendrocyte metabolic interactions 
 The metabolic interactions between neurons and oligodendrocytes have not been as well-
studied as that between neurons and astrocytes. However, two recent studies that revealed a 
connection between glycolytic metabolism in oligodendrocytes and neuronal axonal integrity 
renewed interest in the field (168, 169). These studies have suggested that lactate can 
metabolically support neuronal axons and can be transported from oligodendrocytes to axons via 
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monocarboxylate transporter 1 (MCT1), which is exclusively expressed in oligodendrocytes (168, 
169).  
 Another metabolic pathway of interest that characterizes neuron-to-oligodendrocyte 
interactions involves the enigmatic molecule NAA. NAA is synthesized from acetyl CoA and 
aspartate (170-177). However, the aspartate needed for NAA production can only be synthesized 
de novo in astrocytes, where it is then transported as glutamine to neurons (170-177). After 
which, a recently identified enzyme NAT8L that is exclusively expressed in the mitochondria of 
neurons is responsible for the synthesis of NAA (178). The resultant NAA molecule is then 
released from neurons and taken up by oligodendrocytes, where it is broken down to release 
acetate and aspartate by aspartoacylase, an ezyme that is selectively expressed in 
oligodendrocytes (170-177). It has been suggested that the resultant acetyl groups released 
within oligodendrocytes after NAA breakdown are used as building blocks for myelin to 
generate the insulating sheath that wraps around axons (170-177). The compartamentalization of 
NAA production to neurons has been contested by studies showing that cultured mature 
oligodendrocytes in vitro can produce NAA, suggesting that a parallel mechanism may exist in 
vivo (179). Solving the exclusive compartmentalization of NAA is crucial in understanding the 
astrocytes-neuron-oligodendrocyte metabolic interactions and but more importantly, in our 
interpretation of clinical MRS data that relies on using NAA as a marker for neuronal health and 
viability.  
 
 1.6.3. mTOR pathway and cellular metabolism 
 The mechanistic target of rapamycin (mTOR) signaling pathway is a fundamentally 
important pathway that integrates extracellular signals to intracellular pathways to control 
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cellular growth, size and homeostasis (180). It is first identified as a target of macrolide 
rapamycin in Streptomyces Hygroscopicus bacteria and became known to be an antiproliferative 
agent (180). mTOR is an serine/threonine protein kinase that is part of the phosphoinositide3-
kinase (PI3K)-related family (180). It assembles with several proteins to form two distinct 
complexes, namely mTOR complex 1 (mTORC1) and 2 (mTORC2) (180).  
 mTORC1 is acutely sensitive to rapamycin and is better studied than mTORC2 (180). 
The mTORC1 pathway can sense intracellular as well as extracellular signals like stress, oxygen, 
energy, growth factors and amino acids (180). It can then integrate these signals to provoke a 
cellular response by promoting crucial processes such as protein synthesis, lipogenesis, and 
energy metabolism while inhibiting autophagy and lysosome biogenesis (180). A major upstream 
regulator of mTORC1 includes heterodimer tuberous sclerosis 1 and 2 (TSC1/2) that acts as a 
GTPase-activating protein for the Ras homolog enriched in brain (Rheb) GTPase. GTP-bound 
Rheb interacts directly with mTORC1 and greatly stimulates the kinase activity of mTORC1, 
thus enabling it to phosphorylate downstream effectors. Hence, TSC1/2 negatively regulates 
mTORC1 by converting Rheb from its active GTP bound form to its inactive GDP-bound form 
(181, 182). TSC1/2 integrates many of the signals that converge onto the mTORC1 complex 
(180). For instance, growth factors like insulin and insulin-like growth factor (IGF1) that induces 
the PI3K and Ras pathways can lead to the activation of downstream kinases such as protein 
kinase B (Akt/PKB) (183-185), extracellular-signal-regulated kinase 1/2 (ERK1/2) (186) and 
ribosomal S6 kinase (RSK1) (187). These effector kinases can directly phosphorylate TSC1/2 
and inactivate it, thus stimulating the mTORC1 complex. A similar mechanism is also used by 
proinflammatory cytokines, like tumor necrosis factor (TNFα), to activate the mTORC1 complex 
(188).  In addition, canonical Wnt signaling pathway also stimulates the mTORC1 complex by 
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inhibiting glycogen synthase kinase 3β (GSK-3β), which normally phosphorylates and activates 
TSC2 (189). Besides its upstream regulators, mTORC1 complex can regulate the activity of 
important downstream translational regulators such as S6 kinase 1 (S6K1) and eukaryotic 
translation initiation factor 4E (elF4E)-binding protein (4E-BP1) (190). Activated S6K1 
increases mRNA synthesis, translational initiation as well as translational elongation (180, 190). 
Stimulated 4E-BP1 binds to the elF4F complex and aids in cap-dependent translation (180, 190).  
 mTORC2 is insensitive to acute rapamycin treatment but is sensitive to chronic 
rapamycin treatment in selected cell types (180). It is also not as well-studied as the mTORC1 
pathway (180). The mTORC2 pathway can sense extracellular signals like growth factors and 
can integrate these signals to provoke a cellular response by promoting cytoskeletal organization, 
cellular survival and cellular metabolism (180). Upstream regulators of mTORC2 include PI3K 
of which its mechanism is currently unclear and may include the binding of ribosomes to 
mTORC2 in a PI3K-dependent manner (191). Downstream effectors of mTORC2 include 
predominantly members of the AGC subfamily of kinases such as Akt (192), serum- and 
glucocorticoid-induced protein kinase 1 (SGK-1) (193) and protein kinase C-α (PKC- α) (194, 
195). Activated Akt can control several cellular pathways like metabolism, survival, apoptosis, 
growth and proliferation (180). Stimulated SGK-1 can regulate processes like cellular growth 
and transport of ions (180). Activated PKC- α can control cellular shape via changes to the actin 
cytoskeleton (194, 195).  
 While it is known that mTOR pathways can control cell growth, size and survival by 
regulating energy metabolism, it remains unclear how it controls mitochondrial oxidative 
metabolism. Interestingly, it has been shown that mTOR controls mitochondrial oxidative 
function through a YY1-PPARGC1Α transcriptional complex (196). This links Ppargc1α to the 
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mTOR signaling pathway and cellular metabolism, and presents an important basis to understand 
the molecular mechanisms underlying Ppargc1α action in the neocortex and particularly in 
SCPN postnatal differentiation. The background information presented here will inform my 
global discussion in Chapter 4 where I conclude with a hypothetical model on potential ways 
Ppargc1α mediates its effects on myelination.   
 In Chapter 4, I conclude with a discussion on the implications of my findings on 
enhancing our knowledge of neuronal survival, spongiform lesion development, and more 
importantly, neocortical myelination in which I include a hypothetical model on potential ways 
Ppargc1α mediates its function to affect myelination by integrating previous work and my new 
data. I also discuss how these results enable us to better delineate the role of Ppargc1α in 
governing various aspects of postnatal SCPN differentiation. Lastly, I discuss the role of 
Ppargc1α as a metabolic switch and its implication in cell differentiation and cell fate. I hope the 
work presented in this dissertation will motivate future research into the function of Ppargc1α in 
the brain, especially in SCPN of the neocortex. Future work is necessary to delve into the role 
played by Ppargc1α in neocortical myelination and to probe how Ppargc1α mediates its function 
in neuron-to-glia communications.  
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Chapter 2:  
Ppargc1α in the dorsal forebrain is not necessary to control neuronal survival and does not 
contribute to spongiform-like lesions in the internal capsule. 
 
Author contribution: I designed all the experiments and interpreted all the data, with the input 
of Professor Paola Arlotta. I performed all in situ hybridizations and the majority of the 
colocalization analyses to determine the expression profile of Ppargc1α in the brain. I performed 
all the Nissl histological staining and did pilot immunohistochemistry analysis for neurons and 
distinct PN subtypes on both Ppargc1α null mutants and the newly generated conditional null 
mutants for Ppargc1α in the dorsal telencephalon. I also executed preliminary cell death analysis 
by immunostaining for caspase 3 on the Ppargc1α null and conditional null mutants. Travis 
Hallett ascertained the results by performing additional immunohistochemical analysis for 
neurons, PN subclasses and caspase 3 on the Ppargc1α null and conditional null mutants. He 
also performed all the Neurosilver histological staining. I established the exact localization of the 
spongiform lesions to the internal capsule in the striatum and determined the time course of their 
appearance in Ppargc1α null mice. I performed similar localization analyses of these lesions in 
neuron-specific Ppargc1α conditional null mice and confirmed the results of prior studies. I 
generated two new and distinct conditional null mice models for Ppargc1α – one in the dorsal 
telencephalon and the other in the thalamus – and performed similar spongiform lesion 
localization and time course analysis on these mice. Edward Stronge and Travis Hallett 
performed the colocalization of Ppargc1α to Parvalbumin-expressing interneurons. 
Publication: These data will be published separately or in conjunction with Chapter 3. 
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2.1. Abstract. 
 Ppargc1α is implicated to be a survival factor for neurons and is linked to Huntington’s 
disease (HD) as well as Parkinson’s disease (PD). Yet, in these prior studies, Ppargc1α function 
was elucidated in a cellular context of acute stress or even concurrent neurodegeneration. Hence, 
it remains unknown whether the developmental function of Ppargc1α is to govern neuronal 
survival. 
 Focusing on the neocortex, I report that Ppargc1α alone is cell-intrinsically not sufficient 
to affect neuronal survival. Examination of Ppargc1α null and newly generated conditional null 
mutants in the dorsal forebrain demonstrated that global and conditional loss of Ppargc1α do not 
lead to any gross cortical or neuronal abnormalities, where distinct PN populations are born, 
specified and positioned normally in the neocortex. Cell death analysis also showed that there is 
no enhanced cell death in these mutants. Therefore, Ppargc1α is not cell-autonomously required 
for neuronal survival in the neocortex, especially in the native cellular state where there is no 
acute external stress or neurodegeneration. 
 These findings motivated another study to investigate whether Ppargc1α is important for 
neuronal survival in the context of accumulated chronic stress caused by aging. Remarkably, 
examination of 18-month-old Ppargc1α null and conditional null mutants revealed similar 
results: there are neither gross cortical, neuronal or PN subtype-specific anomalies nor enhanced 
cell death in these mutants. Thus, aging together with the loss of Ppargc1α, do not cause 
neuronal death. In all, my results refine our current understanding of Ppargc1α’s role in the 
neocortex with regard to neuronal survival. Ppargc1α alone is not necessary to maintain survival 
and may be important only in the context of acute cellular stress. 
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 Previous studies have also shown that global loss of Ppargc1α leads to spongiform-like 
lesions in the striatum and suggests that these lesions resemble degenerative lesions observed in 
mice models of Huntington’s disease (HD). Yet, it is unclear where these lesions are exactly 
localized, when they develop and whether they persist with age or recover with time. Most 
importantly, it is unknown what neuronal subclass in the brain contributes to these lesions. 
Understanding the cellular origins of these lesions will provide new insights into common 
disease mechanisms behind distinct disorders that share similar characteristic lesions.  
 Here, I describe in detail that global loss of Ppargc1α causes spongiform-like lesions to 
develop by P28 and persist with age through 18 months. These lesions are localized within the 
axonal bundles of the internal capsule (IC) through which descending fibers of subcerebral 
projection neurons (SCPN) and ascending axons of thalamocortical projection neurons (TCPN) 
extend. Interestingly, I find that Ppargc1α is preferentially expressed in SCPN, including 
corticospinal motor neurons (CSMN), as well as in selected nuclei of the thalamus during 
postnatal development. In order to determine whether cell-autonomous loss of Ppargc1α in 
SCPN or TCPN causes these lesions, I generated two new conditional null mutant lines that 
ablated Ppargc1α specifically from one of these two neuronal populations and determined if 
similar lesions develop. Surprisingly, cell-intrinsic loss of Ppargc1α in SCPN or TCPN does not 
contribute to spongiform-like lesions in the IC. These data suggests that formation of these 
lesions may involve a more complex mechanism that either includes the simultaneous loss of 
Ppargc1α in multiple neuronal regions, or a hitherto unexamined neuronal subclass. It is also 
possible that systemic components contribute to the development of these lesions.  
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2.2. Introduction. 
 Neurons in the central nervous system can be induced to die by apoptosis (98, 99). 
Extrinsic apoptotic pathways operate through the stimulation of death receptors by extracellular 
ligands to induce downstream JNK (c-Jun-N-terminal kinase) pathways that activate effector 
caspases (99). They can also combine with intrinsic apoptotic pathways at the mitochondria (99). 
Intrinsic apoptotic pathways cause the mitochondria to release cytochrome c that results in the 
assembly of the apoptosome complex which further stimulates effector caspases to kill the cell 
(99). Translocation of apoptotic factors like BH3 proteins to the mitochondrial membrane to 
cause the release of cytochrome c from the mitochondria highlights the key role played by this 
organelle (99).  
 Many neuronal survival factors promote survival by inhibiting apoptotic pathways at 
distinct sites of action: upstream of the mitochondria, at the mitochondria to prevent the release 
of pro-apoptotic factors, or downstream of the mitochondria (99). Upstream of the mitochondria, 
there are decoy proteins that prevent apoptosis by competing with pro-apoptotic ligands for 
binding with death receptors such as cFLIP/cFLAR (100, 101), or by sequestering the ligands 
like DCR3 (102). Downstream of the mitochondria, survival factors can either act as decoys or 
they can associate with and prevent cytochrome c from forming the apoptosome (103, 104).  At 
the mitochondria, neuronal survival factors typically prevent the permeabilization of 
mitochondrial membranes and the release of apoptotic factors. Many well-known factors include 
the anti-apoptotic BCL2-like family members (105) and the uncoupling proteins from the UCP 
family that reduce reactive oxygen species (ROS) (106).  
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 Interestingly, Ppargc1α is known to be important for mitochondrial biogenesis in skeletal 
muscle (51, 54, 61) and can induce UCP-1 expression in brown fat (42). Hence, Ppargc1α is 
purported to be important for cell survival.  
 In the context of neurodegenerative diseases, previous studies have involved Ppargc1α in 
repressing the neurodegeneration of striatal neurons in a mouse model of HD by suppressing 
ROS and protecting against mitochondrial dysfunction, thereby enhancing neuronal survival 
against oxidative insults (72-74). In the context of PD, prior work has shown that when exposed 
to the neurotoxin MPTP, Ppargc1α null mice show greater dopaminergic cell death, similar to 
what is observed in mice with PD (72). In this case, enhanced cell death was caused by excessive 
oxidative damage to the dopaminergic neurons present in the substantia nigra, as evident by an 
increase in nitrosylated proteins–a marker for ROS-induced cell damage (72). The association of 
Ppargc1α with PD is also supported by a genome-wide expression study showing that 
mitochondrial genes responsive to Ppargc1α are underexpressed in patients with PD (75), as 
well as another recent study showing that PARIS–a parkin interacting molecule that contributes 
to neurodegeneration in PD–transcriptionally represses Ppargc1α (76). In addition, there is some 
preliminary work linking Ppargc1α to ALS (77-79), multiple sclerosis (80), Alzheimer’s disease 
(81), bipolar disorder and schizophrenia (82). However, notably in all these studies, the 
contribution of Ppargc1α to neuronal survival is achieved only in the context of acute cellular 
stress or ongoing neurodegeneration. It remains unknown if Ppargc1α is sufficient to govern 
neuronal survival in a native cellular context. Indeed, it is imperative to elucidate whether 
Ppargc1α itself is critical for neuronal survival. Doing so will not only augment our knowledge 
of disease mechanisms behind neuronal death, but also will instruct the development of potential 
therapeutic solutions to enhance neuronal survival. 
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 Here, I hypothesize that Ppargc1α plays a cell-autonomous role in the dorsal forebrain to 
control their survival. To test this hypothesis, I examined Ppargc1α null mutant mice and newly 
generated conditional null mutant mice for Ppargc1α in the dorsal telencephalon, employing a 
number of neuron and PN subtype-selective markers to allow precise delineation of the 
development of distinct subpopulations of cortical neurons. Surprisingly, I found that in the 
absence of Ppargc1α, there are no gross cortical or neuronal abnormalities where distinct PN 
populations are born, specified and positioned normally in the neocortex. Moreover, cell death 
analysis by immunostaining and histological methods further demonstrated that there is no 
enhanced cell death caused by global or conditional loss of Ppargc1α in the dorsal forebrain. 
Hence, Ppargc1α is not cell-intrinsically required to regulate neuronal survival in the neocortex, 
particularly where there is no acute cellular stress.  
 These findings prompted me to explore whether Ppargc1α is important for neuronal 
survival in the event of chronic cellular stress caused by aging. I hypothesize that Ppargc1α 
plays a cell-autonomous role in SCPN to control neuronal survival in the context of aging. I 
tested this hypothesis by examining 18-month-old Ppargc1α null and conditional null mutant 
mice with similar methodologies. Interestingly, I discovered similar results in these aged mice: in 
the absence of Ppargc1α, there are no gross cortical or neuronal abnormalities and distinct PN 
populations are maintained normally in the neocortex. Moreover, there is no increased cell death 
caused by global or conditional loss of Ppargc1α in the dorsal forebrain, even in these 18-month-
old mutant mice. Therefore, I conclude that Ppargc1α is not cell-intrinsically required to govern 
neuronal survival in the neocortex, even in the context of aging.  
 Previous studies have also shown that Ppargc1α-/- mice display not only behavioral 
abnormalities in terms of hyperactivity, hindlimb clasping and motor impairment indicative of 
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neuronal anomalies, but also, strikingly, develop lesions predominantly in the striatum that are 
reminiscent of those in HD mice (63). Yet, it remains unknown where these lesions are exactly 
localized in the striatum, when they develop and whether they persist with age or recover with 
time. Most importantly, it is unclear from which neuronal subclass do these lesions originate.  
 Here, I also examined the lesions in the striatum of Ppargc1α-/- mice across various ages 
using brightfield as well as immunohistological methodologies, and for the first time, describe in 
detail that these lesions are localized within the axonal bundles of the IC along the 
anteroposterior axis, develop by P28 and persist with time through 18 months of age. In order to 
determine the cell population responsible for these lesions, I elucidated the developmental time 
course, areal distribution and cell type specificity of Ppargc1α expression in the brain. Focusing 
on the cortex and the thalamus, I found that it is selectively expressed in SCPN of deep layer V 
in the neocortex and in certain TCPN that reside in the ventroposterior region of the thalamus. 
Since SCPN and TCPN extend axonal projections through the IC where spongiform lesions are 
localized in the mutant, I hypothesize that Ppargc1α plays a cell-intrinsic function in SCPN or 
TCPN in preventing the formation of these lesions in the IC. To test this hypothesis, I generated 
two distinct conditional null mutants, one in the dorsal forebrain and the other in the thalamus. I 
investigated the formation of these lesions, if any, in these mutants across various ages 
employing similar brightfield as well as immunohistological methods. Surprisingly, I found that 
cell-autonomous conditional loss of Ppargc1α in the neocortex or thalamus does not cause 
spongiform-like lesions, even in mutants at 18 months of age. Therefore, I conclude that 
Ppargc1α is not required in SCPN or TCPN to cause spongiform lesions in the IC. My data 
further suggest that the development of these lesions may implicate a more complicated 
mechanism that either involves the concurrent loss of Ppargc1α in multiple neuronal regions, or 
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a thus far unexamined neuronal subtype, or even the contribution of systemic components to the 
development of these lesions.  
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2.3. Results. 
 2.3.1. Selection of Ppargc1α as an interesting candidate to study neuronal survival. 
 I took advantage of the availability of this new microarray database, as described in 
section 1.2.5., to search for novel Fezf2-regulated genetic controllers of important aspects of 
SCPN/CSMN postnatal differentiation, particularly in neuronal survival. The screen revealed 
732 statistically significant genes that were either upregulated or repressed by Fezf2 at various 
stages of development. Of these genes, I first focused on 30 prime candidates that were highly 
upregulated by Fezf2 within 24 and/or 48 hrs following Fezf2 overexpression. From these, I 
further selected 24 novel genes with unknown function in SCPN/CSMN development and 
performed a thorough literature search on each one of them to determine if any could be 
implicated in specific aspects of SCPN/CSMN development. Subsequently, I narrowed down 
this list to 4 novel candidate genes, which included 2 transcription factors, 1 transcriptional 
coactivator, and 1 axon guidance molecule. Eventually, I decided to focus my analysis on 
Ppargc1α because of my interest in studying potential molecular signals that govern SCPN-
specific survival. I chose Ppargc1α primarily because of (i) available studies implicating 
Ppargc1α in neuronal survival and in suppressing striatal neurodegeneration in Huntington’s 
disease (72-74), and secondarily, due to (ii) the specific upregulation of this gene upon Fezf2 
overexpression and its restricted expression by microarray in SCPN/CSMN and not CPN (5), as 
well as (iii) prior work describing its fundamental role in regulating complex biological 
programs in a tissue-specific manner, which includes mitochondrial biogenesis, adaptive 
thermogenesis in brown adipose tissue, and fiber-type switching in skeletal muscles, among 
many others (38, 39, 61, 197, 198). I have been very fortunate to have established a collaboration 
with Dr. Bruce Spiegelman (Dana Farber Cancer Institute) who has graciously shared with us 
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Ppargc1α null mutants (Ppargc1α-/- ), floxed conditional mutants (Ppargc1αfl/fl) and relevant 
reagents such as Ppargc1α antibodies for immunohistochemistry (IHC). Thus, I identified 
Ppargc1α as a very interesting gene candidate that potentially contributes to SCPN/CSMN-
selective survival or other crucial aspects of SCPN/CSMN differentiation and function at late 
stages of maturation, a previously unexplored topic.   
 
 2.3.2. Ppargc1α is expressed in SCPN of layer V during postnatal development.  
  2.3.2.A. Temporal and spatial analysis. 
 To determine the temporal and spatial expression profile of Ppargc1α in the brain, I 
performed in situ hybridization (ISH) for Ppargc1α on wild type C57BL/6 coronal cortical 
sections at various embryonic ages from E13.5 to E18.5 and postnatal ages from P0 to P28. In 
the neocortex, I discovered that Ppargc1α is preferentially expressed in layer V at lower levels 
during P0 (Figure 2.1.D.) and at high levels progressively increasing throughout postnatal 
development from P3 to P28 (Figures 2.1.E to 2.1.H., data not shown for P21), but is not 
expressed at embryonic ages from E13.5 to E18.5 (Figures 2.1.A. to 2.1.C.). I also found that 
Ppargc1α is predominantly absent from other neocortical layers (Figures 2.1.D. to 2.1.H.). In 
addition, it is expressed in smaller cells scattered across the neocortex (Figures 2.1.D. to 2.1.H.), 
which I have confirmed to be Parvalbumin expressing cortical interneurons, as described in 
sections 2.3.1.B. and 2.3.4.A., and further supported by prior studies done in the rat cortex, and 
more recently in the murine cortex (94, 97). This temporal profile of Ppargc1α expression in 
layer V predominantly at postnatal ages is in agreement with the previously published 
microarray data on differential gene expression between major PN subtypes in the neocortex (5), 
as described in section 2.3.1.B., as well as in pilot studies characterizing Ppargc1α expression in  
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Figure 2.1. Ppargc1α is expressed in deep layer V predominantly during postnatal ages.  
(A – C) ISH analysis showed that Ppargc1α is largely absent in the cortical plate during 
embryonic ages from E13.5 to E15.5 and is only expressed from E18.5. The faint expression 
seen in the progenitor zone is weak and undefined and does not seem cellular upon high 
magnification (data not shown).  
(D – H) Ppargc1α is weakly expressed in deep cortical layer V at P0, and progressively increases 
its expression in layer V with time. It is predominantly expressed during postnatal ages from P3 
to P28 (data not shown for P21). Ctx, cortex; LGE, lateral ganglionic eminence; CGE, caudal 
ganglionic eminence; MGE, medial ganglionic eminence; LGP, lateral globus pallidus; Str, 
striatum. Scale bars, 100 μm (A – H).  
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the adult murine brain (199). 
 Anteroposterior and mediolateral expression analysis of Ppargc1α in the neocortex 
revealed that it is expressed in layer V along these axes without evident arealization (Figures 
2.2.A. to 2.2.E.). To confirm this, I performed ISH for Ppargc1α on wild type C57BL/6 sagittal 
cortical sections at P14. Similarly, I found that Ppargc1α is consistently expressed in layer V 
along the rostrocaudal axis (data not shown). Hence, Ppargc1α expression in layer V is not 
spatially arealized along the anteroposterior and mediolateral axes. This temporally and spatially 
distinct expression profile indicates that Ppargc1α is specifically and consistently expressed 
throughout layer V where SCPN reside in the neocortex, and is absent in other cortical layers. It 
also demonstrates that Ppargc1α is important at later stages of development during postnatal 
ages. Thus, these data suggest that Ppargc1α is important for the postnatal differentiation of 
SCPN, including CSMN.  
 Besides its expression in the neocortex, spatial analysis further revealed that Ppargc1α is 
expressed at high levels in the piriform cortex, hippocampus, as well as the diagonal band of 
Broca (Figures 2.2.A. to 2.2.E.). It is also highly expressed in certain regions of the basal ganglia 
such as the globus pallidus (lateral and medial), ventral pallidum, substantia nigra and the 
subthalamic nuclei (Figures 2.2.A. to 2.2.E., data not shown for some regions). In addition, it is 
expressed at high levels in certain thalamic nuclei (i.e., anterodorsal thalamic nucleus, ventral 
posterolateral thalamic nucleus, ventral posteromedial thalamic nucleus and lateral habenular 
nucleus), as well as in distinct regions of the subthalamus including the reticular thalamic 
nucleus (Figures 2.2.A. to 2.2.E., data not shown for some regions). Besides its strong expression 
in these areas, I also detected that Ppargc1α is expressed at low levels in regions like the 
striatum, amygdala and the hypothalamus (Figures 2.2.A. to 2.2.E.., data not shown for some  
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Figure 2.2. Ppargc1α is consistently expressed in deep layer V without evident arealization.  
(A – E) ISH analysis demonstrated that Ppargc1α is expressed along the anteroposterior and 
mediolateral axes without evident arealization. Further analysis on P14 sagittal cortical sections 
further ascertained these results (data not shown). Ctx, cortex; Str, striatum; Pir, piriform cortex; 
DB, diagonal band of Broca; Hip, hippocampus; Rt, reticular thalamic nuclei; LGP, lateral 
globus pallidus; VP, ventroposterior thalamic nuclei (including ventral posterolateral and ventral 
posteromedial thalamic nuclei). Scale bars, 100 μm (A – E). 
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Figure 2.2. (Continued) 
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regions). Temporal analysis from P3 to P28 showed that Ppargc1α is expressed in these areas of 
the brain consistently throughout postnatal development (in at least 3 distinct postnatal ages) 
(Table 2.1.). Results of the temporal and spatial analysis of Ppargc1α expression in the brain  
from P3 to P28 is summarized in Table 2.1.. This is the first expression profile of Ppargc1α in 
the murine brain across multiple postnatal ages and is in line with work done in the adult (199). 
 Together, these data demonstrate that in the neocortex, Ppargc1α is preferentially 
expressed at high levels in layer V where SCPN are located, and is lacking in other cortical 
layers. They also indicate that Ppargc1α expression in layer V is not spatially arealized along the 
anteroposterior and mediolateral axes and that it is selectively expressed at later postnatal stages 
of development. Therefore, Ppargc1α is potentially a novel critical factor for the postnatal 
differentiation of SCPN, including CSMN.  
  2.3.2.B. Cell type specific analysis. 
 To elucidate the neuronal subtype-specific expression of Ppargc1α in the neocortex, I 
looked at the microarray expression profile done on purified CSMN, corticotectal projection 
neurons (CTPN) and callosal projection neurons (CPN) by Arlotta and Molyneaux, et al. (data 
available at NCBI Gene Expression Omnibus accession number GSE2039/GDS1076) (5) . These 
microarray data indicated that Ppargc1α is expressed in CSMN and CTPN, two closely related 
subtypes of SCPN, but not in CPN (Figure 2.3.A.). They also showed that Ppargc1α expression 
in CSMN is negligible at E18.5 and progressively increases from P3 to P14, suggesting a novel 
role for Ppargc1α at postnatal stages of SCPN/CSMN differentiation (Figure 2.3.A.).  
 To verify the previously published microarray data and to determine whether Ppargc1α 
expression in layer V is restricted to SCPN, I performed an ISH for Ppargc1α combined with an 
immunostaining for CTIP2–a marker that is expressed at high levels in SCPN but not CPN in  
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Table 2.1. Temporal and spatial expression profile of Ppargc1α in the brain during 
postnatal development.  
This table summarizes where and when Ppargc1α is expressed in the brain during postnatal ages. 
A check () indicates that Ppargc1α is detected at the stated region and time while a cross (X) 
shows that Ppargc1α is not detected at the stated region and time. ND signifies that Ppargc1α 
expression was not determined at the stated region and time.  
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    P3 P6 P14 P21 P28
Layer V - with small scattered cells spread 
around all cortical layers - from cingulate to 
auditory (no apparent arealization)     
Cerebral 
Cortex 
PIR- piriform cortex     
MS - medial septal nucleus     
LSI - lateral septal nucleus - weaker signal 
than MS     ND 
VDB - nucleus of the vertical limb of the 
diagonal band     
Diagonal  
Band of 
Broca 
HDB - nucleus of the horizontal limb of the 
diagonal band     
Hippocampus 
Hip- Hippocampus - from CA1 to CA3, spread 
from Py (pyramidal cell layer) to Or (Oriens 
layer)     
AD - anterodorsal thalamic nucleus    ND 
IAD - interanterodorsal thalamic nucleus    ND ND 
MD - mediodorsal thalamic nucleus     ND 
CM - central medial thalamic nueclus (weak)     
PF - parafascicular thalamic nucleus    ND ND 
OPC and PC - oval paracentral thalamic 
nucleus       
VLGMC - ventral lateral geniculate nucleus, 
magnocellular part     
VLGPC- ventral lateral geniculate nucleus, 
parvicellular part     
DLG - dorsal lateral geniculate nucleus (weak) NDND ND 
LPLR - lateral posterior thalamic nucleus, 
laterorostral part (weak @ P21)   ND  ND 
LPMR - lateral posterior thalamic nucleus, 
mediorostral part (weak @ P21)   ND  ND 
LDVL- laterodorsal thalamic nucleus, 
ventrolateral part - some parts (weak signal - 
scattered cells) X  ?  ND 
LDDM - laterodorsal thalamic nucleus, 
dorsomedial part X  ND  ND 
VPL - ventral posterolateral thalamic nucleus     
VPM - ventral posteromedial thalamic nucleus     
Parts of Po - posterior thalamic nuclear group   ? ? 
Thalamus 
LHb - lateral habenular nucleus     
Table 2.1. (Continued) 
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    P3 P6 P14 P21 P28 
Rt - reticular thalamic nucleus     
ZI - zona incerta (weak)     Subthalamus 
STh - subthalamic nuclei   ND  
CPu- Striatum- arealized to the most lateral 
edges (P3-P6); few scattered cells (P14)    ND ND 
LGP - lateral globus pallidus     
MGP- medial globus pallidus X   ND ND 
VP- ventral pallidum     
Substantia nigra NDND  ND ND 
Basal Ganglia 
STh - subthalamic nuclei   ND  
PLCo - posterolateral cortical amygdaloid 
nucleus   ND  ND ND 
PMCo - posteromedial cortical amygdaloid 
nucleus  
 
ND ND ND 
MePV - medial amygdaloid nucleus, 
posterovental part   ND ? ND 
MePD? -- medial amygdaloid nucleus, 
posterodorsal part   ND ? ND 
BLP - basolateral amygdaloid nucleus, 
posterior part   ND  
BLA - basolateral amygdaloid nucleus, 
anterior part     
Amygdala 
BMP - basolateral amygdaloid nucleus, 
posterior part   ND  ND 
LPO - lateral preoptic area     ND 
MCPO - magnocellular preoptic nucleus     
DM - dorsomedial hypothalamic nucleus  ND ND ? ND Hypothalamus 
LH- lateral hypothalamic area X  ND  ND 
       
  = strong signal       
  = weaker signal      
Table 2.1. (Continued) 
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Figure 2.3. Ppargc1α is expressed in layer V SCPN and Parvalbumin-expressing 
interneurons but not in CThPN, majority of CPN and glial cells of the neocortex.  
(A) Published microarray analysis revealed that Ppargc1α is preferentially expressed in SCPN 
such as CSMN and CTPN but not in CPN. Ppargc1α expression in CSMN also progressively 
increases with age from E18 to P14 – a result consistent with my new findings as described in 
section 2.3.1. and shown in Figure 2.1.. This figure is adapted from (5).  
(B) Ppargc1α is selectively expressed in majority of CTIP2-positive SCPN of deep layer V 
(arrows). Single positive cells for Ppargc1α and CTIP2 are also detected (arrowheads).  
(C) Ppargc1α is not expressed in CTIP2-positive CThPN of deep layer VI. 
(D) Ppargc1α is not expressed in several SATB2-positive CPN of deep layer V (arrowheads). 
Some double positive cells for Ppargc1α and SATB2 are detected in deep layer V (arrows). In 
contrast, Ppargc1α is not expressed in SATB2-positive CPN of other cortical layers (data not 
shown).  
(E) Ppargc1α is not expressed in CUX1positive CPN of cortical layers II – IV (data shown for 
layer IV). 
(F) Ppargc1α is selectively expressed in Parvalbumin (PV)-positive cortical interneurons (arrows, 
data shown for deep layer V). Single positive cells for Ppargc1α are also detected (arrowheads).  
(G) Ppargc1α is not expressed in OLIG2-positive oligodendrocyte progenitors as well as 
myelinating oligodendrocytes across all cortical layers (data shown for deep layer V). 
(H) Ppargc1α is not expressed in APC-positive mature myelinating oligodendrocytes that are 
located mainly in the deep cortical layers V/VI (data shown for deep layer V). 
(I) Ppargc1α is not expressed in S100β-positive astrocytes across all cortical layers (data shown 
for deep layer V).  
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(J – L) In agreement with the results in G and H, Ppargc1α is not expressed in major white 
matter tracts like the corpus callosum and anterior commissure where oligodendrocytes are found 
in large numbers. Scale bars, 100 μm (J), 50 μm (B – I and K – L). 
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layer V and at lower levels in layer VI CThPN (5)–on P14 wild type C57BL/6 coronal cortical 
sections. I found that several of the CTIP2 expressing cells in layer V expressed Ppargc1α, 
indicating that Ppargc1α is expressed in SCPN (Figure 2.3.B., arrows). Interestingly, cells that 
were single positive for either CTIP2 or Ppargc1α were also detected (Figure 2.3.B. arrowheads). 
The presence of single positive cells for CTIP2 suggests that Ppargc1α labels a subset of SCPN. 
Consistent with prior studies done in the rat and mouse cortex (94, 97), the single positive cells 
for Ppargc1α are possibly Parvalbumin expressing cortical interneurons, a result confirmed by 
data described below, in Figure 2.3.F. as well as in section 2.3.4.A.. In addition, colocalization 
analysis of Ppargc1α and CTIP2 positive CThPN of layer VI revealed that CTIP2 expressing 
cells of layer VI do not express Ppargc1α, showing that Ppargc1α is not expressed in layer VI 
CThPN (Figure 2.3.C.).  Together, these prior data and my new results demonstrate that 
Ppargc1α is specifically expressed in SCPN, including CSMN, of deep layer V but is absent 
from CThPN of deep layer VI postnatally. 
 To ascertain the prior microarray data and to elucidate that Ppargc1α is not expressed in 
CPN, I did an ISH for Ppargc1α combined with an immunostaining for CUX1—a marker that is 
expressed in CPN of upper layers II-V but not in deep layers V-VI (1, 200)—as well as 
SATB2—a marker that is expressed in CPN across all cortical layers from II to VI but not in 
layer V SCPN (34, 35)—on P14 wild type C57BL/6 coronal cortical sections. I found that most, 
if not all, of the CUX1 positive cells of upper layers II-IV do not express Ppargc1α, indicating 
that Ppargc1α is not expressed in CPN of cortical upper layers II-IV (Figure 2.3.E.). 
Colocalization analysis of Ppargc1α and SATB2 positive CPN of deep layer V revealed that 
several SATB2 expressing cells of layer V do not express Ppargc1α, showing that Ppargc1α is 
not expressed in many of layer V CPN (Figure 2.3.D., arrowheads). However, cells that are 
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double positive for Ppargc1α and SATB2 were also detected in layer V (Figure 2.3.D., arrows). 
This suggests that either there is a small subset of layer V CPN that express Ppargc1α, or that 
Ppargc1α is expressed in a subgroup of layer V CTIP2 positive SCPN that continue to express 
SATB2. It is known that at early stages of development, early postmitotic neurons that will give 
rise to distinct SCPN and CPN subtypes in layer V often share similar molecular markers that 
will eventually parcelate and become localized to different subclasses with time (1, 201, 202). In 
fact, immature postmitotic neurons that will give rise to SCPN are double positive for CTIP2 and 
SATB2 (201). Further analysis of SATB2 positive cells in deep layer VI demonstrated that 
SATB2 positive cells of layer VI do not express Ppargc1α, indicating that Ppargc1α is not 
expressed in deep layer VI CPN (data not shown). Consistent with the previously published 
microarray data, my new results show that Ppargc1α is not expressed in CPN of upper layers II – 
IV and deep layer VI, and in some CPN of deep layer V. Thus, with regard to major PN classes 
of the neocortex, Ppargc1α is expressed preferentially in SCPN of layer V but not in CPN and 
CThPN of the neocortex. 
 To study whether Ppargc1α is expressed in Parvalbumin expressing cortical interneurons, 
I performed an ISH for Ppargc1α combined with an immunostaining for PARVALBUMIN, a 
marker that is expressed in a subset of cortical interneurons (203, 204), on P14 wild type 
C57BL/6 coronal cortical sections. I found that PARVALBUMIN expressing cortical 
interneurons across cortical layers II-VI expressed Ppargc1α, indicating that Ppargc1α is 
expressed in Parvalbumin expressing cortical interneurons (Figure 2.3.F., arrows). This is 
consistent with prior work done in the rat and more recently mouse cortex (94, 97). However, I 
also detected cells that are single positive for Ppargc1α throughout cortical layers II-VI (Figure 
2.3.F., arrowheads). Single positive cells for Ppargc1α in layer V are likely to be SCPN as 
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described above and shown in Figure 2.3.B., while similar cells in other layers are potentially 
representative of alternative subsets of cortical interneurons. 
 To investigate whether Ppargc1α is expressed in glial cells, I did an ISH for Ppargc1α 
combined with an immunostaining for (i) OLIG2, a marker that is expressed in oligodendrocyte 
progenitors as well as mature myelinating oligodendrocytes (205), (ii) APC, a marker that is 
expressed only in mature myelinating oligodendrocytes (206, 207), and (iii) S100β, a marker that 
is exclusively expressed in astrocytes (208), on P14 wild type C57BL/6 coronal cortical sections. 
I discovered that OLIG2 expressing oligodendrocyte progenitors and myelinating 
oligodendrocytes as well as APC expressing mature oligodendrocytes do not express Ppargc1α, 
indicating that Ppargc1α is not expressed in oligodendrocyte progenitors as well as mature 
oligodendrocytes of the neocortex (Figure 2.3.G. and 2.3.H.). Furthermore, in line with the above 
result, I did not find Ppargc1α expression in white matter tracts like the corpus callosum and 
anterior commissure where oligodendrocytes are found in large numbers (Figure 2.3.J. to 2.3.L.). 
In addition, I found that S100β expressing astrocytes do not express Ppargc1α, showing that 
Ppargc1α is not expressed in astrocytes (Figure 2.3.I.). Therefore, my new results demonstrate 
that Ppargc1α is not expressed in glial cells of the neocortex, specifically in oligodendrocytes 
and astrocytes. These further support the above result that the smaller scattered cells expressing 
Ppargc1α in the neocortex are likely to be cortical interneurons that have migrated from the 
ventral parts of the brain, in concordance with the result in 2.3.4.A.. 
 A microarray analysis done by Ben Barres and his group showed that Ppargc1α is absent 
in the myelinating oligodendrocytes (209). This is in agreement with my colocalization analysis 
of Ppargc1α expression in the cortex with APC, a marker for mature myelinating 
oligodendrocytes (206, 207), as shown in Figure 2.3.H.. However, their analysis showed that 
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there is weak expression of Ppargc1α in oligodendrocytes and oligodendrocyte progenitors (209). 
This is in contrast with my data showing that Ppargc1α is not expressed in OLIG2 positive 
oligodendrocyte progenitors as well as differentiated postmitotic oligodendrocytes in the 
neocortex. This can be due to a couple of factors. First, the microarray analysis was done on 
cultured oligodendrocytes in vitro and there can be differences in gene expression between 
cultured oligodendrocytes and bona fide oligodendrocytes found in vivo. This could also explain 
the discrepancy with another report suggesting that Ppargc1α is expressed in cultured 
oligodendrocytes and can regulate the expression of myelin basic protein (MBP) in vitro (88). 
Secondly, it is possible that Ppargc1α is expressed in oligodendrocyte progenitors weakly early 
on during development. My temporal expression profile shows that Ppargc1α is weakly 
expressed in the ventricular zone of the ventral telencephalon at E13.5 and E15.5, where MGE-, 
LGE, and CGE-derived oligodendrocyte progenitors are born before migrating to the dorsal 
telencephalon (117). Hence, in this case, the embryonic profile of Ppargc1α expression is in 
agreement with that of the published dataset. Note that this weak expression of Ppargc1α in 
oligodendrocyte progenitors does not contradict our conclusion that neuron-specific Ppargc1α is 
important for the establishment of proper myelination of the neocortex. This is because prior 
work has shown that even in the event where a single oligodendrocyte population is ablated, 
there is functional compensation by remaining oligodendrocyte populations that will result in a 
normal complement of myelination and oligodendrocytes (117). Furthermore, the MGE-derived 
oligodendrocyte population is eliminated from the neocortex shortly after birth and does not play 
a part in the myelination of the postnatal neocortex (117). Hence, it is unlikely that Ppargc1α in 
oligodendrocyte progenitors play a significant role in causing the hypomyelination phenotype as 
observed in the adult cortex, a novel phenotype that is further described in Chapter 3.   
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 In conclusion, Ppargc1α is consistently expressed in SCPN throughout layer V without 
arealization predominantly during postnatal development from P3 to P28. It is neither expressed 
in the CThPN of layer VI, nor in the majority of CPN across all cortical layers. However, it is 
expressed in Parvalbumin expressing cortical interneurons and likely other subsets of 
interneurons. Ppargc1α is not expressed in glial cells such as oligodendrocytes and astrocytes. 
 
 2.3.3. PN are born, specified and positioned normally in Ppargc1α-/- and Emx1-Cre; 
Ppargc1αfl/fl mice.  
 Although prior studies have implicated Ppargc1α in neuronal survival in the context of 
acute cellular stress and neurodegeneration (72-74), it remains unknown if Ppargc1α is cell-
intrinsically important by itself to control neuronal survival. Here, I hypothesize that Ppargc1α is 
cell-autonomously required in neurons, or in SCPN of the neocortex, to govern survival.  
 If this hypothesis is true, I expect that global and conditional loss of Ppargc1α in the 
dorsal telencephalon will cause neuronal loss. To test this hypothesis and to determine whether 
global and conditional loss of Ppargc1α leads to gross cortical abnormalities–particularly layer 
V defects–in terms of cell numbers, cell size and morphology, I performed Nissl staining on P28 
and 2-month-old Ppargc1α-/-, 2-month-old Emx1-Cre; Ppargc1αfl/fl and their respective matched 
littermate wild type and Ppargc1αfl/fl control coronal cortical sections (n = 3 per genotype at all 
ages). I compared the gross formation of the six distinct cortical layers, the morphology and the 
size of cells residing in each layer–especially those of layer V–in Ppargc1α-/- and Emx1-Cre; 
Ppargc1αfl/fl mutants to that of their respective control mice. I did not detect any obvious, 
significant difference between Ppargc1α-/-, Emx1-Cre; Ppargc1αfl/fl and their respective controls 
at the ages tested (Figures 2.4.A. to 2.4.F., data not shown for 2-month-old Ppargc1α-/- and 
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Figure 2.4. PN are born, specified and positioned normally in Ppargc1α-/- and Emx1-Cre; 
Ppargc1αfl/fl mice.  
(A – F) Nissl staining revealed that the six cortical layers are grossly normal in P28 Ppargc1α-/- 
and wild type mice. High magnification analysis detected distinct large somas of SCPN/CSMN 
(arrows) in cortical layer V of both Ppargc1α-/- and wild type mice at P28. (B – C and E – F) 
Boxed areas in (A) and (D) respectively.  
(G – H and Q – R) IHC stain for NeuN, a neuron-specific marker, showed that neurons across 
the six cortical layers appear normal and comparable between 2 month old Ppargc1α-/- (G – H), 
Emx1-Cre; Ppargc1αfl/fl (Q – R) and their respective controls.  
(I – J and S – T) IHC for CTIP2 that labels layer V SCPN/CSMN and layer VI CThPN showed 
that layer V SCPN and layer VI CThPN are born and can migrate normally to their destined 
layers in Ppargc1α-/- (I – J), Emx1-Cre; Ppargc1αfl/fl (S – T) and their respective controls.  
(K – L and U – V) IHC stain for SATB2, which marked all CPN across layers II to VI, revealed 
that CPN are born and can be positioned normally in their destined layers in 2 month old 
Ppargc1α-/- (K –L), Emx1-Cre; Ppargc1αfl/fl (U – V) and their respective controls.  
(M – N and W – X) In line with results shown in K – L and U – V, IHC for CUX1 that labels 
upper layer CPN, indicated that CPN are born and can migrate normally to their destined layers 
in Ppargc1α-/- (M – N), Emx1-Cre; Ppargc1αfl/fl (W – X) and their respective controls.  
(O – P) In agreement with results shown in I – J and S – T, ISH for Fezf2, which marked all 
SCPN/CSMN in deep layer V at high levels and CThPN in deep layer VI at lower levels, showed 
that SCPN and CThPN are born and can migrate normally to their destined layers in P28 
Ppargc1α-/- and wild type mice. Roman numerals indicate the distinct cortical layers. Scale bars, 
100 μm (A and D, G – X), 10 μm (B – C and E – F). 
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Emx1-Cre; Ppargc1αfl/fl mice). Particularly, distinct large somas of SCPN/CSMN (arrows) in 
layer V were found in Ppargc1α-/-, Emx1-Cre; Ppargc1αfl/fl and their respective control mice at 
the ages tested (Figures 2.4.C. and 2.4.F., data not shown for 2-month-old Ppargc1α-/- and Emx1- 
Cre; Ppargc1αfl/fl mice). This observation suggests that SCPN/CSMN are born, fate specified, 
and are able to reach their destined layer in Ppargc1α-/- and Emx1-Cre; Ppargc1αfl/fl mice. These 
data also indicate that global and conditional loss of Ppargc1α do not cause gross cortical 
anomalies by allowing cortical cells to be born and migrate normally to form the six distinct 
cortical layers. This implies that Ppargc1α is not cell-intrinsically necessary to maintain cell 
survival in the neocortex.  
 To investigate if the global and conditional loss of Ppargc1α leads to gross neuronal 
aberrations, I executed an immunohistochemistry (IHC) stain for NeuN–a marker selective to 
neurons (210) –on adult Ppargc1α-/-, Emx1-Cre; Ppargc1αfl/fl and their respective matched 
littermate wild type and Ppargc1αfl/fl control coronal cortical sections at 2 months of age (n = 3 
per genotype). Similarly, I did not detect any obvious, significant difference between the NeuN 
positive neurons located in all six different cortical layers between Ppargc1α-/- (Figures 2.4.G. 
and 2.4.H.), Emx1-Cre; Ppargc1αfl/fl (Figures 2.4.Q. and 2.4.R.) and their respective matched 
control mice. In agreement with my above findings, this result shows that neurons are born and 
can migrate normally to form the six distinct cortical layers in both Ppargc1α-/- and Emx1-Cre; 
Ppargc1αfl/fl mice. Hence, these data indicate that global and conditional loss of Ppargc1α does 
not cause gross neuronal loss, suggesting that Ppargc1α is not cell-intrinsically required for 
neuronal survival in the neocortex.  
 To study whether the global and conditional loss of Ppargc1α leads to loss of SCPN or 
other major PN subclasses, I stained for markers specific for different PN subclasses on P14, P28 
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and 2-month-old Ppargc1α-/-, 2-month-old Emx1-Cre; Ppargc1αfl/fl and their respective matched 
littermate wild type and Ppargc1αfl/fl control cortical sections (n = 1 per genotype for P14, n = 2 
per genotype for P28, n = 3 per genotype for 2 month-old-animals). Markers included CUX1 for 
CPN in upper layers II/III-IV (1, 200), SATB2 for CPN in upper layers II/III-IV and deep layers 
V/VI (34, 35), and CTIP2 for SCPN/CSMN in layer V (stained at high levels) and 
corticothalamic PN (CThPN) in layer VI (stained at low levels) (5). I did not detect any obvious 
difference in the overall distribution of these distinct neuronal subtypes between Ppargc1α-/- 
(Figures 2.4.I. to 2.4.N.), Emx1-Cre; Ppargc1αfl/fl (Figures 2.4.S. to 2.4.X.) and their respective 
matched control mice (data not shown for P14 and P28 animals). Moreover, I performed in situ 
hybridization (ISH) for Fezf2–which labels all SCPN/CSMN in deep layer V at high levels and 
CThPN in deep layer VI at lower levels (6)–on P28 Ppargc1α-/- and matched littermate wild type 
coronal cortical sections (n = 1 per genotype). Likewise, I found that the distribution of layer V 
and VI PN is comparable between Ppargc1α-/- and wild type control mice (Figures 2.4.O. and 
2.4.P.).  
 To ascertain these results, I quantified the number of CTIP2, CUX1 and SATB2 positive 
PN located at a range of depths covering all cortical layers of 2-month-old adult Ppargc1α-/-, 
Emx1-Cre; Ppargc1αfl/fl and their respective matched littermate wild type and Ppargc1αfl/fl 
control mice over the motor, somatosensory and visual areas. Afterwhich, I performed 
comparative and statistical analyses with a two-tailed student’s T test on the total numbers of 
these distinct cell types over the three areas. I did not find any significant difference in the total 
numbers of CTIP2 (average total number of CTIP2 positive PN: motor area, wild type, 637 ± 78; 
Ppargc1α-/-, 637 ± 41; p = 9.96 x 10-1; Ppargc1αfl/fl, 724 ± 169; Emx1-Cre; Ppargc1αfl/fl, 725 ± 
152; p = 9.93 x 10-1, somatosensory area, wild type, 464 ± 121; Ppargc1α-/-, 497 ± 157; p = 6.90 
  69
x 10-1; Ppargc1αfl/fl, 547 ± 57; Emx1-Cre; Ppargc1αfl/fl, 529 ± 38; p = 5.50 x 10-1, visual area, 
wild type, 319 ± 7; Ppargc1α-/-, 315 ± 55; p = 8.83 x 10-1; Ppargc1αfl/fl, 340 ± 50; Emx1-Cre; 
Ppargc1αfl/fl, 329 ± 44; p = 7.22 x 10-1), SATB2 (average total number of SATB2 positive PN: 
motor area, wild type, 1076 ± 181; Ppargc1α-/-, 887 ± 133; p = 9.58 x 10-2; Ppargc1αfl/fl, 1020 ± 
215; Emx1-Cre; Ppargc1αfl/fl, 912 ± 108; p = 3.04 x 10-1, somatosensory area, wild type, 951 ± 
214; Ppargc1α-/-, 838 ± 276; p = 4.47 x 10-1; Ppargc1αfl/fl, 895 ± 49; Emx1-Cre; Ppargc1αfl/fl, 
886 ± 104; p = 8.45 x 10-1, visual area, wild type, 582 ± 127; Ppargc1α-/-, 542 ± 191; p = 7.74 x 
10-1; Ppargc1αfl/fl, 655 ± 115; Emx1-Cre; Ppargc1αfl/fl, 548 ± 52; p = 1.02 x 10-1), and CUX1 
positive PN (average total number of CUX1 positive PN: motor area, wild type, 448 ± 77; 
Ppargc1α-/-, 422 ± 21; p = 6.13 x 10-1; Ppargc1αfl/fl, 521 ± 126; Emx1-Cre; Ppargc1αfl/fl, 448 ± 
71; p = 2.42 x 10-1, somatosensory area, wild type, 487 ± 49; Ppargc1α-/-, 439 ± 27; p = 1.02 x 
10-1; Ppargc1αfl/fl, 460 ± 52; Emx1-Cre; Ppargc1αfl/fl, 422 ± 71; p = 3.56 x 10-1, visual area, wild 
type, 314 ± 70; Ppargc1α-/-, 317 ± 99; p = 9.71 x 10-1; Ppargc1αfl/fl, 387 ± 67; Emx1-Cre; 
Ppargc1αfl/fl, 376 ± 23; p = 7.57 x 10-1) (n = 2 to 3 sections per area per animal, n = 3 animals per 
genotype) (Figure 2.5.A. to 2.5.C.). The statistical analysis is summarized in Table 2.2.. These 
results support the above qualitative finding and demonstrate that there is no significant 
difference in the total numbers of distinct PN populations in the Ppargc1α null and conditional 
null mutants, as compared to their respective age-matched littermate controls.  
 Together, these data indicate that the global and conditional loss of Ppargc1α in the 
dorsal forebrain do not affect the birth, specification, migration and laminar positioning of cells 
within the neocortex, including the major PN subclasses and in particular the SCPN/CSMN. This 
is in concordance with my expression profile data, as described in section 2.3.2., showing that  
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Figure 2.5. Quantification of distinct PN populations in adult Ppargc1α-/- and Emx1-Cre; 
Ppargc1αfl/fl mice. 
(A – C) Quantification and statistical analysis with two tailed student’s T test on the total 
numbers of these different CTIP2, SATB2 and CUX1 positive PN populations over the motor, 
somatosensory and visual areas did not detect any statistically significant difference between 2-
month-old adult Ppargc1α-/-, Emx1-Cre; Ppargc1αfl/fl and their respective matched littermate 
wild type and Ppargc1αfl/fl control mice. WT refer to wild type mice while KO refer to 
Ppargc1α-/- mutant mice. cWT refer to Ppargc1αfl/fl mutant control mice while cKO refer to 
Emx1-Cre; Ppargc1αfl/fl mutant mice.  
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Figure 2.5. (Continued) 
  72
 
 
 
 
 
 
 
Figure 2.5. (Continued) 
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Figure 2.5. (Continued) 
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Table 2.2. Statistical analysis of the total numbers of distinct PN populations in adult 
Ppargc1α-/- and Emx1-Cre; Ppargc1αfl/fl mice.  
This table summarizes the p values obtained after statistical analysis with two tailed student’s T 
test on the total numbers of distinct CTIP2, SATB2 and CUX1 positive PN over the motor, 
somatosensory and visual areas. No significant values p ≤ 0.05 were obtained. Hence, there is no 
statistically significant difference in these populations between Ppargc1α-/-, Emx1-Cre; 
Ppargc1αfl/fl and their respective matched littermate wild type and Ppargc1αfl/fl control mice.  
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P values (two tailed student’s T test) 
WT and KO 
Motor Somatosensory Visual 
CTIP2 0.996 0.690 0.883 
SATB2 0.0958 0.447 0.774 
CUX1 0.613 0.102 0.971 
 
P values (two tailed student’s T test) 
cWT and cKO 
Motor Somatosensory Visual 
CTIP2 0.993 0.550 0.722 
SATB2 0.304 0.845 0.102 
CUX1 0.242 0.356 0.757 
 
 
 
 
 
Table 2.2. (Continued) 
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Ppargc1α is largely expressed postnatally, after the fate specification and migration of most 
cortical PN have already occurred.  
 In conclusion, these data indicate that global and conditional cell-intrinsic loss of 
Ppargc1α do not cause the obvious neuronal loss that is expected if Ppargc1α is cell-
autonomously important for survival in neurons. Therefore, they demonstrate that Ppargc1α is 
cell-intrinsically not necessary for neuronal survival in the neocortex, and suggest that its 
involvement in neuronal survival is context dependent.  
 
 2.3.4. No enhanced cell death observed in Ppargc1α-/- and Emx1-Cre; Ppargc1αfl/fl 
mice. 
 My hypothesis is that Ppargc1α is cell-autonomously important for neuronal and/or 
SCPN-selective survival, even in the absence of environmental triggers. If this hypothesis is true, 
I predict that the global and conditional loss of Ppargc1α in the dorsal telencephalon will lead to 
enhanced cell death. To test this, I performed a IHC stain for caspase 3 that identifies apoptotic 
cells (211), and a histological Neurosilver stain that detects degenerating cells and axons (212), 
on adult Ppargc1α-/-, Emx1-Cre; Ppargc1αfl/fl and their respective matched littermate wild type 
and Ppargc1αfl/fl control coronal cortical sections at 2 months of age (n = 3 per genotype). I 
performed the same stains on P7 C57Bl/6 wild type and Neurosilver control coronal sections that 
acted as positive controls. While I found caspase 3 positive cells and silver stained cells on the 
positive controls, I did not observe any obvious or significant difference in the number of 
caspase 3-positive cells or silver-stained cells or axons between Ppargc1α-/-, Emx1-Cre; 
Ppargc1αfl/fl and their respective control mice (Figures 2.6.A. to 2.6.E., data not shown for 
caspase 3). This indicates that there is no enhanced cell death in both Ppargc1α-/- and Emx1-Cre;  
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Figure 2.6. No enhanced cell death observed in Ppargc1α-/- and Emx1-Cre; Ppargc1αfl/fl mice. 
(A – E) Neurosilver staining did not detect any dark silver stained cells that are dying in the 
neocortices of 2 month old adult (A) wild type, (B) Ppargc1α-/-, (C) Ppargc1αfl/fl and (D) Emx1-
Cre; Ppargc1αfl/fl mice. Degenerating dark silver stained cells (arrows) were found in the 
accompanying adult rat positive control. Similar results were obtained with immunostaining for 
caspase 3 (data not shown). Scale bars, 100 μm (A – E). 
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Figure 2.6. (Continued) 
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Ppargc1αfl/fl mice, as compared to their respective control mice. Thus, these data reveal that 
global and conditional cell-intrinsic loss of Ppargc1α do not cause enhanced cell death in the 
neocortex, demonstrating that Ppargc1α is not cell-intrinsically required for neuronal survival in 
the neocortex. This conclusion is further supported by my outcomes in section 2.3.3., showing 
that distinct PN subtypes are born, specified and positioned normally in the neocortex. In all, 
these studies, as described in sections 2.3.3. and 2.3.4.,  demonstrate that the developmental 
function of Ppargc1α in the neocortex is not to maintain neuronal survival in the neocortex.  
 Yet, it is important to note that these findings do not contradict previous work that 
implicated Ppargc1α in neuronal survival. In prior studies, the involvement of Ppargc1α in 
neuronal survival is achieved either in the circumstance where toxic substances–like kainic acid 
or MPTP–were administered to induce cell death (72), or in the situation where Ppargc1α null 
mice were crossbred to mice models of neurodegeneration such as the HD knock in mouse 
models with CAG repeats (73). This, together with my results, suggest that Ppargc1α is 
important for survival in the event of acute cellular stress or an unbalanced non-homeostatic 
cellular state, where the lack of Ppargc1α increases the cells’ susceptibility to die. In contrast, 
the cell-autonomous loss of Ppargc1α alone in the context of a balanced cellular homeostatic 
state or during normal development does not cause cell death, showing that Ppargc1α is not 
required to govern neuron and/or SCPN-specific survival. These data are significant in refining 
our current understanding of the developmental role of Ppargc1α in the brain by clarifying that 
its involvement in survival is context dependent in the event of acute cellular stress or 
neurodegeneration. 
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 2.3.5. PN are maintained normally in aged 18 month old Ppargc1α-/- and Emx1-Cre; 
Ppargc1αfl/fl mice.  
 Together with prior work (72-74), my findings, as described in sections 2.3.3. and 2.3.4., 
demonstrate that the developmental function of Ppargc1α is not required for neuronal survival in 
the neocortex, except in the context of cellular stress. These results motivated me to explore 
whether Ppargc1α is important for neuronal survival in the neocortex, in the context of aging. 
Aging is an intricate balance between damage and repair, presents as a complex progression in 
the accrual of molecular damage that affects normal cellular function, and is intricately 
associated with cellular stress response mechanisms that includes mitochondrial oxidative stress 
pathways (213-215). Since aging presents as an accumulated chronic stress state, I hypothesize 
that Ppargc1α plays a cell-autonomous role in SCPN to control neuronal survival in the context 
of aging, where aging is a robust contributory factor that, when combined with the loss of 
Ppargc1α, can cause enhanced cell death. This is the first study that investigates the role of 
Ppargc1α and its contribution to neuronal survival in the neocortex in terms of aging. The study 
is significant as it will illuminate our understanding of whether Ppargc1α plays a different role in 
survival with time or age. If Ppargc1α proves to be only crucial for neuronal survival in aged but 
not young animals, this result will provide insights into Ppargc1α’s role in neural deterioration 
since many neurodegenerative diseases are late-onset and are linked to mitochondrial 
dysfunction (216, 217).  
 If this hypothesis is true, I expect that the loss of Ppargc1α combined with aging, will 
cause neuronal and/or neocortical-specific loss due to increased cell death. To test this 
hypothesis and to investigate whether the global and conditional loss of Ppargc1α in aged mice 
leads to gross cortical abnormalities—particularly layer V defects—in terms of cell numbers, cell 
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size and morphology, I bred Ppargc1α-/-, Emx1-Cre; Ppargc1αfl/fl and their respective matched 
littermate wild type and Ppargc1αfl/fl control mice for 18 months, and performed Nissl staining 
on coronal cortical sections from these aged mice (n = 5 Ppargc1α-/-, n = 4 Emx1-Cre; 
Ppargc1αfl/fl, n = 2 wild type and n = 4 Ppargc1αfl/fl). I compared the gross formation of the six 
distinct cortical layers, the morphology and the size of cells residing in each layer—especially 
those of layer V in Ppargc1α-/- and Emx1-Cre; Ppargc1αfl/fl mutant mice—to that of their 
respective controls. I did not find any obvious, significant difference between aged Ppargc1α-/-, 
Emx1-Cre; Ppargc1αfl/fl and their respective control mice (data not shown). Particularly, distinct 
large somas of SCPN/CSMN in layer V were detected in both aged Ppargc1α-/-, Emx1-Cre; 
Ppargc1αfl/fl and their respective control mice at 18 months of age (data not shown), showing that 
the SCPN/CSMN are maintained normally in aged Ppargc1α-/- and Emx1-Cre; Ppargc1αfl/fl 
mutant mice. These data also indicate that global and conditional loss of Ppargc1α do not cause 
gross cortical anomalies by maintaining cortical cells in the six distinct cortical layers, thereby 
suggesting that Ppargc1α is not cell-intrinsically necessary to maintain cell survival in the 
neocortex, even in the event of aging. 
 To study whether the global and conditional loss of Ppargc1α in the neocortices of aged 
mice cause gross neuronal aberrations, I executed an IHC stain for NeuN—a marker for all 
subtypes of neurons (210) —on aged 18-month-old Ppargc1α-/-, Emx1-Cre; Ppargc1αfl/fl and 
their respective matched littermate wild type and Ppargc1αfl/fl control cortical sections (n = 5 
Ppargc1α-/-, n = 4 Emx1-Cre; Ppargc1αfl/fl, n = 2 wild type and n = 4 Ppargc1αfl/fl). Similarly, I 
did not detect any obvious, significant difference between the NeuN positive neurons located in 
all six different cortical layers between aged Ppargc1α-/- (Figures 2.7.A. and 2.7.B.), Emx1-Cre; 
Ppargc1αfl/fl (Figures 2.7.I. and 2.7.J.), and their respective control mice. Agreeing with my 
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Figure 2.7. PN are maintained normally in aged 18 month old Ppargc1α-/- and Emx1-Cre; 
Ppargc1αfl/fl mice.  
(A – B and I – J) IHC stain for NeuN, a neuron-specific marker, showed that neurons across the 
six cortical layers appear normal and comparable between aged 18 month old Ppargc1α-/- (A – 
B), Emx1-Cre; Ppargc1αfl/fl (I – J) and their respective controls.  
(C – D and K – L) IHC stain for SATB2, which marked all CPN across layers II to VI, revealed 
that CPN are maintained normally in their destined layers in aged 18 month old Ppargc1α-/- (C – 
D), Emx1-Cre; Ppargc1αfl/fl (K – L) and their respective controls.  
(E – F and M – N) In agreement with results shown in C – D and K – L, immunostaining for 
CUX1, that labeled CPN in upper layers II/III-IV, indicated that CPN are maintained normally in 
their destined layers in aged 18 month old Ppargc1α-/- (E – F), Emx1-Cre; Ppargc1αfl/fl (M – N) 
and their respective controls.  
(G – H and O – P) ISH for Fezf2, which marked all SCPN/CSMN in deep layer V at high levels 
and CThPN in deep layer VI at lower levels, showed that SCPN and CThPN are maintained 
normally in their destined layers in aged 18 month old Ppargc1α-/- (G – H), Emx1-Cre; 
Ppargc1αfl/fl (O – P) and their respective controls. Roman numerals indicate the distinct cortical 
layers. Scale bars, 100 μm (A – P). 
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Figure 2.7. (Continued) 
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above findings, this shows that neurons are maintained normally in aged Ppargc1α-/- and Emx1-
Cre; Ppargc1αfl/fl mice. Hence, these data indicate that global and conditional loss of Ppargc1α 
combined with aging, do not cause gross significant neuronal loss in the neocortex, implying that 
Ppargc1α is cell-autonomously not required for neuronal survival in the neocortex, even in the 
event of aging caused by cellular stress. 
 To determine whether the global and conditional loss of Ppargc1α in aged mice leads to 
abnormalities in different PN populations, I stained for markers specific to various subclasses on 
aged 18-month-old Ppargc1α-/-, Emx1-Cre; Ppargc1αfl/fl and their respective matched littermate 
wild type and Ppargc1αfl/fl control cortical sections (n = 5 Ppargc1α-/-, n = 4 Emx1-Cre;  
Ppargc1αfl/fl, n = 2 wild type and n = 4 Ppargc1αfl/fl). Markers included CUX1 for CPN in upper 
layers II/III-IV (1, 200), SATB2 for CPN in upper layers II/III-IV and deep layers V/VI (34, 35). 
I did not find any significant difference in the overall distribution of CUX1 positive and SATB2 
positive CPN across all cortical layers between aged Ppargc1α-/- (Figures 2.7.C. to 2.7.F.), 
Emx1-Cre; Ppargc1αfl/fl (Figures 2.7.K. to 2.7.N.), and their respective control mice. Moreover, I 
performed ISH for Fezf2, which labels all SCPN/CSMN in deep layer V at high levels and 
CThPN in deep layer VI at lower levels (6), on aged 18 month old Ppargc1α-/-, Emx1-Cre; 
Ppargc1αfl/fl and their respective littermate control coronal cortical sections (n = 4 Ppargc1α-/-, n 
= 4 Emx1-Cre; Ppargc1αfl/fl, n = 1 wild type, and n = 4 Ppargc1αfl/fl mice). Similarly, I 
discovered that the distribution of layer V and VI corticofugal PN is comparable between aged 
Ppargc1α-/- (Figures 2.7.G. and 2.7.H.), Emx1-Cre; Ppargc1αfl/fl (Figures 2.7.O. and 2.7.P.) and 
their respective control mice. Thus, these data show that the PN subpopulations of upper layers 
II/III-IV and deep layer V/VI are maintained normally in aged 18-month-old Ppargc1α-/- and 
Emx1-Cre; Ppargc1αfl/fl mice. Together, these data demonstrate that global and conditional cell-
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intrinsic loss of Ppargc1α in the neocortex, in combination with cellular stress caused by aging, 
do not cause obvious neuronal loss. They also show that global and conditional loss of Ppargc1α, 
in conjunction with aging, do not affect the maintenance of cortical cells—particularly distinct 
PN classes such as SCPN/CSMN—within the neocortex in terms of their laminar positioning and 
numbers. Thus, these data suggest that Ppargc1α is not cell-intrinsically required for neuronal 
survival in the neocortex, even in the context of aging. 
  
 2.3.6. No enhanced cell death observed in aged 18 month old Ppargc1α-/- and Emx1-
Cre; Ppargc1αfl/fl mice. 
 My hypothesis is that Ppargc1α is cell-autonomously important for neuronal and/or 
SCPN-selective survival in the neocortex, in the presence of cellular stress caused by aging. If 
this hypothesis is true, I predict that the global loss of Ppargc1α will lead to increased cell death. 
To test this, I performed an IHC stain for caspase 3 that identifies apoptotic cells (211) and a 
histological Neurosilver stain that detects degenerating cells and axons (212) on aged 18-month-
old Ppargc1α-/-, Emx1-Cre; Ppargc1αfl/fl and their respective matched littermate wild type and 
Ppargc1αfl/fl control cortical sections (n = 5 Ppargc1α-/-, n = 4 Emx1-Cre; Ppargc1αfl/fl, n = 2 
wild type and n = 4 Ppargc1αfl/fl), as well as on P7 C57Bl/6 wild type and Neurosilver control 
coronal sections that acted as positive controls. Surprisingly, I did not detect any obvious or 
significant difference in the number of caspase 3-positive cells or silver-stained cells between 
aged 18-month-old Ppargc1α-/-, Emx1-Cre; Ppargc1αfl/fl and their respective control mice 
(Figures 2.8.A. to 2.8.E., data not shown for caspase 3). These data indicate that there is no 
enhanced cell death in aged 18-month-old Ppargc1α-/- and Emx1-Cre; Ppargc1αfl/fl mice, as 
compared to their respective control mice. Therefore, global and conditional loss of Ppargc1α in 
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Figure 2.8. No enhanced cell death observed in aged 18 month old Ppargc1α-/- and Emx1-
Cre; Ppargc1αfl/fl mice. 
(A – E) Neurosilver staining did not detect any dying dark silver stained cells in the neocortices 
of aged 18 month old adult (A) wild type, (B) Ppargc1α-/-, (C) Ppargc1αfl/fl and (D) Emx1-Cre; 
Ppargc1αfl/fl mice. Degenerating dark silver stained cells (arrows) were found in the 
accompanying adult rat positive control. Similar results were obtained with immunostaining for 
caspase 3 (data not shown). Scale bars, 100 μm (A – E). 
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Figure 2.8. (Continued) 
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SCPN, in conjunction with a state of cellular stress caused by aging, do not cause enhanced cell 
death. This indicates that Ppargc1α is cell-autonomously not necessary for cell survival in the 
neocortex, even in response to cellular aging. This conclusion is further supported by my 
findings in section 2.3.5., which show that distinct PN subpopulations are maintained normally 
in the neocortex with no observable neuronal loss. Together, these studies as shown in sections 
2.3.5. and 2.3.6., demonstrate for the first time that the developmental function of Ppargc1α is 
not to govern neuronal survival in the neocortex, even in the context of cellular aging as a stress 
factor. These outcomes seek to refine our current comprehension of Ppargc1α’s function in 
neural development of the dorsal telencephalon, specifically its role in neuronal survival, or 
conversely, neural degeneration. 
 
 2.3.7. Loss-of-function analysis: spongiform-like lesions are localized to axonal 
bundles of the IC and persist with age in Ppargc1α-/- mice, even to 18 months of age.  
 Previous reports have briefly described that Ppargc1α-/- mice develop spongiform lesions 
in the striatum and deep cortical layer V/VI (62, 63). To determine the exact localization of these 
lesions and the time course of their appearance, I examined brightfield images of Ppargc1α-/- and 
matched wild type littermate coronal cortical sections in PBS at various stages of postnatal 
development, namely P14, P28, 2 months, 3 months, 6 months and 18 months of age (n = 3 per 
genotype for all ages except n = 2 wild type and n = 5 Ppargc1α-/- mice at 18 months of age). 
While spongiform lesions in the mutant striatum were not found at P14, I detected distinct 
lesions in the striatum of Ppargc1α-/- mice at P28, 2 months, 3 months, 6 months, and 18 months, 
as compared to the wild type controls (data not shown). Fiber bundles of the IC of Ppargc1α-/- 
mice also appeared to be smaller in diameter and partially defasciculated (Figures 2.9.E and 
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Figure 2.9. Brightfield analysis showed that lesions are closely associated with or localized 
within the IC along the anteroposterior axis in Ppargc1α-/- mice.  
(A – F) Brightfield analysis in phosphate buffer saline (PBS) showed that lesions developed in 
close association with or within the anterior part of the IC (red arrows) of P28 Ppargc1α-/- mice 
(D – F), as compared to wild type controls (A – C). (B – C and E – F) Boxed areas in (A) and 
(D) respectively.  
(G – L) Similarly, brightfield analysis in PBS showed that lesions developed in close association 
with or within the posterior part of the IC (red arrows) of P28 Ppargc1α-/- mice (J – L), as 
compared to wild type controls (G – I). (H – I and K – L) Boxed areas in (G) and (J) respectively. 
Scale bars, 100 µm (A – B, D – E, G – H and J – K), 10 µm (C, F, I and L). 
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Figure 2.9. (Continued) 
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2.9.F.). Strikingly, high magnification analysis of the striatum revealed that these lesions (red 
arrows) are in close association with, or are exactly localized within, the fiber tracts of the IC—
the pathways taken by SCPN/CSMN efferent axons among others (20, 21) (Figure 2.9.F.). 
Anteroposterior analysis demonstrated that these lesions (red arrows) are found at both anterior 
(Figure 2.9.F.) and posterior positions in the IC (Figure 2.9.L.). Mediolateral and dorsoventral 
analysis did not detect any evident arealization of these lesions within the IC (Figures 2.9.E. and  
2.9.K.). These data also indicate that these lesions develop by P28 and persist with age into 
adulthood and even old age. Comparative analysis between the various ages also showed that the 
severity of these lesions is maintained from P28 to 6 months of age but appeared to decrease by 
18 months of age when lesions are fewer, smaller and are located at more anterior positions of 
the IC (data not shown). Hence, temporal and spatial analysis showed that these spongiform-like 
lesions develop within the axonal bundles of the IC along the rostrocaudal axis, are not arealized 
along the mediolateral and dorsoventral axes, are absent at P14 but are formed by P28 and persist 
throughout adulthood and old age. 
 To better delineate the position of the lesions, I defined the limits of the fiber bundles of 
the IC by staining for Myelin Basic Protein (MBP)—a protein found within the myelin sheath 
that surrounds the axonal fibers (112)—on Ppargc1α-/- and matched wild type littermate coronal 
cortical sections at P14, P28, 2 months, 3 months, 6 months and 18 months of age (n = 3 per 
genotype for all ages except n = 2 wild type and n = 5 Ppargc1α-/- mice at 18 months of age). 
Confirming my initial finding, I detected that the lesions (red arrows) in Ppargc1α-/- mice are 
closely associated with, or are even within, the IC at both anterior (Figures 2.10.E. and 2.10.F.) 
and posterior positions (Figures 2.10.K. and 2.10.L.). I also found that they are not spatially 
arealized along the mediolateral and dorsoventral axes (data not shown). I further ascertained  
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Figure 2.10. Immunostaining showed that lesions are closely associated with or localized 
within axonal bundles of the IC along the anteroposterior axis in Ppargc1α-/- mice.  
(A – F) Immunohistochemistry analysis for Myelin Basic Protein showed that lesions developed 
in close association with or within the anterior part of the IC (red arrows) of P28 Ppargc1α-/- 
mice (D – F), as compared to wild type controls (A – C). (B – C and E – F) Boxed areas in (A) 
and (D) respectively.  
(G – L) Similarly, immunostaining for myelin basic protein showed that lesions developed in 
close association with or within the posterior part of the IC (red arrows) of P28 Ppargc1α-/- mice 
(J – L), as compared to wild type controls (G – I). (H – I and K – L) Boxed areas in (G) and (J) 
respectively.  
(M – N) Immunohistochemistry for Neurofilament, a neuronal marker, further ascertained that 
the spongiform-like lesions are closely associated with or localized within axonal fibers of the IC 
(red arrows). Scale bars, 100 µm (A, D, G and J), 10 µm (B – C, E – F, H – I, K – L and M – N). 
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that these lesions in the IC are not present at P14 but develop by P28 and are maintained 
throughout adulthood and old age at 18 months (Figures 2.10.C. and 2.10.D.). Similar 
comparative analysis between various ages also verified my finding that the severity of these 
lesions is maintained from P28 to 6 months of age (Figures 2.11.C. and 2.11.D.) but appeared to 
decrease by 18 months of age when lesions are fewer, smaller and are located at more anterior 
positions of the IC (data not shown). 
  To further validate that these lesions are associated with the axonal bundles of the IC, I 
delineated the axonal bundles of the IC by staining for another marker NEUROFILAMENT, a 
protein that is found within axonal fibers (218), on Ppargc1α-/- and matched wild type littermate 
cortical sections at P28 (n = 3 per genotype). Confirming my results, I found that the lesions are 
in close association with, or are exactly localized within, the fiber tracts of the IC (red arrows) at 
both anterior (Figure 2.10.N.) and posterior regions (data not shown). I also discovered that these 
lesions are NEUROFILAMENT negative (red arrows), indicating that they are devoid of axon 
fibers (Figure 2.10.N.).   
 Expanding on published observations (62, 63), my new data is the first long-term 
descriptive study illustrating the exact location and developmental time course of these 
spongiform-like lesions in the striatum due to the global loss of Ppargc1α. They revealed that 
these lesions in the caudate putamen are closely associated with, or are exactly localized within, 
axonal bundles of the IC along the rostrocaudal axis, without evident arealization along the 
mediolateral and dorsoventral axes. My data also demonstrated that these lesions are not formed 
at P14 but develop by P28 and persist throughout adulthood and even old age. Since global loss 
of Ppargc1α causes lesions to develop within the IC, I conclude that Ppargc1α is cell-
autonomously necessary to prevent the formation of these spongiform-like lesions.  
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Figure 2.11. Spongiform-like lesions in Ppargc1α-/- mice develop by P28 and persist with 
age through adulthood and even old age of 18 months.  
(A – D) Spongiform-like lesions are not found at P14 (data not shown) but are formed at P28 
(red arrows), 2 months (data not shown), 3 months (data not shown), 6 months (red arrows) and 
even to the old age of 18 months (data not shown) in Ppargc1α-/- mice (C – D), as compared to 
wild type controls (A – B). High magnification of a representative lesion is shown in C’ and D’ 
at P28 and 6 months respectively. Scale bars, 50 µm (A – D), 10 µm (C’ and D’). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  97
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.11. (Continued) 
  98
 2.3.8. Loss-of-function analysis: smaller and much fewer spongiform-like lesions 
develop in the IC of adult CamkIIα-Cre; Ppargc1αfl/fl mice.  
 A recent report by Ma et al. showed that neuronal loss of Ppargc1α causes the formation 
of spongiform-like lesions in the striatum, albeit the lesions are smaller and fewer in numbers 
(219). This supports a role for Ppargc1α in neurons, indicating that it is required in neurons to 
control the development of these lesions. To ascertain their finding, I performed brightfield and 
MBP immunostaining analysis on 4-month-old CamkIIα-Cre; Ppargc1αfl/fl and matched 
Ppargc1αfl/fl littermate control cortical sections (n = 3 animals per genotype) (a gift from 
Professor Jiandie D. Lin, University of Michigan). I confirmed their finding and detected lesions 
in the IC in CamkIIα-Cre; Ppargc1αfl/fl mice, as compared to matched Ppargc1αfl/fl littermate 
controls (Figure 2.12.B.). Notably, these lesions are significantly less severe as compared to the 
Ppargc1α-/- mutants; the lesions are much smaller in size or diameter and much fewer in 
numbers (Figures 2.12.B., 2.10.E, 2.10.F., 2.11.C. and 2.11.D.). Anteroposterior, mediolateral 
and dorsoventral analysis did not unveil any evident arealization (data not shown). In all, these 
data show that neuronal loss of Ppargc1α causes the formation of smaller and fewer spongiform 
lesions localized to the IC in the striatum with no apparent spatial arealization, indicating that 
neuron-specific Ppargc1α is partly responsible for the formation of these IC localized lesions. 
Thus, Ppargc1α is cell-intrinsically required in neurons to govern the development of these 
lesions, making it clinically relevant to identify the neuronal subclass from which these lesions 
originate in order to identify potential degenerative cell types. These data also suggest that a non-
neuronal, possibly systemic component or a more complex multifactorial mechanism may be 
involved in the formation of these lesions.  
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Figure 2.12. Smaller and much fewer spongiform-like lesions develop in the IC of adult 
CamkIIα-Cre; Ppargc1αfl/fl mice. 
(A – B) Immunohistochemistry analysis for Myelin Basic Protein showed that lesions developed 
in 4 month old adult CamkIIα-Cre; Ppargc1αfl/fl mice (red arrows), as compared to Ppargc1αfl/fl 
controls. These lesions are smaller and much fewer in numbers as compared to that observed in 
Ppargc1α-/- mutants. They are also not spatially arealized along the anteroposterior, mediolateral 
and dorsoventral axes (data not shown). Similar results were obtained with brightfield analysis 
(data not shown). Scale bars, 100 µm (A – D). 
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 2.3.9. Loss-of-function analysis: spongiform-like lesions do not develop in the IC of 
Emx1-Cre; Ppargc1αfl/fl mice, even in aged 18 month old mutants. 
 Since Ppargc1α is expressed specifically in SCPN that project their descending axons 
through the IC (20, 21) where the spongiform-like lesions are localized, I hypothesize that 
Ppargc1α plays a cell-autonomous role in SCPN to regulate the development of these lesions. To 
test this hypothesis, I generated conditional null mutants for Ppargc1α in the dorsal forebrain and 
employed similar brightfield and immunohistological methodologies, as described above in 
sections 2.3.7. and 2.3.8. to characterize the lesion formation, if any, in these mutants.   
  2.3.9.A. Generation of Emx1-Cre; Ppargc1αfl/fl mice. 
 Since my prior results in section 2.3.2. showed that Ppargc1α is highly expressed in layer 
V SCPN that extend descending axonal projections through the IC to reach subcerebral targets 
(20, 21), and given that Ppargc1α is expressed in cortical and subcortical structures, I crossed a 
loxP-flanked (floxed) Ppargc1α line (63) with an Emx1-Cre line (220) to generate Emx1-
Cre;Ppargc1αfl/fl mutants that are conditionally null for Ppargc1α in the dorsal telencephalon to 
study if cell-autonomous conditional loss of Ppargc1α in the neocortex causes these IC localized 
lesions. I verified the ablation of Ppargc1α in the dorsal telencephalon by using combined ISH 
for Ppargc1α against the deletion region from exon 3 to 5 and immunohistochemistry (IHC) for 
CTIP2, a marker of SCPN. I found that Ppargc1α is not expressed in layer V CTIP2 positive 
SCPN in Emx1-Cre; Ppargc1αfl/fl mutants (Figure 2.13.F.), as compared to control Ppargc1αfl/fl 
mice (Figure 2.13.C.), indicating that there is loss of Ppargc1α in SCPN in Emx1-Cre; 
Ppargc1αfl/fl mutants. In agreement with the fact that Emx1 is not expressed in the ventral 
telencephalon, Ppargc1α expression remains unchanged in smaller scattered cells across the 
neocortex of Emx1-Cre; Ppargc1αfl/fl mutants (Figure 2.13.E.), likely representing Parvalbumin  
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Figure 2.13. Emx1-Cre efficiently excises Ppargc1a in neocortical projection neurons.  
(A and D) ISH for Ppargc1α against the deletion region from exon 3 to 5 showed that Ppargc1α 
is expressed in deep cortical layer V (red arrows) and ventral structures like the lateral globus 
pallidus and reticular thalamic nuclei in 2 month old control Ppargc1αfl/fl mice. In contrast, 
Ppargc1α is absent in deep cortical layer V while its expression is retained in ventral structures 
like the lateral globus pallidus and reticular thalamic nuclei in 2 month old Emx1-Cre; 
Ppargc1αfl/fl conditional null mutants.  
(B and E) High magnification analysis of boxed area in (A) and (D) respectively.  
(C and F) Combined ISH for Ppargc1α (exon 2 – 5) and CTIP2, a marker for layer V SCPN, 
revealed that Ppargc1α is expressed in CTIP2-positive SCPN in control Ppargc1αfl/fl mice but 
not in Emx1-Cre; Ppargc1αfl/fl conditional null mutants. Ctx, cortex; Str, striatum; Hip, 
hippocampus; Rt, reticular thalamic nuclei; LGP, lateral globus pallidus. Scale bars, 100 µm (A 
– B and D – E) and 10 µm (C and F). 
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expressing GABAergic or other cortical interneurons that have migrated from the ventral 
forebrain to the cortex during embryonic development (94, 97). Its expression is also retained in 
ventral brain structures, such as the lateral globus pallidus and reticular thalamic nuclei, of 
Emx1-Cre; Ppargc1αfl/fl and Ppargc1αfl/fl mice (Figures 2.13.A. and 2.13.D.). Therefore, the 
generation of Emx1-Cre; Ppargc1αfl/fl mice provide me with the best possible model with current 
techniques to look at the specific loss of Ppargc1α in the neocortex and enable me to investigate 
whether Ppargc1α is cell-intrinsically required in SCPN to control the formation of spongiform 
lesions in the IC through which descending axonal projections of SCPN extend. 
  2.3.9.B. Temporal and spatial analysis of spongiform lesions in Emx1-Cre; 
Ppargc1αfl/fl mice from P28 to 18 months of age. 
 To test my hypothesis by elucidating whether cell-autonomous loss of Ppargc1α in 
SCPN causes these lesions and to determine the time course of these lesions, if any, in the 
striatum, I repeated similar brightfield and MBP immunostaining analysis on P28, 2 month, 3 
month, 6 month and 18 month old Emx1-Cre; Ppargc1αfl/fl and matched Ppargc1αfl/fl littermate 
control cortical sections (n = 3 animals per genotype for all ages). Interestingly, I did not find 
clear IC localized lesions in the Emx1-Cre; Ppargc1αfl/fl mice at all ages investigated (Figures 
2.14.A. to 2.14.H., data not shown for 2-month-old mutants). However, I did detect occasional 
small vacuolar lesions (yellow arrows) in the IC of a subset of the conditional mutants examined 
(Figures 2.14.E. and 2.14.F.) (n = 2 for P28 and n = 1 for 3-month-old Emx1-Cre; Ppargc1αfl/fl 
mutants). Comparative temporal analysis across all ages revealed that these lesions are not 
formed, even in 18-month-old mutants, indicating that these lesions are not delayed in their 
formation. In all, these data demonstrate that the formation of spongiform lesions in the IC is 
largely not dependent on the specific ablation of Ppargc1α in the dorsal forebrain, and show that 
  105
Figure 2.14. Spongiform-like lesions do not develop in the IC of Emx1-Cre; Ppargc1αfl/fl 
mice, even in 18 month old mutants. 
(A – H) Immunostaining against myelin basic protein demonstrated that lesions do not develop 
within the axonal bundles of the IC of Emx1-Cre; Ppargc1αfl/fl conditional null mutants, as 
compared to control Ppargc1αfl/fl mice at P28 (A and E), 2 months (data not shown), 3 months (B 
and F), 6 months (C and G) and 18 months of age (D and H). Occasional small vacuolar lesions 
(yellow arrows) in the IC of a subset of the conditional mutants examined were detected (n = 2 
for P28 and n = 1 for 3 month old Emx1-Cre; Ppargc1αfl/fl mutants). Similar results were 
obtained with brightfield analysis (data not shown). Scale bars, 50 µm (A – H). 
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the lesions observed in the IC of the Ppargc1α null mutants do not affect descending corticofugal 
projections. Hence, I conclude that Ppargc1α is not cell-autonomously necessary in SCPN to 
regulate the development of these lesions.  
 
 2.3.10. Loss-of-function analysis: spongiform-like lesions do not develop in the IC of 
adult Gbx2-CreER; Ppargc1αfl/fl mice. 
 Besides its expression in SCPN, given that Ppargc1α is also expressed in certain TCPN 
populations that project their ascending axons through the IC (20, 21) where the spongiform-like 
lesions are localized, I hypothesize that Ppargc1α plays a cell-intrinsic role in TCPN to govern 
lesion formation. To test this hypothesis, I generated conditional null mutants for Ppargc1α in 
the thalamus and used similar brightfield and immunohistological methods, as described above 
in sections 2.3.7. to 2.3.9. to characterize lesion formation, if any, in these mutants. 
  2.3.10.A. Generation of Gbx2-CreER; Ppargc1αfl/fl mice. 
 Since TCPN extend ascending axonal projections through the IC to reach cortical targets 
(20, 21), I crossed a loxP-flanked (floxed) Ppargc1α line (63) with an Gbx2-CreER line (221) to 
generate Gbx2-CreER; Ppargc1αfl/fl mutants that are conditionally null for Ppargc1α in the 
thalamus to investigate whether cell-autonomous loss of Ppargc1α in TCPN causes these IC 
localized lesions. The generation of Gbx2-CreER; Ppargc1αfl/fl mice provide me with an 
exemplary model to look at the selective loss of Ppargc1α in the thalamus and allow me to 
investigate whether Ppargc1α is cell-intrinsically required in TCPN to control lesions 
development in the IC where ascending axonal projections of TCPN extend through.  
  2.3.9.B. Temporal and spatial analysis of spongiform lesions in Gbx2-CreER; 
Ppargc1αfl/fl  mice from P28 to 2 months of age. 
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 To test my hypothesis by determining whether cell-autonomous loss of Ppargc1α in 
TCPN causes these lesions and to determine the time course of these lesions, if any, in the 
striatum, I repeated similar brightfield and MBP immunostaining analysis on P28 and 2-month-
old Gbx2-CreER; Ppargc1αfl/fl and matched Ppargc1αfl/fl littermate control cortical sections (n = 
2 animals per genotype at P28, n = 1 Ppargc1αfl/fl and n = 3 Gbx2-CreER; Ppargc1αfl/fl at 2 
months of age). Surprisingly, I did not detect clear IC localized lesions in the striatum of Gbx2-
CreER; Ppargc1αfl/fl and Ppargc1αfl/fl mice at these ages (Figures 2.15.A. and 2.15.B.). These 
data suggest that the formation of spongiform lesions in the IC is largely not dependent on the 
specific ablation of Ppargc1α in the thalamus, and further imply that the lesions observed in the 
IC of the Ppargc1α null mutants do not affect ascending afferent projections.   
 To confirm that the absence of spongiform lesions in the internal capsule of adult Gbx2-
CreER; Ppargc1αfl/fl mice occurred despite the loss of Ppargc1α in the thalamus, I performed 
ISH for Ppargc1α against the deletion region of exon 3 to 5 in all of the Gbx2-CreER; 
Ppargc1αfl/fl and matched Ppargc1αfl/fl littermate mutants under investigation. For a subset of 
mutants, the ISH procedure did not work (2 animals per genotype at P28, n = 1 Ppargc1αfl/fl and 
n = 3 Gbx2-CreER; Ppargc1αfl/fl at 2 months of age) (data not shown). Hence, it remains 
inconclusive whether the formation of spongiform lesions in the IC is dependent or not on the 
specific ablation of Ppargc1α in the thalamus. For another subset of mutants, I detected 
Ppargc1α expression in the thalamus in both Gbx2-CreER; Ppargc1αfl/fl and matched 
Ppargc1αfl/fl littermate mice (n = 1 animal per genotype at P28 and 2 months of age) (Figure 
2.16.A. and 2.16.B., data not shown for P28). Thus, for these mutants, the lack of spongiform 
lesion formation may be attributed to the incomplete ablation of Ppargc1α in the thalamus. To 
conclude definitively, in the future, these data would need to be further verified with analysis of  
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Figure 2.15. Spongiform-like lesions do not develop in the IC of adult Gbx2-CreER; 
Ppargc1αfl/fl mice. 
(A – B) Immunostaining against myelin basic protein demonstrated that lesions do not develop 
within the axonal bundles of the IC of Gbx2-CreER; Ppargc1αfl/fl conditional null mutants, as 
compared to control Ppargc1αfl/fl mice, at P28 (data not shown) and 2 months. Similar results 
were obtained with brightfield analysis (data not shown). Scale bars, 50 µm (A – B). 
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Figure 2.16. Ppargc1α expression in Gbx2-CreER; Ppargc1αfl/fl mutants.  
(A – B) For a subset of mutants, I detected Ppargc1α expression in the thalamus in both Gbx2-
CreER; Ppargc1αfl/fl and matched Ppargc1αfl/fl littermate mice (n = 1 animal per genotype at P28 
and 2 months of age) (data not shown for P28). Thus, for these mutants, the lack of spongiform 
lesion formation is attributed to the incomplete ablation of Ppargc1α in the thalamus. For 
another subset of mutants, multiple ISH analyses failed where the procedure did not work (i.e. 
control wild type sections did not show any Ppargc1α expression in the cortex despite of 
repeated ISH attempts) (2 animals per genotype at P28, n = 1 Ppargc1αfl/fl and n = 3 Gbx2-
CreER; Ppargc1αfl/fl at 2 months of age) (data not shown). Hence, it remains inconclusive 
whether the formation of spongiform lesions in the IC is dependent or not on the specific 
ablation of Ppargc1α in the thalamus for these mutants. Scale bars, 100 µm (A – B).  
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Figure 2.16. (Continued) 
  113
additional mutants with clear ISH profiles demonstrating Ppargc1α ablation in the thalamus. 
 
 2.3.11. MBP-positive vacuoles develop in neocortices of Ppargc1α-/- and Emx1-Cre; 
Ppargc1αfl/fl mice.  
 Besides the generation of spongiform-like lesions in the striatum, I also found a hitherto 
undescribed phenomomen of MBP positive circular vacuoles of various sizes in the neocortices 
of Ppargc1α-/- and Emx1-Cre; Ppargc1αfl/fl mice. 
 IHC for MBP—a protein found within the myelin sheath that surrounds the axonal fibers 
(112)—on Ppargc1α-/- and matched wild type littermate coronal cortical sections at P14, P28, 2 
months, 3 months, 6 months and 18 months of age revealed the presence of MBP positive 
vacuoles in the Ppargc1α-/- cortex (n = 3 per genotype for all ages except n = 2 wild type and n = 
5 Ppargc1α-/- mice at 18 months of age). While I did not find vacuoles at P14 (data not shown), I 
found them (red arrows) in Ppargc1α-/- but not in wild type mice at P28, 2 months, 3 months and 
6 months (Figure 2.17.A. – B. and 2.17.E. – F., data not shown for 2 and 3 months). High 
magnification analysis of these vacuoles revealed circular ring structures of various sizes that are 
positive for MBP (Figure 2.17.B’. and 2.17.F’.). Interestingly, I observed that the number of 
vacuoles seemed to decrease with age as Ppargc1α-/- mice had more vacuoles at P28 than at 6 
months (Figure 2.17.B. and 2.17.F.). This observation is also supported by my analysis of 18-
month-old mutants where I did not find any MBP positive vacuoles in their necortices (data not 
shown). This suggests that the vacuolar phenotype “recovers” with age.  
 To determine whether the formation of MBP positive vacuoles is due to the cell-
autonomous loss-of-function of Ppargc1α in the dorsal forebrain, I repeated the analysis on P28, 
2 month, 3 month, 6 month and 18-month-old Emx1-Cre; Ppargc1αfl/fl and matched Ppargc1αfl/fl  
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Figure 2.17. MBP-positive vacuoles develop in the neocortices of Ppargc1α-/- and Emx1-Cre; 
Ppargc1αfl/fl mice.  
(A – D) Immunostaining for MBP on P28 Ppargc1α-/- (B) and Emx1-Cre; Ppargc1αfl/fl (D) 
cortical sections revealed the formation of MBP-positive vacuoles (red arrows) that are absent in 
wild type (A) and Ppargc1αfl/fl (C) controls. (B’, D’, F’ and H’) High magnification images of 
MBP-positive vacuoles in B, D, F and H respectively.  
(E – H) IHC for MBP on 6-month-old Ppargc1α-/- (F) and Emx1-Cre; Ppargc1αfl/fl (H) cortical 
sections revealed the presence of vacuoles (red arrows) but in fewer numbers, as compared to 
that at P28. Scale bars, 50 µm (A – H), 10 µm (B’, D’, F’ and H’). 
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littermate cortical sections (n = 3 animals per genotype). I found similar vacuoles in Emx1-Cre; 
Ppargc1αfl/fl mice but not in Ppargc1αfl/fl controls at all ages up to 6 months of age but not at 18 
months of age (Figure 2.17.C. – D. and 2.17.G. – H., data not shown for 2-month-old and 3-
month-old mutants). High magnification analysis of these vacuoles also revealed circular ring 
structures of various sizes that are positive for MBP (Figure 2.17.D’. and 2.17.H’.). Similarly to 
Ppargc1α-/- mice, I also found that the number of vacuoles in Emx1-Cre; Ppargc1αfl/fl mice 
decrease with age (Figure 2.17.D. and 2.17.H.). In all, these data indicate that the formation of 
vacuoles in the cortex is at least in part caused by the cell-autonomous loss-of-function of 
Ppargc1α in the dorsal telencephalon.  
 These MBP positive vacuoles differ from the spongiform-like lesions found in the 
striatum because (i) they “recover” with age with peak formation at P28 and 2 months before 
decreasing at 3 to 6 months and eventually disappear at 18 months while the spongiform-like 
lesions persist with age from P28 to 18 months, and (ii) they are only revealed with MBP 
staining while the lesions can be observed with both brightfield as well as immunostaining for 
MBP. Hence, I conclude that these MBP positive vacuoles are a distinct phenotype from the 
spongiform-like lesions found in the internal capsule. I also conclude that Ppargc1α in the dorsal 
telencephalon is necessary to generate these MBP positive vacuoles but not IC-localized lesions. 
 
 2.3.12. MBP-positive vacuoles are distributed throughout the neocortex.  
 To determine whether the distribution of the vacuoles corresponds to particular cortical 
layers and possibly affects preferentially selected neuronal populations of the cortex, I imaged 
matched sections of 2-month-old Emx1-Cre; Ppargc1αfl/fl and matched Ppargc1αfl/fl littermate 
controls (n = 3 per genotype, 2 hemispheres per area, for each mouse) and superimposed a red 
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dot in place of every vacuole that I observed in their cortices. I found that the vacuoles are 
distributed throughout the cortex along the anterior-posterior axis, with less vacuoles detectable 
in the upper layers II/III (Figure 2.18.A. – B., 2.18.D. – E. and 2.18.G. – H.). For quantification, 
I superimposed on matched sections boxes of defined width (in three areas) that span the 
thickness of the cortex at matched locations on each section and divided each box into ten 
equally-sized bins, with bin 1 located nearer to the pia and bin 10 nearer to the corpus callosum. 
Fold differences were determined by dividing the number of vacuoles found in each bin within a 
given area of Emx1-Cre; Ppargc1αfl/fl mice over that found in the littermate control Ppargc1αfl/fl 
mice (Figure 2.18.C., 2.18.F. and 2.18.I.). The statistical analysis is summarized in Table 2.3.. 
Preliminary analysis confirmed my initial finding that the vacuoles are distributed throughout 
layers IV-VI of the cortex, across all areas (Figure 2.18.C., 2.18.F. and 2.18.I.). However, it is 
unclear whether the absence of vacuoles in upper layers II/III (bin 2) is due to their genuine 
absence or the fact that very few axons stain for MBP in these layers, compromising detection. It 
is also possible that I may detect more vacuoles in the deep layers because MBP staining is 
limited in the upper layers and this limition may relate to the hypomyelination defect as 
described in Chapter 3. 
 
 2.3.13. Preliminary electron microscopy analysis reveals limitations in identifying 
MBP-positive vacuoles without a definitive marker.  
 To better define and understand the nature of these MBP-positive vacuoles in the 
neocortex, I performed electron microscopy to visualize these vacuoles at a high resolution. 
Under the electron microscope, myelin is easily identified without the need to immunostain for 
any proteins associated with the myelin sheath. Pilot analysis on P28 Ppargc1α-/- and wild type  
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Figure 2.18. MBP-ppositive vacuoles are distributed throughout the neocortex.  
(A – I) Immunostaining for MBP on 2 month old Ppargc1αfl/fl (A, D, G) and Emx1-Cre; 
Ppargc1αfl/fl (B, E, H) cortical sections showed that the vacuoles (red dots) are distributed 
throughout the cortex. (C, F, I) Vacuoles were quantified in 2 month old Ppargc1αfl/fl and Emx1-
Cre; Ppargc1αfl/fl mice. Fold differences were determined by dividing the number of vacuoles 
found in each bin within a given area of Emx1-Cre; Ppargc1αfl/fl mice over that found in the 
Ppargc1αfl/fl controls. Bin 1 is located nearer to the pia while bin 10 is located nearer to the 
corpus callosum (CC). Primary motor, somatosensory and visual areas were quantified. * p<0.05, 
** p<0.01, two tailed student’s T test. Scale bars, 100 µm (A – H).   
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Table 2.3. Statistical analysis of the fold difference of MBP positive vacuoles between adult 
Emx1-Cre; Ppargc1αfl/fl and Ppargc1αfl/fl mutants.  
This table summarizes the p values obtained after statistical analysis with two tailed student’s T 
test on the fold difference between the number of MBP positive vacuoles spread throughout all 
the cortical layers divided into ten bins from pia to corpus callosum (CC) in 2-month-old 
Ppargc1αfl/fl and Emx1-Cre; Ppargc1αfl/fl mice. Numbers in red represent significant values ≤ 
0.05.  
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P values (two tailed student’s T test) 
 
Motor Somatosensory Visual 
Pia 1 0.181 0.0488 0.0741 
2 0.423 1.00 0.667 
3 0.155 0.318 0.423 
4 0.249 0.270 0.562 
5 0.441 0.0522 0.0832 
6 0.235 0.109 0.00600 
7 0.0669 0.776 0.300 
8 0.0229 0.290 0.210 
9 0.113 0.223 0.141 
CC 10 0.0742 0.312 0.150 
 
 
 
Table 2.3. (Continued) 
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littermate control mice revealed the difficulties in identifying these MBP-positive vacuoles or 
circular structures as cross sections of axons in the neocortex also present themselves as circular 
rings of myelin (n = 1 animal per genotype) (Figure 2.19.A.). Without immunostaining for a 
specific marker that defines these vacuoles, I cannot distinguish with confidence whether a 
circular ring of myelin belongs to an abnormal vacuole or to a normal axon. 
 I have tried to define these vacuoles with markers like prohibitin that have been reported 
to identify neuroaxonal spheroids found in the brain. However, this marker did not identify these 
vacuoles of interest. Hence, the nature of these vacuoles remains elusive and further analyses 
will be limited by the lack of specific markers.  
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Figure 2.19. Preliminary electron microscopy analysis reveals limitations in identifying 
MBP-positive vacuoles without a definitive marker. 
(A – D) Under the electron microscope, myelin is easily identified as dark circular rings (red 
arrows) without the need to immunostain for any proteins associated with the myelin sheath. 
Pilot analysis on P28 Ppargc1α-/- mutant revealed the difficulties in identifying these MBP-
positive vacuoles or circular structures as cross sections of axons in the neocortex also present 
themselves as circular rings of myelin. Scale bars, 2 µm (A – B and D), 10 µm (C).   
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Figure 2.19. (Continued) 
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2.4. Discussion. 
 Previous studies have involved Ppargc1α in neuronal survival, purporting that its 
functional role—by suppressing ROS and protecting against mitochondrial dysfunction—
promotes neuronal survival against oxidative insults (72-74). However, these studies were 
conducted in one of two circumstances: where toxic substances like kainic acid or neurotoxin 
MPTP were administered to induce cell death (72), or where Ppargc1α null mice were crossbred 
to mice models of neurodegeneration such as the HD knock in mouse models with CAG repeats 
(73). Most importantly, in all of these studies, the contribution of Ppargc1α to neuronal survival 
is achieved only in the context of acute cellular stress or concurrent neurodegeneration. Hence, it 
remains unknown whether the developmental function of Ppargc1α is to regulate neuronal 
survival. 
 Focusing on the neocortex, I presented a study that investigates the developmental role of 
Ppargc1α in neuronal survival. I employed genetic null and newly generated conditional null 
mutant mice for Ppargc1α in the neocortex to study whether Ppargc1α is cell-autonomously 
necessary for neuronal and/or SCPN-selective survival in the neocortex. Surprisingly, loss-of-
function analysis showed that in the absence of Ppargc1α alone, there are no gross cortical or 
neuronal abnormalities where distinct PN subtypes are born, specified and positioned normally 
in the neocortex. In addition, cell death analysis further revealed that there is no increased cell 
death caused by global or conditional loss of Ppargc1α in the dorsal forebrain. Hence, my 
findings demonstrate that Ppargc1α is not cell-autonomously required to control neuronal 
survival where there is no concurrent acute cellular stress or neuronal degeneration.  
 These results also motivated me to elucidate whether Ppargc1α is cell-intrinsically 
required for neuronal survival in response to aging as a cellular stress factor. This study is 
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significant because it will allow us to better distinguish Ppargc1α’s role in the neocortex in 
relation to neuronal survival and to determine whether that differs with time or age. To address 
this, I present the first long-term aging study of 18-month-old Ppargc1α null and newly 
generated conditional null mutant mice for Ppargc1α in the dorsal forebrain. Interestingly, I 
discovered similar results in these aged mice where in the absence of Ppargc1α, there are no 
gross cortical or neuronal abnormalities and the main PN subtypes are maintained normally in 
the neocortex. Furthermore, there is no enhanced cell death caused by global or conditional loss 
of Ppargc1α in the dorsal forebrain, even in these 18-month-old mutant mice. Thus, I conclude 
that Ppargc1α is not cell-autonomously necessary to regulate neuronal survival in the neocortex, 
even in the context of cellular stress triggered by aging. 
 Building on prior studies (62, 63), I also report that transcriptional co-activator Ppargc1α 
is required to prevent the generation of spongiform-like lesions in the striatum. I depicted the 
first long-term study describing the exact location, arealization and developmental time course of 
these striatal lesions. My results demonstrated that global ablation of Ppargc1α causes lesions to 
be generated either in close association with, or localized within axonal bundles of the IC, where 
SCPN and TCPN among other neuronal subtypes project through. These lesions are not spatially 
arealized along the anteroposterior, mediolateral and dorsoventral axes. They are also not formed 
at P14 but develop by P28 and persist throughout adulthood and even into old age of 18 months.  
 Besides their position and temporal development, it is important to comprehend the 
cellular origins of these lesions. This will allow us not only to understand possible degenerative 
regions, but more crucially, to elucidate if these lesions affect SCPN axonal extensions that 
project through the IC. To determine this, I first studied the temporal, spatial and cell type 
specific expression profile of Ppargc1α in the brain. My results showed that Ppargc1α is 
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preferentially expressed in layer V SCPN and in certain TCPN populations primarily during 
postnatal ages. They also demonstrated that Ppargc1α is absent in other major PN subtypes such 
as CThPN of deep layer VI and the majority of CPN across all cortical layers as well as in glial 
cells.   
 Since Ppargc1α is preferentially expressed in SCPN and certain thalamic nuclei that 
project through the IC where the spongiform lesions are localized, I investigated whether 
Ppargc1α plays a cell-intrinsic function in SCPN or TCPN to govern the formation of 
spongiform-like lesions in the IC, by generating novel conditional null mutants for Ppargc1α in 
the dorsal telencephalon and thalamus respectively. Strikingly, I found that conditional loss of 
Ppargc1α in the neocortex or thalamus does not cause these lesions in the IC, even in 18-month-
old mutants. This indicates that these lesions are not delayed in their formation and they are 
never formed throughout the lifespan of these mutants. Therefore, as illustrated in Figure 2.20., I 
conclude that Ppargc1α is cell-autonomously not necessary in SCPN or TCPN to cause 
spongiform lesions in the IC. 
 It is possible that striatal neurons may contribute to lesion formation in the IC. However, 
a recent report by Cowell and her group suggests that striatal neurons are predominantly 
unaffected in the Ppargc1α null mutant (96). They explored the transcriptional profile of general 
striatal projection markers (e.g. Gad1, Calb1, Opm), striatal direct pathway markers (e.g. Pdyn, 
Tac1, Drd1a), striatal indirect pathway markers (e.g. Penk1 and Drd2) and striatal interneuron 
markers (e.g. Parvalbumin, Calb2, NPY, Chat and Nos1) in the Ppargc1α null mutant (96). 
Besides the known decrease in Parvalbumin expression, they found that majority of the striatal 
markers remained unchanged in the Ppargc1α null mutant, except for unexpected increases in 
gene expression of general striatal PN markers like Calb1 and Opm, direct pathway markers such 
  131
Figure 2.20. Spongiform lesion formation across multiple mutant models for Ppargc1α in 
the brain.  
(A – E) Representative images of the IC delineated by myelin basic protein staining across wild 
type (A), Ppargc1α-/- (B), Ppargc1αfl/fl (C), Emx1-Cre; Ppargc1αfl/fl (D), Gbx2-CreER; 
Ppargc1αfl/fl (E). Conditional null mutants do not develop the IC localized lesions (red arrows) 
that are observed in the null mutant for Ppargc1α. Schematics above the images show where 
Ppargc1α is expressed (white areas) and where it is ablated (yellow areas). Ctx, cortex; Str, 
striatum; CC, corpus callosum; Hip, hippocampus; Th, thalamus. Scale bars, 50 µm (A – E). 
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Figure 2.20. (Continued) 
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as Pdyn and Tac1, indirect pathway markers like Penk1 and Drd2, as well as interneuron marker 
such as NPY (96). The expression profile of the abovementioned markers in the Ppargc1α null 
mutant are in stark contrast with that of the R6/2 Huntington’s disease mice model where there is 
concurrent degeneration of striatal neurons. In the R6/2 mice, there are significant decreases in 
the gene expression of general striatal PN marker like Gad1, striatal direct pathway marker such 
as Pdyn, striatal indirect pathway markers like Penk1 and Drd2, as well as many interneuron 
markers such as Calb2, NPY, Chat and Nos1(96). These prior results suggest that the striatal 
neurons are relatively normal in the Ppargc1α null mutant and that Ppargc1α do not regulate 
survival without any acute cellular stress. This further supports my results in the neocortex that 
Ppargc1α is not required for neuronal survival in the native cellular state without acute cellular 
stress or in the context of chronic stress caused by aging.  
 My findings show that Ppargc1α is cell-intrinsically not required to govern neuronal 
survival during normal development, either in the lack of acute external environmental stress 
triggers or in the context of cellular stress caused by aging. Together with previous work (72-74), 
my data purport that Ppargc1α is implicated in neuronal survival, but only in the context of an 
unbalanced non-homeostatic cellular state caused by acute cellular stress or neurodegeneration. 
In this case, the absence of Ppargc1α may increase the cells’ susceptibility to die, potentially by 
interfering with the ROS defense system and mitochondrial function, or by thus far unexplored 
mechanisms. It also suggests that the increased cell death observed in previous work is caused by 
possible additive or more complex effects of already innate cell toxicity or death. 
 For future work, it will be interesting to determine other novel downstream effectors 
responsible for Ppargc1α role in neuronal survival in the event of acute cellular stress and 
neurodegeneration. Although mitochondrial genes involved in the ROS defense system have 
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been involved in prior work (72-74), it remains to be determined whether other currently 
unidentified genes are also implicated, and if so, how Ppargc1α controls the expression of these 
genes and the molecular pathways that enable them to be crucial for cell survival. 
 Prior work shows that neuron-specific loss of Ppargc1α causes smaller and fewer 
spongiform-like lesions in the striatum (219). I ascertained these results in section 2.3.3. and 
described in further detail the localization and arealization of these lesions in the neuron-specific 
conditional null mutants for Ppargc1α. These data show that selective loss of Ppargc1α in 
neurons is only partly accountable for the development of IC localized lesions. This shows that 
while Ppargc1α in neurons is necessary to control lesion development, it does so only to a 
certain extent. My above findings show that Ppargc1α alone, in either SCPN or TCPN, is not 
required to control lesion development. Thus, these data in totality suggest that lesion generation 
requires either the concurrent absence of Ppargc1α in SCPN and TCPN, or the specific loss of 
Ppargc1α in a thus far unexamined region like the substantia nigra where Ppargc1α is highly 
expressed, or in the striatum where Ppargc1α is weakly expressed up to P7. I have tested the 
possibility that these lesions may necessitate concurrent loss of Ppargc1α in SCPN and TCPN by 
generating double conditional null mutants for Ppargc1α. Unfortunately, breeding these animals 
has been difficult; four breeding cycles with foster dams over the past eight months did not yield 
any animals with the genotype of interest. Hence, it remains unknown if lesion formation is 
caused by the singular loss of Ppargc1α in a defined neuronal region or by the additive deficit of 
Ppargc1α in multiple neuronal regions. 
 Since my data and others have demonstrated that neuron-selective absence of Ppargc1α 
leads to smaller and fewer lesions (219) as compared to that of the null mutant, there is a non 
neuronal, potentially systemic or a more complex multifactorial mechanism responsible for these 
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lesions. A recent study has shown that Ppargc1α expression in muscles can stimulate the 
production of FNDC5, a precursor that is cleaved and secreted as irisin—a newly identified 
hormone or myokine that can stimulate a broad program of brown adipose tissue development 
(222). Irisin secretion is stimulated by exercise and can lead to improvements in obesity and 
glucose homeostasis (222). However, its function in brain development remains unexplored and 
it remains to be seen whether irisin is involved in the development of spongiform lesions in the 
IC. It will be interesting to determine whether a systemic or secreted component like irisin, or a 
hitherto unidentified molecule leading to a multiplex pathway, is responsible for lesion formation. 
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Chapter 3: 
Neuron-specific Ppargc1α is required to control myelination in the neocortex. 
 
 
 
 
 
Author contribution: I designed all the experiments and interpreted all the data, with the input 
of Professor Paola Arlotta. I performed all in situ hybridizations and majority of the 
colocalization analyses to determine the expression profile of Ppargc1α in the brain (Chapter 2). 
I also ascertained that Ppargc1α expression in SCPN requires Fezf2. Through immuno-staining, 
I studied the neocortical myelination patterns of Ppargc1α null mutants, neuron-specific null 
mutants, as well as newly generated conditional null mutants in the dorsal telencephalon and in 
the thalamus. Together with Travis Hallett, I executed histological and immunohistochemistry 
analyses to demonstrate that projection neurons are normal and that there is no enhanced cell 
death in these mutants (Chapter 3). In addition, I established the method to determine metabolic 
levels in the Ppargc1α conditional null mutants with Kelly Chatman from the Small Molecule 
Mass Spectrometry Facility at Harvard University and advice from Dr. Giulio Srubek Tomassy. 
Travis Hallett characterized the different oligodendrocyte populations in the Ppargc1α 
conditional null mutants while Dr. Simona Lodato performed the in utero electroporation 
experiment. I thank Dr. Giulio Srubek Tomassy for his advice in this project.  
Publication: These data will be published either in conjunction with Chapter 2 and/or Chapter 3.  
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3.1. Abstract. 
 Myelin is a compacted multilayer lipid membrane that sheaths axons and provides 
neurons with electrical insulation in order to increase the conduction velocity and efficient 
propagation of action potentials. The generation of myelin, undertaken by oligodendrocytes in 
the central nervous system, is dependent on a multitude of intrinsic as well as extrinsic factors, 
among which the reciprocal interactions between neurons and oligodendrocytes is an essential 
contributor.  
 Here, I report for the first time that Ppargc1α, a cell-autonomous transcriptional co-
activator in subcerebral projection neurons (SCPN), is necessary for proper myelination of the 
neocortex, a process governed by oligodendrocytes. Employing various genetic null and newly 
generated conditional null mutants for Ppargc1α, I demonstrate that global or conditional loss of 
Ppargc1α in neurons or in the neocortex causes hypomyelination across all cortical layers. Aging 
studies of these null and conditional null mutants at 18 months further reveal that these 
hypomyelination defects are not due to a delay in myelination because they persist with age. 
Moreover, the hypomyelination phenotypes are not caused by gross cortical abnormalities, loss 
of projection neuron subtypes or enhanced cell death. However, overexpression of Ppargc1α did 
not result in ectopic myelination. Initial results of research into the mechanistic action of 
Ppargc1α show that the loss of Ppargc1α leads to decreased neuronal metabolism, suggesting 
that secreted metabolites can act as mediators for neuron-specific Ppargc1α to interact with 
oligodendrocytes to control myelination. Hence, these data indicate that neuron-specific 
Ppargc1α is required for the proper establishment of neocortical myelination, and suggest a 
novel function for Ppargc1α in neuron-to-glia communication to regulate myelination.  
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3.2. Introduction. 
 The myelin sheath provides neurons with electrical insulation. It greatly enhances the 
conduction speed of action potentials and thus enables efficient saltatory propagation of nerve 
impulses over long distances (112, 113). It is produced by Schwann cells in the peripheral 
nervous system (PNS) or by oligodendrocytes in the central nervous system (CNS). It consists of 
consecutive wrapping and subsequent compaction of stacked glial plasma membrane bilayers 
over the neuronal axon (112, 113). In essence, myelin is a lipid-rich membrane that is filled with 
glycosphingolipids and cholesterol. It also has a myriad of proteins such as the myelin basic 
proteins (MBP) and proteolipid proteins (PLP/DM20) (112, 113).  
 In the CNS, the generation of the myelin sheath by oligodendrocytes is temporally and 
spatially controlled. It also crucially depends on a number of cell-intrinsic as well as non-cell-
intrinsic factors (112). Cell-autonomous factors include basic helix – loop – helix transcription 
factor Olig2 (125, 128, 223, 224) and HMG transcription regulator Sox10 (131, 132) that affect 
oligodendrocyte birth, specification and differentiation. Non-cell-autonomous factors include 
hormones like thyroid hormone, growth and trophic factors such as fibroblast growth factor 2 
(FGF-2) and insulin-like growth factor 1 (IGF-1) (112, 113, 139). Interestingly, there is an 
increasing appreciation in the field that neuron-derived factors are important for myelination. 
Notably, reciprocal neuron and glia communication is important for oligodendrocyte 
development as well as proper myelination. This is supported by studies demonstrating that 
neurons can govern oligodendrocyte development by influencing their proliferation, 
differentiation and survival in order to make certain the appropriate ratio of oligodendrocytes to 
axonal surface for myelination (113, 139). Moreover, neuronal axons must be myelinated at the 
correct time during development and not before the neurons are equipped to be myelinated (113, 
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140). On the other hand, oligodendrocytes have to interact with neurons to arrange protein 
complexes at the nodes of Ranvier (113, 141-144) and have been demonstrated to affect axonal 
cytoskeleton and transport (113, 145, 146). Hence, complementary interactions between neurons 
and oligodendrocytes are crucial for oligodendrocyte development and myelination.  
 Neuron-derived molecules, whether secreted or not, are implicated at different stages of 
oligodendrocyte development from proliferation to differentiation. Some known secreted signals 
include platelet-derived growth factor subunit A (PDGF-A), neurotrophin 3 (NT-3), ciliary 
neurotrophic factor (CNTF), FGF-2 and IGF-1 (113, 147-149). PDGF-A is a soluble molecule 
released by both neurons and astrocytes. Loss-of-function experiments have shown that it 
regulates the proliferation and survival of oligodendrocyte progenitors (113, 150-152). Gain-of-
function analyses have demonstrated that PDGF-A overexpression leads to an increase in the 
number of oligodendrocytes (153). Besides secreted factors, non-secreted molecules that can act 
as cell surface receptors such as Jagged 1 (154) and contactin (155) are also involved in neuron-
to-glia signaling. Jagged 1 is a cell surface ligand on neuronal axons that can interact with the 
Notch 1 receptor on oligodendrocytes. Hence, Notch signaling is stimulated in oligodendrocytes 
to inhibit their differentiation (154). Jagged 1 expression also decreases with age, which parallels 
with the onset of myelination (113, 154). Thus, neurons can regulate the timing of 
oligodendrocyte differentiation to affect myelination via molecules like Jagged 1.  
 Besides oligodendrocyte development, neuron-derived signals can also influence 
myelination itself. Studies have shown that neuronal electrical activity is required to induce 
myelination (156). Axonal electrical activity after target innervation may lead to the secretion of 
promyelinating molecules like adenosine (157), and may induce changes in axonal protein 
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expression (158). For instance, polysialated adhesion molecule NCAM on the cell membrane 
may be decreased to enable myelination (159).  
 Although this prior work has enriched our current knowledge about the non-cell-
autonomous neuron-derived factors that affect oligodendrocyte development as well as 
myelination, many molecular pathways and their communication affecting neuron-to-glia 
communication remains unknown. Here, I present data showing that transcriptional co-activator 
Ppargc1α plays a novel role in neurons to affect myelination in the neocortex. I discovered that 
Ppargc1α is exclusively expressed in SCPN but is excluded from oligodendrocyte progenitors as 
well as mature oligodendrocytes of the neocortex. Yet, genetic null and newly generated 
conditional null mutants for Ppargc1α in neurons or in the dorsal telencephalon demonstrate that 
global, neuron- and neocortical-specific loss of Ppargc1α cause hypomyelination across all 
cortical layers. Aging studies of these null and conditional null mutants at 18 months further 
reveal that these hypomyelination defects are not due to a delay in myelination because they 
persist with age. Furthermore, the hypomyelination abnormalities are not due to gross cortical 
anomalies, or loss of PN, or even enhanced cell death. However, gain-of-function analyses show 
that overexpression of Ppargc1α did not induce ectopic myelination. Hence, neuron-specific 
Ppargc1α is cell-autonomously required for proper neocortical myelination.  
 Initial results into the mechanistic action of Ppargc1α reveal that the conditional loss of 
Ppargc1α in the dorsal forebrain leads to decreased neuronal metabolism, suggesting that 
secreted metabolites might act as mediators for neuron-specific Ppargc1α to interact with 
oligodendrocytes to control myelination. In all, this study is the first report describing that 
Ppargc1α acting in neurons of the neocortex can affect myelination.  
 
  141
3.3. Results. 
 3.3.1. Ppargc1α expression in SCPN of layer V requires Fezf2.  
 Since prior work has shown that Fezf2 is a critical transcription factor that is necessary 
and partly sufficient for the specification and differentiation of SCPN (6-9, 37), and that 
Ppargc1α is expressed in SCPN during postnatal development after the early expression of Fezf2, 
as shown in Chapter 2 and described in section 2.3.2.A. and 2.3.2.B., I hypothesize that 
Ppargc1α expression in layer V SCPN requires Fezf2. To test this hypothesis, I mined a new 
microarray dataset established by Simona Lodato and Alyssa Meleski, of our laboratory, in 
which they identified molecular pathways that act downstream of Fezf2 (Lodato et al., 
unpublished). Microarray analysis showed that Ppargc1α mRNA expression is significantly 
upregulated upon Fezf2 overexpression, with greater induction at 24 hours (fold = 2.5, p = 1.17 x 
10-6) than at 48 hours (fold = 1.9, p = 1.54 x 10-3) (Figure 3.1.A.) (Lodato et al., unpublished). 
This indicates that Ppargc1α mRNA is ectopically induced upon Fezf2 overexpression.  
 To determine whether Fezf2 is necessary for Ppargc1α expression in SCPN, I performed 
an ISH for Ppargc1α on P28 tissue from Fezf2-/- and matched wild type littermates (n = 3 
animals per genotype). Strikingly, the expression of Ppargc1α in SCPN is completely lost in 
Fezf2-/- mice, as compared to wild type controls (red arrows) (Figure 3.1.B. to 3.1.E.). In contrast, 
small, scattered cells expressing Ppargc1α, likely representing Parvalbumin-expressing 
interneurons, remain in the neocortex of Fezf2-/- mice, similar to what is observed in wild type 
controls (Figure 3.1.B. to 3.1.E.) (94, 97). This effect is specific because the expression of 
Ppargc1α in other areas of the brain such as the reticular thalamic nuclei is comparable between 
Fezf2-/- and wild type mice (data not shown). Thus, these data indicate that Fezf2 is required 
either directly or indirectly for Ppargc1α expression in SCPN.  
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Figure 3.1. Ppargc1α expression in SCPN of layer V requires Fezf2.  
(A) Microarray analysis by Simona Lodato anad Alyssa Melaski revealed that Ppargc1α mRNA 
expression is significantly upregulated upon Fezf2 overexpression, with greater induction at 24 
hrs (fold = 2.5, p = 1.17 x 10-6) than at 48 hrs (fold = 1.9, p = 1.54 x 10-3). ** represents p value 
≤ 0.01, * represents p value ≤ 0.05. This figure is adapted from Lodato et al., unpublished.  
(B – E) ISH for Ppargc1α showed that Ppargc1α is expressed in SCPN of layer V (red arrows) 
of P28 wild type (B – C) but not in Fezf2-/- mice (D – E). In contrast, small scattered cells 
expressing Ppargc1α, which likely represent Parvalbumin-expressing interneurons, remain in the 
neocortex of wild type and Fezf2-/- mice. (C and E) Boxed areas in (B) and (D) respectively. Ctx, 
cortex; Str, striatum; AC, anterior commissure. Roman numerals indicate the distinct cortical 
layers. Scale bars, 100 μm (B and D), 10 μm (C and E). 
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Figure 3.1. (Continued) 
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 Together with the preferential expression of Ppargc1α in SCPN, as shown in section 
2.3.2., the data suggest that Ppargc1α is a novel downstream target of Fezf2, potentially 
controlling key aspects of SCPN/CSMN development downstream of this critical transcription 
factor, from postnatal stages to adulthood.  
 
 3.3.2. Ppargc1α-/- mice are hypomyelinated across all cortical layers.  
 In the process of analyzing the axonal connectivity of Ppargc1α-/- mice by observing 
Ppargc1α-/- cortical sections in PBS and stained by MBP, as described in Chapter 2, I have 
always observed a seemingly hypomyelinated neocortex in Ppargc1α-/- mice. To confirm my 
observations and better determine whether the global loss of Ppargc1α causes myelination 
abnormalities in the neocortex, and if so, how these anomalies develop with time, I examined 
brightfield images of Ppargc1α-/- and matched wild type littermate coronal cortical sections in 
phosphate buffer saline (PBS) at various stages of development, namely P14, P28, 2 months, 3 
months and 6 months of age (n = 3 per genotype for all ages). I found that the neocortices of 
Ppargc1α-/- mice are hypomyelinated in the deep layers (red arrows) as well as the corpus 
callosum (data not shown), as compared to their wild type counterparts (Figure 3.2.A. and 
3.2.B.). Time course analysis revealed that this hypomyelination aberration is apparent at P14 
and becomes more severe with time, persisting through adulthood of 6 months (Figure 3.2.A and 
3.2.B., data shown for 6 months of age but not for earlier ages). Anteroposterior analysis showed 
that the neocortices of Ppargc1α-/- mutants are hypomyelinated throughout the rostrocaudal axis, 
with a more severe phenotype observed caudally (data not shown). Therefore, these data showed 
that global loss of Ppargc1α results in hypomyelination defects of the neocortex, supporting my 
hypothesis that Ppargc1α is necessary for proper myelination of the neocortex.  
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Figure 3.2. Ppargc1α-/- mice are hypomyelinated across all cortical layers.  
 (A – B) Brightfield analysis in PBS revealed that the neocortices of 6 month old Ppargc1α-/- 
mutant mice are hypomyelinated in the deep layers (red arrows) as well as in the corpus callosum 
(data not shown), as compared to their wild type controls. Time course analysis also showed that 
this hypomyelination aberration is apparent at P14 and become more severe with time, persisting 
through adulthood of 6 months of age (data shown for 6 months of age but not for earlier ages). 
Anteroposterior analysis also demonstrated that the neocortex is hypomyelinated throughout the 
rostrocaudal axis, with a more severe phenotype observed caudally (data not shown). 
(C – F) Immunohistochemistry analysis for Myelin Basic Protein, a protein found within the 
myelin sheath that surrounds the axonal fibers, confirmed the results obtained by brightfield 
analysis, as shown in A and B. Interestingly, the upper layers of Ppargc1α-/- mutant mice are also 
hypomyelinated (red arrows), particularly layer I fibers, as compared to wild type mice. (D and 
F) Boxed areas in (C) and (E) respectively. Scale bars, 100 μm (A – L). 
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 To ascertain my results obtained by brightfield analysis, I defined the myelinated fibers 
of the neocortex by staining for Myelin Basic Protein (MBP)—a protein found within the myelin 
sheath that surrounds the axonal fibers (112)—on Ppargc1α-/- and matched wild type littermate 
coronal cortical sections at P14, P28, 2 months, 3 months and 6 months of age (n = 3 per 
genotype for all ages). Confirming my initial finding, I found that the neocortices of Ppargc1α-/- 
mutant mice are hypomyelinated in the deep layers as well as the corpus callosum (data not 
shown), as compared to their wild type counterparts (Figure 3.2.C. and 3.2.E.). Surprisingly, I 
discovered that the upper layers are also hypomyelinated (red arrows), particularly layer I fibers, 
in the neocortex of Ppargc1α-/- mutant mice, as compared to wild type mice (Figure 3.2.C. to  
3.2.F.). Time course analysis also verified that this hypomyelination abnormality is apparent at 
P14 and become more severe with time, persisting through 6 months of age (data shown for 6 
months of age but not for earlier ages). Anteroposterior analysis further affirmed that the 
neocortex is hypomyelinated throughout the rostrocaudal axis, with a more severe phenotype 
observed caudally (data not shown). Hence, these data demonstrate that global loss of Ppargc1α 
results in hypomyelination anomalies of the neocortex across all cortical layers, supporting my 
hypothesis that Ppargc1α is necessary for establishing the correct neocortical myelination pattern.  
 To ensure that the hypomyelination aberrations are not due to a delay in myelination, I 
performed brightfield analysis as well as immunostaining for MBP on aged Ppargc1α-/- and 
matched wild type littermate coronal cortical sections at 18 months of age (n = 5 Ppargc1α-/-, n = 
2 wild type mice). I found that 18-month-old Ppargc1α-/- mutant mice continue to be 
hypomyelinated in the neocortex, if not more severely hypomyelinated when compared to 
younger mice (data not shown). These data showed that the hypomyelination defect observed is 
not caused by a delay in myelination, thus indicating that the hypomyelination is persistent with 
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age, does not recover with time and develop as early as P14. Therefore, Ppargc1α is necessary 
for proper myelination of the neocortex.  
 In all, my data revealed that global loss of Ppargc1α results in hypomyelination of both 
the upper and deep layers of the neocortex. These results demonstrate that Ppargc1α is necessary 
for establishing the correct myelination pattern of the neocortex.  
 Interestingly, as described in section 2.3.2.B., Ppargc1α is expressed in SCPN and in 
subsets of cortical interneurons but not in the majority of CPN and notably not in 
oligodendrocytes. Yet, global loss of Ppargc1α results in hypomyelination not only of the layers 
where SCPN reside in deep layer V, but also of the upper layers where CPN that do not express 
Ppargc1α are located. Furthermore, Ppargc1α is not expressed in oligodendrocytes but loss of 
Ppargc1α results in an abnormality of myelination, a process exclusively controlled by 
oligodendrocytes. Hence, my results suggest that Ppargc1α plays a novel role in SCPN that is 
important for the maintenance of myelination by oligodendrocytes.  
  
 3.3.3. CamKIIα-Cre; Ppargc1αfl/fl mice are hypomyelinated across all cortical layers.  
 To investigate whether the hypomyelination anomaly seen in Ppargc1α-/- mice is due to 
the specific loss of Ppargc1α in neurons, I examined the myelination pattern of CamKIIα-Cre; 
Ppargc1αfl/fl mice (gift from Professor Jiandie Lin, University of Michigan) by brightfield 
analysis on adult 4-month-old CamKIIα-Cre; Ppargc1αfl/fl and matched Ppargc1αfl/fl littermate 
coronal cortical sections in PBS (n = 3 per genotype). I found a similar hypomyelination 
aberration in CamKIIα-Cre; Ppargc1αfl/fl mice where their neocortices are hypomyelinated in the 
deep layers as well as in the corpus callosum, as compared to the Ppargc1αfl/fl controls (data not 
shown). Anteroposterior analysis also detected that the hypomyelination defect is more severe at 
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posterior regions of the neocortex, as compared to more anterior regions (data not shown). Thus, 
my data demonstrate that neuronal selective loss of Ppargc1α results in a hypomyelinated 
neocortex, indicating that Ppargc1α in neurons is necessary for proper myelination of the 
neocortex. 
 To ascertain my results obtained with brightfield analysis, I delineated the myelinated 
fibers of the neocortex by immunostaining for MBP on adult 4-month-old CamKIIα-Cre; 
Ppargc1αfl/fl and matched Ppargc1αfl/fl littermate coronal cortical sections (n = 3 per genotype). 
Confirming my initial finding, I discovered that the neocortices of CamKIIα-Cre; Ppargc1αfl/fl 
mice are hypomyelinated in the deep layers as well as in the corpus callosum, as compared to 
their Ppargc1αfl/fl counterparts (data not shown). Surprisingly, further analysis revealed that the 
upper layers are also hypomyelinated (red arrows), particularly layer I fibers, in the neocortex of 
CamKIIα-Cre; Ppargc1αfl/fl mice, as compared to Ppargc1αfl/fl controls (Figure 3.3.A. and 
3.3.B.). Anteroposterior analysis further verified that the neocortex is hypomyelinated 
throughout the rostrocaudal axis, with a more severe phenotype observed caudally (data not 
shown). Therefore, these new data demonstrate that neuronal loss of Ppargc1α results in 
hypomyelination abnormalities of the neocortex across all cortical layers, indicating that 
Ppargc1α in neurons is necessary for establishing the correct neocortical myelination pattern.  
 
 3.3.4. Emx1-Cre; Ppargc1αfl/fl mice are hypomyelinated across all cortical layers. 
 To study if the hypomyelination anomaly seen in Ppargc1α-/- mice is due to specific loss 
of Ppargc1α in the dorsal forebrain, and if so, how these aberrations develop with time, I 
examined the myelination pattern of Emx1-Cre; Ppargc1αfl/fl mice by brightfield analysis of 
Emx1-Cre; Ppargc1αfl/fl and matched Ppargc1αfl/fl littermate coronal cortical sections in PBS at  
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Figure 3.3. CamKIIα-Cre; Ppargc1αfl/fl mice are hypomyelinated across all cortical layers. 
(A – B) Immunostaining for Myelin Basic Protein showed that CamKIIα-Cre; Ppargc1αfl/fl 
mutant mice are hypomyelinated in the deep (data not shown) and upper layers (red arrows), 
particularly in layer I fibers, of the neocortex, as compared to Ppargc1αfl/fl controls. 
Anteroposterior analysis also demonstrated that the neocortex is hypomyelinated throughout the 
rostrocaudal axis, with a more severe phenotype observed caudally (data not shown). Dotted 
lines indicate the boundary of the pia. Scale bars, 100 μm (A – B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  151
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. (Continued) 
  152
various stages of development, namely P14, P28, 2 months, 3 months and 6 months of age (n = 3 
per genotype for all ages). Strikingly, I discovered that the neocortices of Emx1-Cre; 
Ppargc1αfl/fl mice are hypomyelinated in the deep layers (red arrows) as well as in the corpus 
callosum (data not shown), as compared to their Ppargc1αfl/fl counterparts (Figure 3.4.A. and 
3.4.B.). Time course analysis also revealed that this hypomyelination defect is apparent at P14 
and becomes more severe with time, persisting through adulthood of 6 months of age (Figure 
3.4.A and 3.4.B., data shown for 6 months of age but not for earlier ages). Anteroposterior 
analysis further detected that the neocortices of Emx1-Cre; Ppargc1αfl/fl mutant mice are 
hypomyelinated throughout the rostrocaudal axis, with a more severe phenotype observed 
caudally (data not shown). Hence, these new data are in agreement with the results obtained with 
Ppargc1α-/- mice, as shown in section 3.3.2.. They demonstrate that preferential loss of 
Ppargc1α in the dorsal telencephalon results in hypomyelination abnormalities of the neocortex, 
thus supporting my hypothesis that neuron-specific Ppargc1α is necessary for establishing the 
proper myelination pattern of the neocortex. 
 To ascertain my findings with brightfield analysis, I defined the myelinated fibers of the 
neocortex by staining MBP on Emx1-Cre; Ppargc1αfl/fl and matched Ppargc1αfl/fl littermate 
coronal cortical sections at P14, P28, 2 months, 3 months and 6 months of age (n = 3 per 
genotype for all ages). Confirming my initial finding, I found that the neocortices of Emx1-Cre; 
Ppargc1αfl/fl mice are hypomyelinated in the deep layers as well as in the corpus callosum, as 
compared to their Ppargc1αfl/fl controls (Figure 3.4.C. and 3.4.E.). Surprisingly, I discovered that 
the upper layers are also hypomyelinated (red arrows), particularly layer I fibers, in the neocortex 
of Emx1-Cre; Ppargc1αfl/fl mutant mice, as compared to Ppargc1αfl/fl mice (Figure 3.4.C. to 
3.4.F.). Time course analysis also verified that this hypomyelination defect is apparent at P14 
  153
Figure 3.4. Emx1-Cre; Ppargc1αfl/fl mice, even aged 18 month old mutants, are 
hypomyelinated across all cortical layers. 
(A – B) Brightfield analysis in PBS revealed that the neocortices of 6 month old Emx1-Cre; 
Ppargc1αfl/fl mutant mice are hypomyelinated in the deep layers (red arrows) as well as in the 
corpus callosum (data not shown), as compared to their Ppargc1αfl/fl controls. Time course 
analysis also showed that this hypomyelination aberration is apparent at P14 and become more 
severe with time, persisting through adulthood of 6 months of age (data shown for 6 months of 
age but not for earlier ages). Anteroposterior analysis demonstrated that the neocortex is 
hypomyelinated throughout the rostrocaudal axis, with a more severe phenotype observed 
caudally (data not shown). 
(C – F) Immunohistochemistry analysis for Myelin Basic Protein – a protein found within the 
myelin sheath that surrounds the axonal fibers, confirmed the results obtained by brightfield 
analysis, as shown in A and B. Interestingly, the upper layers of Emx1-Cre; Ppargc1αfl/fl mutant 
mice are also hypomyelinated (red arrows), particularly the layer I fibers, as compared to 
Ppargc1αfl/fl mice. (D and F) Boxed areas in (C) and (E) respectively.  
(G – L) Brightfield analysis in PBS (G – H) and immunostaining for Myelin Basic Protein (I – L) 
revealed similar if not more severe hypomyelination (red arrows) of the deep and upper layers of 
aged 18 month old Emx1-Cre; Ppargc1αfl/fl mutant mice, as compared to Ppargc1αfl/fl controls. 
These results indicate that the hypomyelination defect observed is not caused by a delay in 
myelination, and that the hypomyelination is persistent with age, does not recover with time and 
develop as early as P14. (J and L) Boxed areas in (I) and (K) respectively. Scale bars, 100 μm (A 
– L). 
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and become more severe with time, persisting throughout adulthood of 6 months of age (data not 
shown). Anteroposterior analysis further determined that the neocortex is hypomyelinated 
throughout the rostrocaudal axis, with a more severe phenotype observed caudally (data not 
shown). Therefore, these data demonstrate that specific loss of Ppargc1α in the dorsal forebrain 
results in hypomyelination anomalies of the neocortex across all cortical layers, indicating that 
neuron-specific Ppargc1α is necessary for correct neocortical myelination.  
 To ensure that the hypomyelination aberrations are not due to a delay in myelination, I 
performed brightfield analysis as well as immunostaining for MBP on aged Emx1-Cre; 
Ppargc1αfl/fl and matched Ppargc1αfl/fl littermate coronal cortical sections at 18 months of age (n 
= 4 per genotype). I discovered that 18-month-old Ppargc1αfl/fl mice continue to be 
hypomyelinated in the neocortex, if not more severely hypomyelinated when compared to 
younger mice (Figure 3.4.G. to 3.4.L.). These data reveal that the hypomyelination abnormalities 
observed are not caused by a delay in myelination, and indicate that the defects are persistent 
with age and do not recover with time and develop as early as P14. Thus, neuron-specific 
Ppargc1α is necessary for establishing proper myelination patterns of the neocortex.  
 In all, my new findings show that neuron-specific loss of Ppargc1α causes 
hypomyelination of the neocortex across all cortical layers. They further demonstrate that 
Ppargc1α is cell-autonomously required by SCPN for establishing the correct neocortical 
myelination pattern. These results are novel because the function of Ppargc1α in the neocortex 
has not been elucidated thus far and notably neuron-specific expression of Ppargc1α affects an 
oligodendrocyte-executed process of myelination in the neocortex. Furthermore, this is the first 
report purporting that Ppargc1α plays a role in neuron glia interactions to affect neocortical 
myelination.  
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 3.3.5. Gbx2-CreER; Ppargc1αfl/fl mice are not hypomyelinated across all cortical 
layers. 
 To investigate whether selective loss of Ppargc1α in TCPN can affect the myelination of 
their afferent axons in the neocortex as they project to cortical layers I and IV through the deep 
cortical layers V/VI (20, 21), I examined the myelination pattern of Gbx2-CreER; Ppargc1αfl/fl 
mice by brightfield analysis of Gbx2-CreER; Ppargc1αfl/fl and matched Ppargc1αfl/fl littermate 
coronal cortical sections in PBS at P28 and 2 months of age (n = 2 animals per genotype at P28, 
n = 1 Ppargc1αfl/fl and n = 3 Gbx2-CreER; Ppargc1αfl/fl at 2 months of age). Surprisingly, I found 
that the neocortices of Gbx2-CreER; Ppargc1αfl/fl mice are myelinated normally in the deep 
layers as well as in the corpus callosum, similar to their Ppargc1αfl/fl controls (data not shown). 
Time course analysis revealed that the myelination patterns of Gbx2-CreER; Ppargc1αfl/fl mice 
are normal at P28 and 2 months of age, comparable to their Ppargc1αfl/fl controls (data not 
shown). Anteroposterior analysis further determined that the neocortices of Gbx2-CreER; 
Ppargc1αfl/fl mice display a normal myelination pattern throughout the rostrocaudal axis (data not 
shown). Hence, these data demonstrate that specific loss of Ppargc1α in the thalamus does not 
affect the myelination pattern of their axons as they innervate the neocortex, indicating that 
Ppargc1α in TCPN is not required for establishing proper myelination patterns of the neocortex. 
These results also support the conclusion in section 3.3.4. that Ppargc1α in neurons is necessary 
to establish a correct neocortical myelination pattern.  
 To ascertain my findings with brightfield analysis, I delineated the myelinated fibers of 
the neocortex by staining MBP on Gbx2-CreER; Ppargc1αfl/fl  and matched Ppargc1αfl/fl 
littermate coronal cortical sections at P28 and 2 months of age (n = 2 animals per genotype at 
P28, n = 1 Ppargc1αfl/fl and n = 3 Gbx2-CreER; Ppargc1αfl/fl at 2 months of age). Confirming my 
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initial finding, I found that the neocortices of Gbx2-CreER; Ppargc1αfl/fl mice are myelinated 
normally in the deep layers as well as in the corpus callosum, similar to their Ppargc1αfl/fl 
counterparts (data not shown.). Moreover, I discovered that the upper layers are also myelinated 
normally, even in layer I fibers, in the neocortex of Gbx2-CreER; Ppargc1αfl/fl mice (Figure 
3.5.A. and 3.5.B.). Time course analysis revealed that the myelination patterns of Gbx2-CreER; 
Ppargc1αfl/fl mice are normal at P28 and 2 months of age, comparable to that of the Ppargc1αfl/fl 
controls (data not shown). Anteroposterior analysis also showed that the neocortices of Gbx2-
CreER; Ppargc1αfl/fl mice display a normal myelination pattern throughout the rostrocaudal axis 
(data not shown). Therefore, these data demonstrate that selective loss of Ppargc1α in the 
thalamus does not affect the myelination pattern of their axons as they innervate the neocortex, 
indicating that Ppargc1α in TCPN is not required for establishing the proper myelination pattern 
of the neocortex. These results further support the conclusion in section 3.3.4. that Ppargc1α in 
neurons of the neocortex is necessary to establish a correct myelination pattern. 
 In all, these new findings revealed not only that specific loss of Ppargc1α in the thalamus 
does not affect the myelination pattern of their axons as they innervate the neocortex, but also 
that it does not cause the hypomyelination defects of the neocortex as observed in the different 
null and conditional null mutants for Ppargc1α as described hitherto. These novel data further 
support my results in section 3.3.5., showing that the hypomyelination aberration seen in the 
neocortex is caused specifically by the loss of Ppargc1α in neocortical neurons. Thus, my loss-
of-function analysis with distinct genetic null and conditional null mice models for Ppargc1α 
indicates that Ppargc1α is cell-autonomously required in SCPN to establish a proper myelination 
pattern in the neocortex.  
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Figure 3.5. Gbx2-CreER; Ppargc1αfl/fl mice are not hypomyelinated across all cortical layers. 
(A – B) Immunostaining for Myelin Basic Protein showed that 2 month old adult Gbx2-CreER; 
Ppargc1αfl/fl mutant mice are myelinated normally in the deep (data not shown) and upper layers, 
particularly in the layer I fibers, of the neocortex as compared to Ppargc1αfl/fl controls. Time 
course and anteroposterior analysis further demonstrated that the neocortex is myelinated 
normally throughout the rostrocaudal axis from P28 and 2 months of age (data not shown). Scale 
bars, 100 μm (A – B). 
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 As shown in Chapter 2, global or selective loss of Ppargc1α in the dorsal forebrain does 
not result in gross cortical abnormalities or observable losses of major PN classes such as SCPN, 
CThPN and CPN (Figure 2.4., Figure 2.5. and Table 2.2.). Moreover, global or exclusive loss of 
Ppargc1α in the dorsal telencephalon does not result in enhanced cell death (Figure 2.6.). Similar 
results were obtained in aged 18-month-old Ppargc1α null and conditional null mutants (Figure 
2.7. and 2.8.). Hence, these data indicate that the hypomyelination defects in the deep and upper 
cortical layers across the distinct null and conditional null mutants for Ppargc1α, as described in 
sections 3.3.2. to 3.3.4., are not due to a loss of neurons or increase in cell death.  
 
 3.3.6. Characterization of oligodendrocytes in Emx1-Cre; Ppargc1αfl/fl mice. 
 Since global or conditional loss of Ppargc1α either in neurons or the dorsal forebrain 
causes hypomyelination in the neocortex across all cortical layers, I hypothesize that the 
hypomyelination is due either to loss, abnormal migration, or anomalous maturation of 
oligodendrocytes. To test this hypothesis, together with Travis Hallet, an undergraduate student 
in the laboratory, I characterized distinct oligodendrocyte progenitors and mature myelinating 
oligodendrocytes by immunostaining for (i) OLIG2, a marker that is expressed in 
oligodendrocyte progenitors as well as mature myelinating oligodendrocytes (205), (ii) PDGFRα, 
a marker that is expressed exclusively in oligodendrocyte progenitors (112, 225-227), and (iii) 
APC, a marker that is expressed only in mature myelinating oligodendrocytes (206, 207), on 2-
month-old adult Emx1-Cre; Ppargc1αfl/fl and matched Ppargc1αfl/fl littermate coronal cortical 
sections (n = 3 animals per genotype). I did not find any qualitative difference in these various 
oligodendrocyte classes between Emx1-Cre; Ppargc1αfl/fl and matched Ppargc1αfl/fl controls 
(Figure 3.6.A. to 3.6.F.). These data show that oligodendrocyte progenitors as well as mature  
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Figure 3.6. Characterization of oligodendrocytes in Emx1-Cre; Ppargc1αfl/fl mice. 
(A – F) Immunostaining for OLIG2 (A – B), a marker that is expressed in oligodendrocyte 
progenitors as well as mature myelinating oligodendrocytes, (ii) PDGFRα (C – D), a marker that 
is expressed exclusively in oligodendrocyte progenitors, and (iii) APC (E – F), a marker that is 
expressed only in mature myelinating oligodendrocytes, revealed no observable difference in 
these distinct oligodendrocyte populations between 2 month old adult Emx1-Cre; Ppargc1αfl/fl 
and matched Ppargc1αfl/fl mutant mice. CC, corpus callosum. Roman numerals indicate the 
distinct cortical layers. Scale bars, 100 μm (A – F). 
(G) Quantification and statistical analysis with two tailed student’s T test on the total numbers of 
these different OLIG2, PDGFRα and APC positive oligodendrocyte populations did not detect 
any statistically significant difference between 2 month old adult Emx1-Cre; Ppargc1αfl/fl and 
matched Ppargc1αfl/fl mutant mice. cKO refer to Emx1-Cre; Ppargc1αfl/fl mutant mice while 
cWT refer to Ppargc1αfl/fl mutant controls. 
(H – J) Quantification and statistical analysis with two tailed student’s T test on the distribution 
of OLIG2 (H), PDGFRα (I) and APC (J) positive oligodendrocyte populations showed that there 
is no significant difference between Emx1-Cre; Ppargc1αfl/fl and matched Ppargc1αfl/fl mutant 
mice with respect to OLIG2 and PDGFRα positive populations. However, there seems to be a 
change in the spread of APC positive oligodendrocytes, where there is an increase in the 
numbers in the upper layers in Emx1-Cre; Ppargc1αfl/fl mutants, as compared to Ppargc1αfl/fl 
controls. ** represents p value ≤ 0.01, * represents p value ≤ 0.05. 
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myelinating oligodendrocytes are born, specified and can migrate despite a specific loss of 
Ppargc1α in the neocortex. They suggest that Ppargc1α in the neocortex is not required for the 
birth, specification and migration of oligodendrocyte progenitors as well as mature myelinating 
oligodendrocytes. This is further supported by the results shown in Chapter 2 where Ppargc1α is 
not expressed in OLIG2 positive oligodendrocyte progenitors and oligodendrocytes as well as 
APC positive myelinating oligodendrocytes. It is also in concordance with data from Chapter 2 
and section 2.3.4. where no enhanced cell death was detected in the neocortices of 2-month-old 
Emx1-Cre; Ppargc1αfl/fl and matched Ppargc1αfl/fl mutant mice. Notably, as described in sections 
3.3.2. to 3.3.4., the mutant Emx1-Cre; Ppargc1αfl/fl neocortex remains myelinated but less so 
than normal, hence it is not surprising that there is no overt loss of oligodendrocytes in these 
mutants. 
 To ascertain these results, we quantified the number of OLIG2, PDGFRα and APC 
positive oligodendrocytes located at a range of depths covering all cortical layers of 2-month-old 
adult Emx1-Cre; Ppargc1αfl/fl and matched Ppargc1αfl/fl mutant mice, and performed 
comparative and statistical analyses with a two-tailed student’s T test on the total numbers as 
well as the distribution of these different oligodendrocyte populations across ten bins from pia to 
just above the corpus callosum. We did not find any significant difference in the total numbers of 
OLIG2 (average total number of OLIG2 positive oligodendrocytes: Ppargc1αfl/fl, 247 ± 65; 
Emx1-Cre; Ppargc1αfl/fl, 286 ± 88; p = 4.01 x 10-1), PDGFRα (average total number of PDGFRα 
positive oligodendrocytes: Ppargc1αfl/fl, 126 ± 21; Emx1-Cre; Ppargc1αfl/fl, 134 ± 16; p = 5.13 x 
10-1) and APC positive oligodendrocytes (average total number of APC positive 
oligodendrocytes: Ppargc1αfl/fl, 193 ± 67; Emx1-Cre; Ppargc1αfl/fl, 252 ± 97; p = 2.46 x 10-1) (n 
= 2 sections per animal, n = 3 animals per genotype) (Figure 3.6.G.). These results support the 
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above qualitative finding and demonstrate that there is no significant difference in the total 
numbers of distinct oligodendrocyte progenitors as well as myelinating oligodendrocytes. Travis 
Hallett is currently confirming these quantifications by analyzing additional sections across more 
animals. Together, these data reveal that oligodendrocyte progenitors as well as mature 
myelinating oligodendrocytes are born, specified and can migrate despite a specific loss of 
Ppargc1α in the dorsal forebrain, indicating that Ppargc1α is not necessary for the birth, 
specification and migration of oligodendrocyte progenitors as well as mature myelinating 
oligodendrocytes. These results also suggest that the hypomyelination defects are due to inherent 
anomalies in the oligodendrocytes’ ability to generate the myelin sheath, and not by a reduction 
in numbers of oligodendrocytes.  
 Interestingly, comparative and statistical analysis of the distribution of distinct 
oligodendrocyte populations across ten bins did not detect significant differences between Emx1-
Cre; Ppargc1αfl/fl and matched Ppargc1αfl/fl mutant mice with respect to OLIG2 and PDGFRα 
positive populations (Figure 3.6.H. and 3.6.I.). These data demonstrate that conditional loss 
Ppargc1α in the dorsal forebrain does not affect the spread of OLIG2 and PDGFRα positive 
oligodendrocyte populations, indicating that Ppargc1α is not required for the distribution of 
OLIG2 positive oligodendrocytes and PDGFRα positive oligodendrocyte progenitors in the 
neocortex. In contrast, there seems to be significantly more APC positive mature myelinating 
oligodendrocytes in the Emx1-Cre; Ppargc1αfl/fl mutants, particularly in the upper layers, as 
compared to Ppargc1αfl/fl control mice (average number of APC positive oligodendrocytes in Bin 
10 closest to pia: Ppargc1αfl/fl, 1.33 ± 0.816; Emx1-Cre; Ppargc1αfl/fl, 5 ± 2.53; p = 7.02 x 10-3; 
average number of APC positive oligodendrocytes in Bin 9: Ppargc1αfl/fl, 5.5 ± 2.95; Emx1-Cre; 
Ppargc1αfl/fl, 9.5 ± 1.52; p = 1.44 x 10-2) (Figure 3.6.J.). Results of the statistical analysis of the 
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distribution of distinct oligodendrocyte populations are presented in Table 3.1.. These data show 
that loss of Ppargc1α leads to a slight increase in the number of APC oligodendrocytes in the 
upper layers, indicating that there is a slight shift in the spread of these oligodendrocytes. This 
change in the distribution of APC positive myelinating oligodendrocytes may be due to a natural 
response mechanism to increase the number of APC positive oligodendrocytes to ameliorate and 
myelinate the cortex back to its normal levels, in response to a loss of Ppargc1α in the neocortex 
and subsequent hypomyelination. This functional compensation is supported by prior work 
showing that when one oligodendrocyte population is ablated by diphtheria toxin, there is a 
functional compensation by the remaining populations where mutant mice display not only have 
a normal complement of myelin and oligodendrocytes but also normal behavior (117). Hence, 
the remaining oligodendrocytes may be in the process of ameliorating the hypomyelination 
defect. Another possibility is that while there is a slight increase in the number of APC positive 
oligodendrocytes, they may be abnormal in generating the myelin sheath, thus accounting for the 
hypomyelination phenotype. Travis Hallett is currently confirming these quantifications by 
analyzing additional sections across more animals.  
 Functional compensation by oligodendrocytes may account for the changes in the 
distribution of oligodendrocyte populations but it may not account for the persistant 
hypomyelination. To this, it is likely that the hypomyelination phenotype, particularly in the 
upper layers, remains a neuronal defect that is persistant with age, regardless of continual 
compensation by oligodendrocytes. It is possible that the hypomyelination is a secondary 
outcome of a defect in local neuronal branching. Previous work has shown that mTOR controls 
mitochondrial oxidative function through a YY1-Ppargc1α transcriptional complex (196). More 
recently, it has been reported that Ppargc1α can control the expression of BDNF via FNDC5 
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Table 3.1. Statistical analysis of the distribution of distinct oligodendrocyte populations 
between adult Emx1-Cre; Ppargc1αfl/fl and Ppargc1αfl/fl mutants.  
This table summarizes the p values obtained after statistical analysis with two tailed student’s T 
test on the numbers of distinct oligodendrocyte populations spread throughout all the cortical 
layers divided into ten bins from pia to corpus callosum (CC). Numbers in red represent 
significant values ≤ 0.05.  
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P values (two tailed student’s T test) 
 
OLIG2 PDGFRα APC 
Pia 10 0.939 0.785 0.00702 
9 0.0938 0.0607 0.0144 
8 0.0784 0.114 0.178 
7 0.822 1.00 0.338 
6 0.236 0.779 0.255 
5 0.315 0.447 0.286 
4 0.371 0.940 0.359 
3 0.499 0.380 0.891 
2 0538 0.929 0.298 
CC 1 0.716 0.0836 0.337 
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expression in the hippocampus or in primary cortical neurons (228). These pathways and 
molecules are all involved in the establishment of a proper dendritic pattern (229). First, the 
PI3K-mTOR kinase pathway is known to be important for regulating cell size and has been 
shown to be crucial to control dendritic size (229-231). Moreover, it can also govern dendritic 
complexity and branching pattern, in conjunction with the mitogen activated protein kinase 
(MAPK) kinase pathway (230). BDNF can stimulate both the PI3K-mTOR as well as MAPK 
pathways to induce primary dendritic formation (232). Notably, it has been recently shown that 
Ppargc1α is required for the formation and maintenance of neuronal dendritic spines (95). Since 
Ppargc1α is involved in dendritic arborization, it is possible that defective neuronal dendritic 
arborization from SCPN leads to abnormal synapses that detrimentally affects the axonal 
projections of ascending fibers to the cortex in the upper layers. These abnormal afferent axons 
may then lead to defective myelination in the upper layers of the neocortex via mechanisms as 
described in Chapter 4.  
 
 3.3.7. Gain-of-function analysis: Ppargc1α overexpression in cortical progenitors 
fated to be CPN did not induce ectopic myelination.  
 Loss-of-function analysis, as shown in sections 3.3.2. to 3.3.4., demonstrated that 
Ppargc1α is required in neurons to establish proper neocortical myelination. Gain-of-function 
analysis is important to determine if Ppargc1α is sufficient to induce myelination. To test 
whether overexpression of Ppargc1α in otherwise fated cortical progenitors can induce ectopic 
myelination, together with Dr. Simona Lodato, a postdoctoral fellow in the laboratory, I 
overexpressed Ppargc1α by ultrasound-guided in utero electroporation in E15.5 cortical 
progenitors that are fated to form upper layer CPN. In vivo electroporation enables me to 
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exercise control over the timing and location of misexpression in an otherwise wild type 
environment (233). I expressed Ppargc1α under the control of a constitutively active CMV 
enhancer / β actin promoter with an IRES-enhanced GFP element for easy identification of 
electroporated cells (Ppargc1αGFP, Figure 3.7.A.). Dr. Simona Lodato electroporated this vector 
construct into the neocortical ventricular zone of developing E15.5 wild type embryos while I 
recovered the electroporated embryos at two developmental stages, namely P16 (n = 5 animals 
across 2 distinct experiments) and P21 (n = 7 across 2 different experiments). I identified the 
electroporated cells by immunostaining for GFP and examined the myelination pattern by 
immunostaining for MBP on coronal cortical sections of electroporated neocortices at P16 and 
P21. Electroporation with Ppargc1αGFP at E15.5 results in the transfection of cells that give rise 
to CPN predominantly of upper layers II/III where Ppargc1α is normally not expressed. 
Harvesting of electroporated pups at P16 and P21 allows me to easily identify any ectopic 
myelination due to the induction of Ppargc1α because the upper layers II/III are not fully 
myelinated at these stages. Although I found many electroporated GFP positive cells in the upper 
layers II/III, I did not detect any ectopic MBP positive cells or fibers in the vicinity of the GFP 
positive cells or more broadly in the upper layers II/III, when compared to the unelectroporated 
contralateral control hemispheres (Figure 3.7.B. to 3.7.G.). Therefore, my data demonstrate that 
overexpression of Ppargc1α in upper layer CPN does not induce ectopic myelination in the 
neocortex, indicating that Ppargc1α is insufficient to induce ectopic myelination in the neocortex. 
 
 3.3.8. Decrease in neuronal metabolism in deep layers of Emx1-Cre; Ppargc1αfl/fl 
mice. 
 Since Ppargc1α is implicated to be important for energy metabolism in tissue with high  
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Figure 3.7. Ppargc1α overexpression in cortical progenitors fated to be CPN did not induce 
ectopic myelination.  
(A) A schematic showing the Ppargc1αGFP construct that was in utero electroporated at E15.5 
into wild type cortical progenitors fated to be upper layer CPN. Electroporated pups were 
subsequently harvested at P16 and P21.  
(B – G) Immunostaining for GFP and Myelin Basic Protein (MBP) revealed that while GFP 
positive cells that overexpress Ppargc1α can migrate and occupy their destined position in the 
upper layers, they do not induce obvious ectopic myelination at P16 (data not shown) and P21, as 
compared to the unelectroporated control contralateral hemisphere. Scale bars, 100 μm (B – G). 
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Figure 3.7. (Continued) 
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metabolic demand like brown adipose tissue (42, 61), skeletal muscle (51, 54, 61) and the heart 
(38, 40, 69), I hypothesize that Ppargc1α is important for metabolic control in SCPN of the 
neocortex. To test my hypothesis and determine if Ppargc1α is necessary for neuronal 
metabolism in the deep cortical layers, I extracted tissue with tissue punches from the deep 
cortical layers of Emx1-Cre; Ppargc1αfl/fl and matched Ppargc1αfl/fl littermate controls at P14 (n 
= 5 Emx1-Cre; Ppargc1αfl/fl and n = 3 Ppargc1αfl/fl animals over 2 distinct experiments) and 2 
months of age (n = 7 Emx1-Cre; Ppargc1αfl/fl and n = 5 Ppargc1αfl/fl animals over 3 different 
experiments) (Figure 3.8.A.). I used high performance liquid chromatography followed by mass 
spectrometry (LC-MS) to determine N-acetylaspartate (NAA) and creatine concentrations, and 
determined the metabolic levels of these tissues using NAA over creatine (NAA/creatine) ratios 
as an indicator for neuronal metabolism.  
 NAA is a metabolite that is synthesized from acetyl CoA and aspartate by enzyme 
NAT8L that is found exclusively in the mitochondria and microsomes of neurons (170-177). It is 
one of the most concentrated molecules in the brain (170-177). Because of its exclusive 
production by neurons and its highly detectable levels by magnetic resonance spectroscopy 
(MRS) analysis, it is currently used as a clinical indicator for neuronal metabolism (234, 235). I 
found that NAA/creatine levels are significantly lower in Emx1-Cre; Ppargc1αfl/fl mice at P14 
(71.2% ± 13.6% , decrease of 28.8% as compared to age-matched control, p = 1.22 x 10-2) and 2 
months of age (86.8% ± 12.3%, decrease of 13.2% as compared to age-matched control, p = 3.97 
x 10-2), as compared to that of Ppargc1αfl/fl controls. These data indicate that there is a decrease 
in neuronal metabolic levels in the deep layers of Emx1-Cre; Ppargc1αfl/fl mice, as compared to 
Ppargc1αfl/fl controls at P14 as well as 2 months of age. Thus, these data show that the specific 
loss of Ppargc1α in the dorsal forebrain, particularly in the deep layers, results in decreased  
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Figure 3.8. Decrease in neuronal metabolism in deep layers of Emx1-Cre; Ppargc1αfl/fl mice. 
(A) A representative image showing that tissue punches (arrows) were used to extract tissue from 
the deep cortical layers V/VI of mutant mice. Insert shows a close-up image of a tissue punch. 
Ctx, cortex; Hip, hippocampus. 
(B) Neuronal metabolism analysis by LC-MS revealed that NAA/creatine levels, clinically 
relevant markers for neuronal metabolism, are significantly lower in Emx1-Cre; Ppargc1αfl/fl 
mice at P14 (71.2% ± 13.6% , decrease of 28.8% as compared to age matched control, p = 1.22 x 
10-2) and 2 months of age (86.8% ± 12.3%, decrease of 13.2% as compared to age matched 
control, p = 3.97 x 10-2), as compared to that of Ppargc1αfl/fl controls. cKO refer to Emx1-Cre; 
Ppargc1αfl/fl mutant mice while cWT refer to Ppargc1αfl/fl mutant controls. Values plotted are 
calculated as percentage ratio of NAA/creatine values of cKO over that of cWT in the same 
controlled experiment. ** represents p value ≤ 0.01, * represents p value ≤ 0.05. 
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neuronal metabolism, demonstrating that Ppargc1α is required for normal neuronal metabolism 
in SCPN.  
 Interestingly, there is a smaller difference in the NAA/creatine levels found in 2 month-
old mutants (~ 13.2%) as compared to P14 mutants (28.8%). This can be due to functional 
compensation with time in response to a decrease in NAA levels. The neuronal metabolic profile 
presents a correlation with the myelination phenotype though it does not prove a causative 
relationship. Since the metabolic profile appears to improve while the hypomyelination defect 
appears to be persistant, if not more severe with time, it is possible that neuronal metabolism 
may not responsible for the hypomyelination phenotype. However, it is also probable that 
neuronal metabolism plays a larger role in affecting myelination at earlier stages of postnatal 
development rather than during adulthood where another mechanism or factor becomes more 
important. In addition, it is also possible that Ppargc1α mediates its function via multiple 
pathways of which one of them implicates neuronal metabolism.   
 Together, these results suggest that Ppargc1α’s metabolic function in SCPN may be 
mechanistically important to regulate communication via yet unidentified secreted metabolites 
betwen SCPN and oligodendrocytes to affect neocortical myelination. 
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3.4. Discussion. 
 Here, I discovered that neuron-selective Ppargc1α plays a novel function in the neocortex 
to affect an oligodendrocyte-specific process of myelination; particularly it is cell-intrinsically 
required to establish a correct pattern of myelination in the neocortex.  
 Firstly, Ppargc1α is expressed primarily during postnatal ages, with increasing 
expression with age. This temporal expression corresponds with the onset of myelination during 
early postnatal ages. However, I found that Ppargc1α is selectively expressed in SCPN and in 
certain cortical interneuron subsets but not in CThPN and the majority of CPN in the neocortex. 
Most importantly, I showed that Ppargc1α is not expressed in glial cells of the neocortex; 
particularly it is excluded from oligodendrocyte progenitors as well as mature myelinating 
oligodendrocytes. This set of findings differs with a recent report purporting that Ppargc1α is 
expressed in cultured oligodendrocytes and can regulate the expression of myelin basic protein 
(MBP) in vitro (88). It is possible that cells cultured in vitro behave differently from cells in vivo. 
In all, my results show that Ppargc1α is a neuron-specific transcriptional co-activator that is not 
expressed in oligodendrocytes in the neocortex during postnatal development when neocortical 
myelination is induced.  
 Remarkably, examination of the neocortical myelination pattern of the Ppargc1α null 
mice revealed hypomyelination defects not only in the deep cortical layers V/VI, but also in the 
upper layers II-IV where Ppargc1α is not expressed. Further analysis of a conditional null 
mutant of Ppargc1α in neurons confirmed that the hypomyelination anomalies observed in the 
null mutant is caused by selective loss of Ppargc1α in neurons. This led me to investigate 
whether Ppargc1α plays a novel role in neocortical neurons to control neocortical myelination. I 
generated a conditional null mutant for Ppargc1α in the dorsal telencephalon, which provides the 
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best possible model to study the effects of Ppargc1α ablation in neocortex. Remarkably, 
brightfield and immunostaining analyses showed that conditional loss of Ppargc1α in the dorsal 
forebrain causes similar hypomyelination defects in the deep and upper layers, even in layer I 
fibers. On the contrary, examination of another newly generated conditional null mutant for 
Ppargc1α in the thalamus showed that ascending projections from TCPN are myelinated 
normally despite the loss of Ppargc1α in TCPN. These new data demonstrated that selective loss 
of Ppargc1α in the thalamus does not affect the myelination pattern of their axons as they 
innervate the neocortex, and most importantly that it does not cause the hypomyelination defects 
of the neocortex, as observed in the different null and conditional null mutants for Ppargc1α 
described so far. In all, my loss-of-function analyses with distinct genetic null and conditional 
null mice models for Ppargc1α indicate that neuron-specific Ppargc1α is cell-autonomously 
necessary to establish a proper myelination pattern in the neocortex. Together with the 
expression profile of Ppargc1α, these new findings present a conundrum where a neuron-specific 
gene in Ppargc1α is required to control an oligodendrocyte-specific process of myelination in the 
neocortex.  
 In addition to loss-of-function analysis, gain-of-function analysis is important to test 
whether Ppargc1α is sufficient to induce ectopic myelination. In utero electroporation 
experiments revealed that the induction of Ppargc1α in cortical progenitors destined to form 
upper layer CPN where Ppargc1α is normally not expressed failed to induce ectopic myelination. 
Therefore, Ppargc1α, though necessary, is not sufficient to induce myelination in the neocortex.  
 Since Ppargc1α is known to be a master regulator of energy metabolism in tissue with 
high metabolic demand such as brown adipose tissue (42, 61), skeletal muscle (51, 54, 61) and 
the heart (38, 40, 69), I investigated whether Ppargc1α is required for normal neuronal 
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metabolism. Initial experiments demonstrated a decrease in neuronal metabolism, or more 
specifically in NAA over creatine ratios, in the deep cortical layers of the conditional null mutant 
for Ppargc1α in the dorsal forebrain. These data revealed that Ppargc1α is necessary for normal 
neuronal metabolic function in the neocortex. They also purport that Ppargc1α may be able to 
directly or indirectly regulate the production of metabolites that are secreted and eventually taken 
up by oligodendrocytes to affect their formation of the myelin sheath.  
 My results demonstrate that Ppargc1α –a transcriptional co-activator–is important for 
neocortical myelination. This is the first involvement of a transcriptional co-activator in 
regulating neocortical myelination as well as in neuron-to-glia interactions. Current research on 
neuron-to-glia communication in oligodendrocyte function and myelin biogenesis is mainly 
focused on secreted factors or membrane-associated cell surface molecules (112, 113). Since 
Ppargc1α is a transcriptional co-activator, it has to partner DNA-docking transcription factors or 
nuclear receptors to mediate its function (46, 47). Therefore, it will be interesting for future work 
to investigate the DNA-binding partners of Ppargc1α and to identify and elucidate their 
downstream effectors to better understand the mechanism of Ppargc1α in controlling 
myelination.  
 Ppargc1α is known to be a master regulator of energy metabolism and mitochondrial 
biogenesis in tissue with high metabolic demand such as brown adipose tissue (42, 61), skeletal 
muscle (51, 54, 61) and the heart (38, 40, 69). My findings purport a similar role for Ppargc1α in 
SCPN as ablation of Ppargc1α in the deep layers of the neocortex leads to decreased neuronal 
metabolism. Moreover, previous studies have reported that Ppargc1α is able to regulate 
mitochondrial density and ATP levels in primary cortical neuron cultures (92). Therefore, it is 
possible that Ppargc1α regulates neuronal mitochondria. This is interesting because neuronal 
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mitochondria have been suggested to be important for myelination and can be a mechanistic link 
between Ppargc1α and myelination. Prior work has shown that mitochondrial size, activity and 
density, and even speed of axonal mitochondrial transport, increase as an adaptation to 
dysmyelination or demyelination in distinct mouse mutant models (236-238). This increase can 
be interpreted as an attempt to stimulate remyelination of demyelinated axons. Furthermore, 
similar axonal mitochondrial changes in response to demyelination and remyelination are well 
documented in mice models of multiple sclerosis (239-241). In fact, there is an increasing 
appreciation in the field that axonal mitochondria are important for regulating myelination. 
Besides Ppargc1α, another mitochondrial-related gene called MRS2 magnesium homeostasis 
factor homolog (MRS2) has also been involved in myelination (242, 243). Through encoding a 
mitochondrial magnesium channel, prior work has reported that a mutation in the MRS2 gene 
causes demyelination in the rat (242, 243). It will be interesting to elucidate if Ppargc1α governs 
the expression of MRS2 or other mitochondrial associated genes, and if so, how they interact 
with each other to regulate neocortical myelination. 
 Interestingly, a tripartite relationship between myelination, axonal mitochondria and 
electrical activity has been proposed (239, 240). Although axonal electrical activity after target 
innervation can regulate myelination (156), myelination and electrical activity can also in turn 
affect the placement and mobility of axonal mitochondria (244). Therefore, these studies purport 
that myelination, electrical activity and axonal mitochondria have a reciprocal three-way 
relationship. In light of this, it will be important to test if Ppargc1α plays a role in controlling 
neuronal electrical activity and if so, determine whether this is the mechanistic pathway for it to 
affect myelination. Alternatively, Ppargc1α may regulate the production of secreted metabolites, 
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or some currently unidentified cell surface molecules that will allow it to communicate with 
oligodendrocytes to govern myelination.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  186
 
Chapter 4: 
Discussion 
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4.1. Role of Ppargc1α in neuronal survival and its implications. 
 4.1.1. Implications of findings for neuronal survival and lesion formation.  
 My findings in Chapter 2 demonstrated that Ppargc1α is cell-autonomously not necessary 
to control neuronal survival during normal development either in the absence of acute external 
environmental stress triggers or in the context of cellular stress caused by aging. Taken together 
with previous work (72-74), my new data suggest that Ppargc1α is involved in neuronal survival, 
but only in the context of an unbalanced non-homeostatic cellular state caused by acute cellular 
stress or neurodegeneration. In this case, the loss of Ppargc1α may increase the cells’ 
susceptibility to die, possibly by interfering with the ROS defense system and mitochondrial 
function or by hitherto unexplored mechanisms. It also suggests that the enhanced cell death 
observed in prior studies is due to potential additive or more complex effects of already inherent 
cell toxicity or death. 
 For future work, it will be interesting to determine the downstream effectors responsible 
for Ppargc1α’s role in neuronal survival in the event of acute cellular stress and 
neurodegeneration. Although mitochondrial genes involved in the ROS defense system have 
been implicated in previous studies (72-74), it remains to be determined whether novel genes 
that have not yet been identified are also involved, and if so, how Ppargc1α regulates the 
expression of these genes and the molecular pathways that enables it to be important for cell 
survival. 
 Previously published reports show that neuron-specific loss of Ppargc1α causes smaller 
and fewer spongiform-like lesions in the striatum (219). I confirmed these results in section 2.3.3. 
and described in further detail the localization and arealization of these lesions in the neuron-
selective conditional null mutants for Ppargc1α. These data demonstrate that preferential loss of 
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Ppargc1α in neurons is only partly responsible for the development of IC localized lesions. This 
indicates that though Ppargc1α in neurons is required to govern the formation of these lesions, it 
does so only to a certain extent. My above findings indicate that Ppargc1α alone, in either SCPN 
or TCPN, is not necessary to control lesion development. Thus, these data in totality suggest that 
lesion formation requires either the simultaneous loss of Ppargc1α in SCPN and TCPN, or the 
conditional loss of Ppargc1α in a hitherto unexamined region like the substantia nigra where 
Ppargc1α is highly expressed, or in the striatum where Ppargc1α is weakly expressed up to P7. I 
have tested the possibility that these lesions may necessitate simultaneous loss of Ppargc1α in 
SCPN and TCPN by generating double conditional null mutants for Ppargc1α. Unfortunately, 
breeding these animals has been difficult; four breeding cycles with foster dams over the past 
eight months did not yield any animals with the genotype of interest. Therefore, it remains to be 
explored whether lesion development is caused by the singular loss of Ppargc1α in a defined 
neuronal domain or by the additive deficit of Ppargc1α in multiple neuronal regions.  
 Since my data and others have shown that neuron-specific loss of Ppargc1α results in 
smaller and fewer lesions (219) as compared to that of the null mutant, there is a non neuronal, 
potentially systemic or a more complex multifactorial mechanism responsible for these lesions. It 
has been recently reported that Ppargc1α expression in muscles can induce the production of 
FNDC5, a precursor that is cleaved and secreted as irisin—a newly identified hormone or 
myokine that can induce a broad program of brown adipose tissue development (222). Irisin 
secretion is induced by exercise and can lead to ameliorations in obesity and glucose homeostasis 
(222). Yet, its role in brain development is unknown and it remains to be seen whether irisin is 
involved in the development of spongiform lesions in the IC. It will be interesting to determine 
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whether a systemic or secreted component like irisin, or a thus far unidentified molecule leading 
to a multiplex pathway, is responsible for lesion formation. 
 
 4.1.2. Implications of findings for SCPN differentiation.  
 While my results in Chapter 2 are important to fill gaps of knowledge in the field about 
the cell-intrinsic function of Ppargc1α in neuronal survival, these findings are also very 
important to inform us about its role in SCPN differentiation. My results in Chapter 2 
demonstrated that distinct classes of PN, particularly SCPN, are born, can migrate normally to 
their appropriate laminar positions and are maintained throughout adulthood to old age. This is in 
concordance with my expression profile data, as described in section 2.3.1., showing that 
Ppargc1α is largely expressed postnatally, after the fate specification and migration of most 
cortical PN have already occurred. Furthermore, cell death analysis did not reveal any significant 
increase in cell death. Hence, these data show that Ppargc1α in SCPN do not affect the birth, 
migration, laminar position and even survival of SCPN. Nissl staining further shows that the 
absence of Ppargc1α in SCPN does not affect their characteristic large pyramidal morphology. 
Hence, my findings show that Ppargc1α in SCPN also does not control SCPN morphological 
characteristics. In fact, Ppargc1α in SCPN do not cause any gross neuronal abnormalities in the 
neocortex. These data are important because they provide insights into potential aspects of SCPN 
differentiation in which Ppargc1α may play a role.  
 Investigating the contribution of Ppargc1α in SCPN to the formation of IC-localized 
lesions is not only important to understand their elusive cellular origins, but more importantly, to 
determine if these lesions affect the axonal extensions of SCPN that project through the IC and 
connect to distant targets like the SC. If conditional loss of Ppargc1α in SCPN causes similar 
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lesions, it is likely that SCPN axonal efferents are affected and bear abnormalities that will 
warrant further investigation. However, my results in Chapter 2 demonstrated that the 
conditional loss of Ppargc1α in SCPN do not cause spongiform lesions in the IC. These suggest 
that Ppargc1α in SCPN have normal axonal efferents and imply that the lesions observed in 
Ppargc1α null mutants do not affect descending subcerebral projections. Moreover, high 
magnification analysis of conditional null mutants for Ppargc1α in SCPN showed that the axonal 
bundles of the IC in these mutants are normally shaped and tightly fasciculated with no overt 
signs of loss, defasciulation or other aberrations. Examination of the cerebral peduncle and the 
dorsal funiculus in the spinal cord of both null and conditional null mutants also did not reveal 
any evident anomalies, indicating that subcerebral projections can extend and find their distant 
targets in the absence of Ppargc1α in SCPN. Therefore, my findings show that the loss of 
Ppargc1α in SCPN does not cause significant axonal aberrations in projections through the IC, 
suggesting that Ppargc1α in SCPN does not play a cell-autonomous role in axonal extension, 
pathfinding through the IC and fasciculation. 
 These implications are also in agreement with my expression profile of Ppargc1α where 
it is expressed in SCPN predominantly during postnatal ages, after initial axonal growth and 
pathfinding of most SCPN has already occurred. SCPN begin their axonal growth as early as 
E13.5 (245). By E17.5, pioneering axons have already projected through the IC to reach the 
upper levels of the mouse brainstem (245). Hence, it is unlikely that Ppargc1α, a mainly 
postnatal gene, plays a role in initial axonal growth and pathfinding by SCPN, which is in 
agreement with my results in Chapter 2. However, it remains to be determined whether 
Ppargc1α plays a role in target innervation and refinement of axonal connectivity which 
normally takes place postnatally (245). 
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 4.1.3. Implications of findings for neocortical myelination. 
 My results from Chapter 2 suggest that Ppargc1α does not play a role in the birth, 
migration, laminar position, survival of SCPN. In addition, they show that conditional loss of 
Ppargc1α in SCPN does not cause overt axonal abnormalities or lesions in the IC. In Chapter 3, I 
showed that that loss of Ppargc1α in SCPN causes hypomyelination, indicating that neuron-
specific Ppargc1α is important for neocortical myelination. Many may argue that this 
hypomyelination defect is caused by loss of neurons and their axons. My results in Chapter 2 
show otherwise where conditional loss of Ppargc1α in SCPN does not cause gross cortical 
abnormalities, PN loss or increased cell death. They also show that the hypomyelination defect is 
not due to loss of SCPN axons. Hence, these data support that the hypomyelination defect is not 
caused by neuronal or axonal loss. These results further show that the hypomyelination occurred 
in a seemingly normal neocortex and further validates that neuron-specific Ppargc1α plays a role 
in myelination.   
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4.2. Role of Ppargc1α in neocortical myelination and its implications.  
 4.2.1. Implications of findings for neocortical myelination. 
 My results in Chapter 3 showed that Ppargc1α–a transcriptional co-activator–is 
important for neocortical myelination. This is the first implication of a transcriptional co-
activator in regulating neocortical myelination as well as in neuron-to-glia interactions. Current 
research on neuron-to-glia communication in oligodendrocyte function and myelin biogenesis is 
mainly focused on secreted factors or membrane-associated cell surface molecules (112, 113). 
Since Ppargc1α is a transcriptional co-activator, it must partner DNA-docking transcription 
factors or nuclear receptors to mediate its function (46, 47). Hence, it will be interesting to 
elucidate the DNA-binding partners of Ppargc1α, as well as to identify and study their 
downstream effectors to gain insights into the mechanism of Ppargc1α in regulating myelination. 
Here, as illustrated in Figure 4.1., I present a hypothetical model that summarizes potential 
pathways through which neuron-specific Ppargc1α can exert its control on neocortical 
myelination. These possible mechanisms are not mutally exclusive and may indeed present a 
multifactorial system via which Ppargc1α in neurons can regulate myelination in the neocortex.  
 1) Ppargc1α is known to be a master regulator of energy metabolism and mitochondrial 
biogenesis in tissue with high metabolic demand such as brown adipose tissue (42, 61), skeletal 
muscle (51, 54, 61) and the heart (38, 40, 69). My results in Chapter 3 support a similar role for 
Ppargc1α in SCPN as loss of Ppargc1α in the neocortex leads to decreased neuronal metabolism. 
Furthermore, prior work has shown that Ppargc1α can regulate mitochondrial density and ATP 
levels in primary cortical neuron cultures (92). Thus, it is likely that Ppargc1α regulates neuronal 
mitochondria. This is interesting because neuronal mitochondria have been implicated in 
myelination and can be a mechanistic link between Ppargc1α and myelination. Studies have  
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Figure 4.1. Model of potential pathways where neuronal Ppargc1α can control neocortical 
myelination.  
Neuronal Ppargc1α can potentially regulate neocortical myelination by (i) controlling neuronal 
mitochondria or mitochondrial genes like MRS2 that eventually regulates the secretion of 
metabolites, or (ii) regulating electrical activity, which forms a tripartite relationship with 
myelination and axonal mitochondria, or (iii) governing the production of FNDC5, which 
controls the secretion of neurotrophin brain-derived neurotrophic factor BDNF which has been 
implicated in myelination of the PNS and CNS. These possible mechanisms are not mutally 
exclusive and may indeed present a multifactorial system via which Ppargc1α in neurons can 
regulate myelination in the neocortex.  
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Figure 4.1. (Continued) 
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shown that mitochondrial size, activity and density, or even speed of axonal mitochondrial 
transport increase as an adaptation to dysmyelination or demyelination in distinct mouse mutant 
models (236-238). This increase can be interpreted as an attempt to induce remyelination of 
demyelinated axons. Moreover, similar axonal mitochondrial changes in response to 
demyelination and remyelination are well documented in mice models of multiple sclerosis (239-
241). In fact, there is an increasing appreciation in the field that axonal mitochondria are 
important for regulating myelination. Besides Ppargc1α, another mitochondrial-related gene 
called MRS2 magnesium homeostasis factor homolog (MRS2) has also been implicated in 
myelination (242, 243). Through encoding a mitochondrial magnesium channel, previous studies 
have demonstrated that a mutation in the MRS2 gene causes demyelination in the rat (242, 243). 
It will be interesting to determine if Ppargc1α controls the expression of MRS2 or other 
mitochondrial associated genes, and if so, how they interact with each other to control 
neocortical myelination. 
 2) Interestingly, a tripartite relationship between myelination, axonal mitochondria and 
electrical activity has been proposed (239, 240). While it has been shown that electrical activity 
in axons after target innervation can regulate myelination (156), it has also been reported that 
myelination and electrical activity can in turn affect the placement and mobility of axonal 
mitochondria (244). Thus, these studies suggest that myelination, electrical activity and axonal 
mitochondria have a reciprocal three-way relationship. In light of this, it will be important to test 
if Ppargc1α plays a role in regulating neuronal electrical activity and if so, determine whether 
this is the mechanistic pathway for it to affect myelination. Alternatively, Ppargc1α may control 
the production of secreted metabolites or some yet unidentified cell surface molecules that will 
enable it to communicate with oligodendrocytes to regulate myelination.   
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 3) Notably, a recent report by the groups of Michael Greenberg and Bruce Spiegelman 
showed that exercise can induce the secretion of BDNF through a Ppargc1α/FNDC5 pathway 
(228). They showed that downregulating Ppargc1α expression in primary cortical neurons by 
lentiviral mediated shRNA knockdown resulted in a significant decrease of FNDC5 mRNA 
expression (228). This reduction is also observed in Ppargc1α null mutants (228). Moreover, 
overexpression of Ppargc1α in primary cortical neurons led to an induction of FNDC5 mRNA as 
well as protein levels (228). Hence, Ppargc1α is necessary and sufficient for FNDC5 expression 
in primary cortical culture (228). In this study, they also showed that ERRα is a key interacting 
transcription factor with Ppargc1α for regulating FNDC5 expression in primary cortical neurons 
(228). They further demonstrated that FNDC5 can regulate BDNF expression in a cell-
autonomous fashion and that recombinant BDNF can decrease FNDC5 gene expression as part 
of a negative feedback loop (228). Therefore, Ppargc1α together with ERRα forms a pathway to 
regulate FNDC5 which in turns affects the expression and eventual secretion of BDNF.  
 This study is significant because BDNF, being a neurotrophic factor, has been implicated 
in the myelination of the PNS (246-249) as well as the CNS (250-253). BDNF has also been 
shown to be able to induce remyelination of injured axons (247-249, 254). Hence, it is highly 
possible that it may be one of the ways Ppargc1α in neurons of the cortex can control 
myelination.   
 4) Secreted molecules, whether metabolites or neurotrophic factors, can help in 
explaining how Ppargc1α can mediate its function throughout all cortical layers despite being 
expressed only in SCPN that reside in deep layer V of the neocortex. However, it is also possible 
that hypomyelination phenotype in the upper layers is only a secondary outcome of a defect in 
local neuronal branching. Previous work has shown that mTOR controls mitochondrial oxidative 
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function through a YY1-Ppargc1α transcriptional complex (196). More recently, it has been 
reported that Ppargc1α can control the expression in the hippocampus or in primary cortical 
neurons (228). These pathways and molecules are all involved in the establishment of a proper 
dendritic pattern (229). First, the PI3K-mTOR kinase pathway is known to be important for 
regulating cell size and has been shown to be crucial to control dendritic size (229-231). 
Moreover, it can also govern dendritic complexity and branching pattern, in conjunction with the 
mitogen activated protein kinase (MAPK) kinase pathway (230). BDNF can stimulate both the 
PI3K-mTOR as well as MAPK pathways to induce primary dendritic formation (232). Notably, 
it has been recently shown that Ppargc1α is required for the formation and maintenance of 
neuronal dendritic spines (95). Since Ppargc1α is involved in dendritic arborization, it is possible 
that defective neuronal dendritic arborization from SCPN leads to abnormal synapses that 
detrimentally affects the axonal projections of ascending fibers to the cortex in the upper layers. 
Abnormal afferent axons may then result in defective myelination in the upper layers of the 
neocortex via potential mechanisms as detailed above.  
 
 4.2.2. Implications of findings for SCPN differentiation.  
 While the results in Chapter 3 have important implications for Ppargc1α in neocortical 
myelination, they also present new questions that challenge our current understanding of SCPN 
development. As shown in Chapters 2 and 3, Ppargc1α in SCPN does not affect their birth, 
migration, laminar position, survival and axonal extension but instead affects their myelination 
pattern. These results call into question whether SCPN actively regulate their own myelination 
instead of taking a more passive role. It is also interesting to note that among major PN 
subclasses of the neocortex, only SCPN express Ppargc1α at high levels; CThPN and the 
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majority of CPN do not. Since SCPN project axons that are extremely long, particularly the 
CSMN that project all the way from the cortex to innervate the SC, it is extremely important to 
have efficient propagation of action potentials for signal transduction. Hence, SCPN may have a 
special requirement for proper myelination that other neuronal subtypes may not require. This 
brings into question whether neuronal subtypes broadly differ in their myelination patterns and 
whether molecular pathways controlling subtype identity include an active regulation of 
myelination. More importantly, it questions whether the myelination pattern of a neuron is part 
of its unique identity, just like morphological characteristics and electrophysiogical patterns. If 
so, this study may prompt others to look at the myelination pattern of distinct neuronal subtypes 
as another mode of classification.  
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4.3. Role of Ppargc1α as a metabolic switch and its implications in cell differentiation and 
cell fate.  
 There is increasing attention paid to the important role that metabolism plays in cellular 
differentiation. Many studies have shown that pluripotent stem cells are highly dependent on 
glycolysis which contrasts with differentiated cells that depend more on oxidative 
phosphorylation (255). Likewise, cancer stem cells have been shown to revert from a more 
differentiated oxidative state to a more rudimentary glycolytic state during malignant 
transformation (256, 257). Nuclear reprogramming of differentiated fibroblasts to induced 
pluripotent stem cells also shows a similar metabolic shift (255, 258-260). Collectively, these 
studies suggest that the metabolic state of a cell is important to mark stages of differentiation. 
Interestingly, Ppargc1α can induce a metabolic switch from glycolysis to oxidative 
phosphorylation in many tissues with high metabolic demand. For instance, in the heart, 
Ppargc1α expression is upregulated during early postnatal ages when the heart is switching from 
an embryonic glycolytic state to a more differentiated oxidative state (69). Hence, it will be 
interesting to determine whether Ppargc1α acts as a metabolic switch in SCPN differentiation 
during postnatal ages, similar to that in the heart, and if so, the consequences of failing to switch 
metabolically and its implications for SCPN differentiation.  
 Besides cellular differentiation, metabolic switches mediated by Ppargc1α can also 
specify cell fates in certain tissue like brown fat and muscle. For instance, Ppargc1α induction in 
white glycolytic fast-twitch skeletal muscle can “fate-switch” them to display genetic and 
physiological features characteristic of red oxidative slow-twitch skeletal muscle (38, 68). 
Likewise, overexpression of Ppargc1α in white fat can convert them to brown fat because of 
increased oxidative phosphorylation (42). These fate-switches occur because these cell types are 
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defined by their metabolic signature. Neuronal subtypes are defined traditionally by their 
morphology, axonal projections, electrophysiology and molecular identities. It will be interesting 
to determine if the metabolic status or the metabolome of a neuron is another characteristic that 
defines its identity and distinguishes it from other subclasses. In particular, it will be interesting 
to investigate if Ppargc1α is critical in defining the metabolic signature of SCPN.  
 In all, the work presented in this dissertation serves to fill knowledge gaps in the field 
about Ppargc1α’s function in the brain with respect to spongiform lesion formation as well as 
neuronal survival. Most importantly, this work serves to provide new insights into the function of 
Ppargc1α in SCPN postnatal differentiation. Novel findings on Ppargc1α’s role in controlling 
neocortical myelination and its implication in neuron-to-glia signaling serve as the beginning for 
many more studies. I hope with this dissertation that I have provided an original contribution to 
the field in enhancing our understanding of Ppargc1α function in SCPN, or more broadly in 
neocortical development.   
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Chapter 5: 
Materials and Methods 
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5.1. Genetic mouse models. 
 5.1.1. Colony maintenance and genotyping. 
 Studies performed on all mouse lines were approved by the Harvard University 
Institutional Animal Care and Use Committee (IACUC) and the Massachusetts General Hospital 
IACUC, and were performed in accordance with institutional and federal guidelines. The day of 
vaginal plug was designated as embryonic day 0.5 (E0.5). The day of birth was designated as 
postnatal day 0 (P0). Mice were maintained on a standard rodent chow or breeder chow diet with 
12-hour light and dark cycles. 
 Wild type C57BL/6 mice were either acquired from Charles River Laboratories in 
Wilmington, Massachusetts, USA, or bred in house. They were used for in situ hybridization 
analysis to determine the temporal and spatial expression profile of Ppargc1α.  
 Ppargc1α-/- mice were generated and generously given by Professor Bruce Spiegelman 
from the Department of Cell Biology, Harvard Medical School in Boston, Massachusetts, USA. 
They were also available from The Jackson Laboratory in Bar Harbor, Maine, USA (strain name: 
B6.129-Ppargc1atm1Brsp/J, stock number: 008597). Ppargc1αfl/fl conditional floxed mice were 
also generated by Professor Bruce Spiegelman and obtained from The Jackson Laboratory in Bar 
Harbor, Maine, USA (strain name: B6.129-Ppargc1atm2Brsp/J, stock number: 09666).  
 Snap frozen brains from 4 month old CamkIIα-Cre; Ppargc1αfl/fl mice were generated 
and generously given by Professor Jiandie D. Lin from the Life Sciences Institute and 
Department of Cell and Developmental Biology, University of Michigan Medical Center in Ann 
Arbor, Michigan, USA. CamkIIα-Cre; Ppargc1αfl/fl and Ppargc1αfl/fl littermate control mice were 
genotyped by a donor laboratory, in accordance to previously published protocols. Brains from 
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mutant mice were not fixed with any fixative before snap freezing with dry ice, and were 
subsequently stored at -80 oC. 
 Emx1-Cre mice were generated by Professor Kevin R. Jones from the Department of 
Molecular, Cellular, and Developmental Biology, University of Colorado in Boulder, Colorado, 
USA. They were generously given by Professor Jeffrey Macklis from the Harvard Stem Cell and 
Regenerative Biology, Harvard University in Cambridge, Massachusetts, USA.  
 Gbx2-CreER mice were generated and generously given by Professor James Y.H. Li 
from the Department of Genetics and Developmental Biology, University of Connecticut Health 
Center in Farmington, Connecticut, USA. 2 to 4 mg of tamoxifen (Catalog number: T5648-1G, 
Sigma-Aldrich, USA) freshly diluted in corn oil at 20 mg/mL (Catalog number: C8267, Sigma-
Aldrich, USA) was administered to pregnant dams carrying Gbx2-CreER; Ppargc1αfl/fl and 
Ppargc1αfl/fl pups at E10.5 for collection at P28 and E12.5 for collection at 2 months of age.  
 DNA were extracted using the DNeasy Blood & Tissue Kit (Catalog number: 69506, 
Qiagen, USA) from toe clippings of all mice between P0 and P7. Genotyping were achieved by 
Polymerase Chain Reaction (PCR) analysis with GoTaq Green Master Mix (Catalog number: 
M7123, Promega, USA). The PCR primers and cycling parameters which were used are 
described in Table 5.1. and Table 5.2. respectively. PCR products were separated by gel 
electrophoresis on 1.5 % agarose gel, except for the conditional floxed allele for Ppargc1α 
(Ppargc1αfl/fl mice) where 2% agarose gel was used. They were then visualized with ethidium 
bromide solution (Catalog number: E1510, Sigma-Aldrich, USA) and Molecular Imager Gel Doc 
XR+ System with Image Lab Software (Catalog number: 170-8195, Bio-Rad, USA).    
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Table 5.1. PCR primers used for genotyping of genetic mice models. 
This table summarizes the different primers used for PCR genotyping of the various genetic mice 
models used in this study, as described in section 2.5.1.. 
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Fezf2 
Wild type Forward 5’ – GGG TTA ATG GGC GGT AAT TT – 3’ 
 Reverse 5’ – GCC ACA GTT GGT TTT GCA C – 3’ 
  Product size ~ 700 base pairs 
Null Forward  5’ – GGGTGTTGGGTCGTTTGTTCGGATCTGCTA - 3’ 
 Reverse 5’ – TCTGGGCGCTCACGGTGACAGGCTGGGATT – 3’ 
  Product size ~ 300 base pairs 
 
Ppargc1α  
Wild type Forward 5’ – CCA GTT TCT TCA TTG GTG TG – 3’ 
 Reverse 5’ – ACC TGT CTT TGC CTA TGA TTC – 3’ 
  Product size ~ 650 base pairs 
Null Forward 5’ – TCC AGT AGG CAG AGA TTT ATG AC – 3’ 
 Reverse 5’ – CCA ACT GTC TAT AAT TCC AGT TC – 3’ 
  Product size ~ 400 base pairs 
Floxed Forward 5’ – TCC AGT AGG CAG AGA TTT ATG AC – 3’ 
 Reverse 5’ – TGT CTG GTT TGA CAA TCT GCT AGG TC – 3’ 
  Product size ~ 400 base pairs or 360 base pairs (without floxed) 
 
 
 
Table 5.1. (Continued) 
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Emx1-Cre 
Wild type Forward 5’ – AAG GTG TGG TTC CAG AAT CG – 3’ 
 Reverse 5’ – CTC TCC ACC AGA AGG CTG AG – 3’ 
  Product size ~ 380 base pairs 
Transgene Forward 5’ – GCG GTC TGG CAG TAA AAA CTA TC – 3’ 
 Reverse 5’ – GTG AAA CAG CAT TGC TGT CAC TT – 3’ 
  Product size ~ 100 base pairs 
 
Gbx2-CreER 
Wild type Forward 5’ – AAG GTG TGG TTC CAG AAT CG – 3’ 
 Reverse 5’ – CTC TCC ACC AGA AGG CTG AG – 3’ 
  Product size ~ 380 base pairs 
Transgene Forward 5’ – GAT ATC TCA CGT ACT GAC GG – 3’ 
 Reverse 5’ – TGA CCA GAG TCA TCC TTA GC – 3’ 
  Product size ~ 300 base pairs 
 
 
 
 
Table 5.1. (Continued) 
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Table 5.2. PCR cycling parameters used for genotyping of genetic mice models. 
This table summarizes the distinct PCR cycling parameters used for PCR genotyping of the 
various genetic mice models used in this study, as described in section 2.5.1.. 
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 Fezf2 Ppargc1α Ppargc1α 
(floxed) 
Emx1-Cre Gbx2-CreER 
Initialization 
95 oC 
5 minutes 
94 oC 
3 minutes 
94 oC 
3 minutes 
95 oC 
5 minutes 
95 oC 
5 minutes 
Denaturation 
94 oC 
30 seconds 
94 oC 
30 seconds 
94 oC 
30 seconds 
94 oC 
30 seconds 
94 oC 
30 seconds 
Annealing 
57 oC 
30 seconds 
58 oC 
30 seconds 
58 oC 
30 seconds 
57 oC 
30 seconds 
57 oC 
30 seconds 
Extension 
72 oC 
30 seconds 
72 oC 
30 seconds 
72 oC 
30 seconds 
72 oC 
30 seconds 
72 oC 
30 seconds 
Final extension 
72 oC 
1 minute 
72 oC 
2 minutes 
72 oC 
2 minutes 
72 oC 
1 minute 
72 oC 
1 minute 
Number of 
cycles 
30 35 35 30 30 
 
 
 
 
 
Table 5.2. (Continued) 
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 5.1.2. Tissue collection and sectioning. 
 For embryonic tissue collection, timed pregnant mouse dams were first anesthetized with 
a lethal dose of Avertin (1.25% 2-2-2 tribromoethanol in 0.63% isomyl alcohol) and their deaths 
were ascertained by cervical dislocation. Embryos were then removed from the uterine horns by 
manual dissection. These embryos were anesthetized by hypothermia with ice for at least 3 
minutes before decapitation. The whole heads were subsequently fixed in 4% paraformaldehyde 
(PFA) in phosphate buffer saline (PBS) at 4 oC overnight (for at least 16 hours), rinsed 3 times 
with 0.1 M PBS (pH 7.4) for at least 10 minutes each at 4 oC, before storing in 0.025% sodium 
azide in PBS (PBS-Azide). For postnatal tissue collection, pups that were P6 and younger were 
anesthetized by hypothermia with ice for at least 3 minutes; while pups that were P7 and older, 
including adult mice that were 2 months and older, were anesthetized with a lethal dose of 
Avertin. Anesthetized mice were perfused transcardially with PBS followed by 4% PFA. Brains 
were manually dissected, post-fixed in 4% PFA at 4 oC overnight, rinsed 3 times with PBS for at 
least 10 minutes each at 4 oC, and is stored in 0.025% PBS-Azide until sectioning. For the snap 
frozen CamkIIα-Cre; Ppargc1αfl/fl as well as Ppargc1αfl/fl littermate control brains, these brains 
were stored at -80 oC upon arrival, thawed only at room temperature (r.t.) when intended to be 
processed for downstream analysis, post-fixed in 4% PFA at 4 oC overnight, rinsed 3 times with 
PBS for at least 10 minutes each at 4 oC, and were sectioned immediately with cold PBS into 
0.025% PBS-Azide. All brains were sectioned at 40 μm thickness with cold PBS either on a 
coronal or sagittal plane with a VT1000S vibrating microtome (Leica Microsystems). Floating 
sections were stored in PBS-Azide at 4 oC. 
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5.2. In situ hybridization. 
 5.2.1. In situ hybridization. 
 Nonradioactive colorimetric in situ hybridization (ISH) with antisense probes labeled 
with Digoxigenin-UTP (DIG-UTP) was utilized in accordance with previously published 
protocols. All clones used to produce probes for ISH were generated by reverse transcriptase-
PCR (RT-PCR) on extracted RNA from murine cortices at various ages with specific primer 
sequences, as listed in Table 2.4.. DIG-labeled probes were generated with DIG RNA Labeling 
Kit (SP6/T7/T3) (Catalog number: 11175025910, Roche Applied Science, USA).  
 ISH procedures were carried out in RNase-free conditions. Floating brain sections were 
first mounted on Superfrost Plus slides (Catalog number: 12-550-15, Fisher Scientific, USA) in 
autoclaved deionised water (dd H2O) and left to dry completely for a minimal time of at least 10 
minutes at r.t.. Dried sections were rehydrated with cold PBS for 5 minutes, permeabilized in 
cold freshly prepared diluted Triton X-100 in distilled water (0.3% for embryonic tissue and 
0.5% for postnatal and adult tissue, Catalog number: T9284-100ml, Sigma-Aldrich, USA) for 10 
minutes, washed with cold PBS for 2 times at 5 minutes each, before further permeabilization 
with cold RIPA buffer (0.5% sodium deoxycholate, 150 mM autoclaved sodium chloride, 50 
mM autoclaved Tris pH 8, 1 mM autoclaved EDTA, 1% Tergitol-type NP40, 0.1% sodium 
dodecyl sulfate in autoclaved dd H2O) 2 times at 10 minutes each. Permeabilized sections were 
re-fixed in cold 4% PFA for 15 minutes, washed with cold PBS for 2 times at 5 minutes each and 
acetylated in a mixture of Triethanolamine Buffer (100 mM Triethanolamine, 0.4% acetic acid in 
autoclaved dd H2O) and 0.25% acetic anhydride for 15 minutes at r.t. before washing with cold 
PBS for 3 times at 5 minutes each. Processed sections were then pre-hybridized for 1 hour at r.t. 
with hybridization solution [50% formamide, 5X saline sodium citrate, 5X Denhardts solution 
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(1μg/mL Ficoll 400, 1μg/mL Polyvinilpyrrolidone, 1μg/mL bovine serum albumin), 500 μg/mL 
salmon sperm DNA, 250 μg/mL yeast RNA in autoclaved dd H2O] that was pre-warmed to 70 
oC. Probes to be hybridized were diluted in hybridization solution to an empirically determined 
concentration ranging from 300 ng/mL to 1μg/mL and pre-warmed to 70 oC for 5 to 10 minutes 
before hybridization to processed sections with glass cover slips for incubation in a humidified 
chamber (50% formamide, 50% 5X saline sodium citrate) overnight at 70 oC. The following day, 
the sections were washed in freshly prepared post-hybridization solution (50% formamide, 2X 
saline sodium citrate, 0.1 Tween-20 in autoclaved dd H2O), prewarmed to 70 oC for 2 times for 1 
hour each in 70 oC, and subjected to further washes in MABT (100 mM malaeiic acid, 150 mM 
sodium chloride, 0.1% Tween-20 in autoclaved dd H2O to pH 7.5) for 2 times at 15 minutes each 
at r.t.. They were then blocked in B2 solution (10% sheep serum in MABT) for 1 hour at r.t. 
before incubation with sheep polyclonal alkaline phosphatase-conjugated anti-DIG primary 
antibody diluted 1:2000 in B2 solution (Fab fragments, catalog number: 11093274910, Roche 
Applied Science, USA) overnight at 4 oC. The next day, the sections were rinsed in MABT for 2 
times at 5 minutes each at r.t. before washing in freshly prepared B3 solution (100 mM 
autoclaved Tris pH 9.5, 50 mM autoclaved magnesium chloride, 100 mM autoclaved sodium 
chloride, 0.1% Tween-20 in autoclaved dd H2O) for 30 minutes at r.t.. Alkaline phosphatase 
activity was detected by reaction with a mixture of filtered BCIP/NBT Liquid Substrate System 
(5-bromo-4-chloro-3'-indolyphosphate p-toluidine and nitro-blue tetrazolium chloride solution, 
catalog number: B1911, Sigma-Aldrich, USA) and 0.1% Tween-20 (Sigma-Aldrich) at r.t., 
where fresh solution was changed every 1 to 4 hours at r.t. or every 6 to 9 hours at 4 oC. The 
chromogenic reactions were allowed to continue until a desired empirically determined time 
point that ranged from 3 hours to more than 1 week. After which, the sections were washed in 
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0.1% Tween-20 (Sigma-Aldrich) in PBS for 3 times at 10 minutes each at r.t., rinsed quickly in 
autoclaved dd H2O once at r.t., dried completely at r.t. for a minimum of 20 minutes, before 
mounting in water-based Fluoromount-G (Catalog number: 0100-01, SouthernBiotech, USA) 
with glass cover slips (Catalog number: 16004-312, VWR, USA) and nail polish for permanent 
storage at 4 oC.  
 
 5.2.2. In situ hybridization combined with immunohistochemistry. 
 ISH procedures were performed as described in 2.5.2.A. and following procedures for 
immunohistochemistry (IHC) after ISH were carried out at r.t. unless otherwise stated. Once the 
desired chromogenic signal was obtained, the sections were washed in 0.1% Tween-20 (Sigma-
Aldrich) in PBS for 3 times at 10 minutes each, re-fixed in 4% PFA for 10 minutes, and rinsed in 
PBS for 3 times at 10 minutes each. Endogenous peroxidases were inactivated by incubating the 
sections in 0.5% hydrogen peroxide in ethanol for 30 minutes with agitation. Sections were then 
washed in PBS for 3 times at 2 minutes each, rinsed in 0.05% Tween-20 (Sigma-Aldrich) in PBS 
for 10 minutes, before blocking in Blocking solution (0.05% Tween-20, 20% serum in PBS) for 
30 minutes. Sections were incubated with primary antibody diluted in 0.05% Tween-20 (Sigma-
Aldrich) and 5% serum in PBS at 4 oC overnight. The following primary antibodies and their 
respective dilutions were used: rat anti-CTIP2, 1:1000 (Catalog number: AB18465, Abcam, 
USA), rabbit anti-CUX1 (CDP M-222), 1:100 (Catalog number: SC13024, Santa Cruz 
Biotechnology, USA), mouse anti-SATB2, 1:50 (Catalog number: AB51502, Abcam, USA), 
rabbit anti-PARVALBUMIN, 1:500 (Catalog number: PV25, Swant, USA), rabbit anti-OLIG2, 
1:100 (Catalog number: 18953, Immuno-biological lab, USA), mouse anti-APC (AP-7, CC-1), 
1:500 (Catalog number: OP80, EMD Millipore, USA), rabbit anti-S100β, 1:2000 (Catalog 
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number: ab41548, Abcam, USA). The next day, the sections were washed in Blocking solution 
for 3 times at 10 minutes each before incubating with relevant biotin-conjugated secondary 
antibody (Vector Laboratories, USA) diluted 1:200 in 0.05% Tween-20 (Sigma-Aldrich) and 5% 
serum in PBS for 1 to 2 hours. The following secondary biotinylated antibodies were used: goat 
anti-rat IgG (Catalog number: BA-9400), goat anti-rabbit IgG (Catalog number: BA-1000), goat 
anti-mouse IgG (Catalog number: BA-9200). The sections were then washed in 0.05% Tween-20 
(Sigma-Aldrich) in PBS for 3 times at 10 minutes each before incubating with freshly prepared 
AB solution (1 drop of solution A and 1 drop of solution B in 5 mL of 0.05% Tween-20 in PBS 
mixed well and kept in dark for 30 minutes before usage, VectaStain Elite ABC kit, catalog 
number: PK-6100, Vector Laboratories, USA) for 1 hour. After which, the sections were washed 
in 0.05% Tween-20 (Sigma-Aldrich) in PBS for 3 times at 10 minutes each. Chromogenic 
reaction was allowed to developed by incubating sections with DAB solution (2 drops of buffer 
solution, 4 drops of DAB, 2 drops of hydrogen peroxidase in 5 mL of distilled H2O mixed well 
and kept in dark before usage, DAB Peroxidase Substrate Kit, 3,3’-diaminobenzidine, catalog 
number: SK-4100, Vector Laboratories, USA)  in the dark for an empirically determined 
duration that ranged from 2 to 30 minutes. Once the desired IHC signal was achieved, the 
chromogenic reaction was stopped by rinsing in distilled H2O. After which, the sections were 
dried completely for a minimum of 20 minutes, before mounting in water-based Fluoromount-G 
(Catalog number: 0100-01, SouthernBiotech, USA) with glass cover slips (Catalog number: 
16004-312, VWR, USA) and nail polish for permanent storage at 4 oC. 
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5.3. Histological staining. 
 5.3.1. Nissl staining. 
 Nissl staining was performed at r.t. unless otherwise stated. Floating sections were 
matched if necessary, and were mounted on Superfrost Plus slides (Catalog number: 12-550-15, 
Fisher Scientific, USA) in autoclaved deionised water (dd H2O) and left to dry completely for at 
least 20 minutes. Sections were dehydrated in 70% ethanol for 2 to 3 minutes, 95% ethanol for 2 
to 3 minutes and then 100% ethanol for 2 times for 2 to 3 minutes each before being immersed in 
xylene for at least 2 hours. After which, the sections were gradually rehydrated by being 
immersed in 100% ethanol for 2 times at 2 to 3 minutes each, 95% ethanol for 2 to 3 minutes, 
and then 70% ethanol for 2 to 3 minutes before they were rinsed in 50% ethanol for 2 to 3 
minutes. Sections were washed in deionised water (ddH2O) for 5 minutes and stained with 
filtered Cresyl Violet stain (0.2% cresyl violet, 0.5% acetic anhydrate, 0.01 M sodium acetate, 
0.02 M sodium hydroxide in ddH2O) for 2 to 5 minutes (determined empirically). Sections were 
then washed in ddH2O for 1 minute, rinsed in 50% ethanol for 2 minutes, bled in 70% ethanol for 
2 to 10 minutes, bled again in 90% ethanol for 2 to 10 minutes before being immersed in 100% 
ethanol for 2 times at 2 to 10 minutes each. The time taken for each bleeding step in a series of 
increasing ethanol washes was determined empirically and was dependent on the final color 
stained by the sections. After the desired color and stain were achieved, sections were 
immediately put in xylene for at least 2 hours, before being mounted in xylene-based DPX 
Mountant (Catalog number: 44581, Sigma-Aldrich, USA) with glass cover slips (Catalog 
number: 16004-312, VWR, USA) for permanent storage at 4 oC. 
 
 5.3.2. Neurosilver staining. 
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 Neurosilver staining was performed at r.t. unless otherwise stated. Floating sections were 
matched if necessary, and were transferred into netwells (Catalog number: 07-200-212, Corning, 
USA). Control sections (Catalog number: PCS101, FD NeuroTechnologies, USA) were used in 
each experiment to act as positive controls for the staining. Neurosilver staining was carried out 
with the FD Neurosilver Kit II (Catalog number: PK301, FD NeuroTechnologies, USA) in 
accordance with the manufacturer’s protocol. All sections were covered during incubation to 
prevent the reagents from splashing and vaporizing. Sections were also fully immersed in the 
solution involved and were incubated free floating with agitation. Sections were rinsed with 
Milli-Q water for 2 times for 5 minutes each and transferred into a mixture containing equal 
volumes of Solutions A and B for 2 times for 10 minutes each before being placed in a mixture 
consisting of equal volumes of Solutions A and B with Solution E (1 drop of Solution E for each 
8 mL of a total volume of Solutions A and B) for 10 minutes. Sections were then transferred into 
a mixture of Solution C and Solution F (1 drop of Solution F for each 25 mL of Solution C) for 2 
times for 2 minutes each. Incubation time with Solution C and F was determined empirically, 
and could be lengthened to decrease the background stain or shortened to increase the staining 
intensity. Sections were then rinsed in a mixture of Solution D and Solution F (1 drop of Solution 
F for each 25 mL of Solution D) for 5 minutes, washed in Milli-Q water for 2 times for 3 
minutes each, immersed in diluted 1X Solution G in Milli-Q water for 2 times for 5 minutes each 
before being shaken in dark for 1 to 2 hours in diluted 1X Solution G. Sections were mounted in 
diluted 1X Solution G on Superfrost Plus slides (Catalog number: 12-550-15, Fisher Scientific, 
USA) and left to dry completely for at least 20 minutes in the dark. Sections were then cleared in 
xylene for 3 times for 3 minutes each before being mounted in xylene-based DPX Mountant 
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(Catalog number: 44581, Sigma-Aldrich, USA) with glass cover slips (Catalog number: 16004-
312, VWR, USA) for permanent storage at 4 oC. 
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5.4. Immunohistochemistry. 
 5.4.1. Fluorescent immunohistochemistry. 
 Fluorescent IHC procedures were carried out at r.t. unless otherwise stated. Floating 
sections were matched, if necessary, and were transferred into netwells (Catalog number: 07-
200-212, Corning, USA). Sections were washed in PBS for 3 times at 5 minutes each with 
agitation before blocking in Blocking buffer (0.3% bovine serum albumin, 8% serum, 0.3% 
Triton X-100 in PBS-Azide) for 1 hour with agitation. The sections were then incubated with 
primary antibody diluted appropriately in Blocking buffer overnight at 4 oC with agitation. The 
following primary antibodies and relevant dilutions were used: mouse anti-NeuN, 1:500 (Catalog 
number: MAB377, Millipore, USA), rabbit anti-CUX1 (CDP M-222), 1:100 (Catalog number: 
SC13024, Santa Cruz Biotechnology, USA), mouse anti-SATB2, 1:50 (Catalog number: 
AB51502, Abcam, USA), rat anti-CTIP2, 1:1000 (Catalog number: AB18465, Abcam, USA).  
 rabbit anti-NEUROFILAMENT 200, 1:200 (Catalog number: N4142, Sigma-Aldrich, USA), rat 
anti-MBP a.a. 82-87, 1:100 (Catalog number: MAB386, Millipore, USA), rabbit anti-OLIG2, 
1:100 (Catalog number: 18953, Immuno-biological lab, USA), rat anti-CD140a (or PDGF 
Receptor α chain), 1:100 (Catalog number: 558774, BD Pharmingen, USA) and mouse anti-APC 
(AP-7, CC-1), 1:500 (Catalog number: OP80, EMD Millipore, USA). The next day, sections 
were washed in PBS for 3 times at 10 minutes each with agitation before incubation with 
appropriate secondary antibodies (Molecular Probes Alexa series, Invitrogen, USA) diluted 
1:750 in Blocking buffer for 2 hours with agitation. After which, the sections were 
counterstained for 4’,6-diamidino-2-phenylindole (DAPI) diluted 1:50000 in PBS for 2 to 4 
minutes with agitation before rinsing in PBS for 3 times at 10 minutes each with agitation. 
Sections were then mounted on Superfrost slides (Catalog number: 22-178-277, Fisher Scientific, 
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USA) in autoclaved deionised water (dd H2O) and left to dry completely for a minimal time of at 
least 20 minutes in the dark. For confocal microscopy, the dried sections were mounted in water-
based Fluoromount-G (Catalog number: 0100-01, SouthernBiotech, USA) or DAPI-
Fluoromount-G if DAPI counterstain was not used prior (Catalog number: 0100-20, 
SouthernBiotech, USA) with glass cover slips (Catalog number: 16004-312, VWR, USA) and 
nail polish for permanent storage at 4 oC. For regular fluorescent microscopy, dried sections were 
mounted in xylene-based DPX Mountant (Catalog number: 44581, Sigma-Aldrich, USA) with 
glass cover slips (Catalog number: 16004-312, VWR, USA) for permanent storage at 4 oC. 
 
 5.4.2. Chromogenic immunohistochemistry. 
 Floating sections were matched, if necessary, and were transferred into netwells (Catalog 
number: 07-200-212, Corning, USA). Sections were washed in PBS for 3 times at 10 minutes 
each with agitation before inactivation of endogenous peroxidases. This inactivation step and 
subsequent procedures were performed in accordance to the IHC method after ISH, as described 
in 2.5.2.B. The following primary antibody and its dilution were used: rat anti-MBP a.a. 82-87, 
1:100 (Catalog number: MAB386, Millipore, USA).  
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5.5. Quantification analysis 
 5.5.1. Quantification of distinct PN populations. 
 5 to 6 anatomically matched sections from each mutant mouse (n = 3 wild type, n = 3 
Ppargc1α-/-, n = 3 Ppargc1αfl/fl and n = 3 Emx1-Cre; Ppargc1αfl/fl mice at 2 months of age) were 
selected and immunostained for CUX1, SATB2 and CTIP2 as described in section 5.4.1.. 
Littermate controls were used in all quantifications. Quantification was done for cells in the 
primary motor, somatosensory aand visual area (n = 2 to 3 sections per area per animal) and 
positive cells were defined by comparing to control staining. Quantification was executed with 
the ImageJ software (Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, 
Maryland, USA, http://imagej.nih.gov/ij/, 1997-2012.). Statistical analysis was achieved with the 
two tailed student’s T test and p values were calculated with Microsoft Excel 2003 software.  
 
 5.5.2. Quantification of distinct MBP-positive vacuoles. 
 5 anatomically matched sections from each mutant mouse (n = 3 Ppargc1αfl/fl and n = 3 
Emx1-Cre; Ppargc1αfl/fl mice at 2 months of age) were selected and immunostained for MBP as 
described in section 5.4.1.. Littermate controls were used in all quantifications. Quantification 
was done for cells in the primary motor, somatosensory aand visual area (n = 1 section per area 
per animal) and positive vacuoles were defined by comparing to control staining. The full 
cortical thickness was divided into 10 bins of equal area. Statistical analysis was achieved with 
the two tailed student’s T test and p values were calculated with Microsoft Excel 2003 software.  
 
 5.5.3. Quantification of distinct oligodendrocyte populations. 
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 5 anatomically matched sections from each mutant mouse (n = 3 Ppargc1αfl/fl and n = 3 
Emx1-Cre; Ppargc1αfl/fl mice at 2 months of age) were selected and immunostained for OLIG2, 
PDGFRα and APC, as described in section 4.5.3.B.. Quantification was done for cells in the 
primary somatosensory area (n = 2 sections per animal, n = 3 animals per genotype) and positive 
cells were defined by comparing to control staining. The full cortical thickness was divided into 
10 bins of equal area. An investigator blinded to the genotype of the samples quantified the 
number of positive cells in each bin. Statistical analysis was achieved with the two tailed 
student’s T test and p values were calculated with Microsoft Excel 2003 software. Travis Hallett 
is currently confirming these quantifications by analyzing additional sections across more 
animals. 
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5.6. Gain-of-function analysis. 
 5.6.1. Vector constructs. 
 For gain-of-function analysis to test the overexpression of Ppargc1α in cortical 
progenitors, a control vector with a constitutively active CMV enhancer / β actin promoter 
driving an internal ribosomal entry site (IRES) was used (6). This construct was generated and 
generously given by Prof. Carlos Lois from the Department of Brain and Cognitive Sciences, 
Massachusetts Institute of Technology in Cambridge, Massachusetts, USA. For the Ppargc1α 
induction construct, PCR fragments of full length Ppargc1α cDNA with XhoI and HpaI 
restriction enzyme sites at its 5’ and 3’ ends respectively were generated from a pSport1 vector 
from Open Biosystems (Accession number: BC066868, clone ID: 30094033, catalog number: 
MMM1013-9201993, Thermo Scientific, USA), with AccuPrime Pfx DNA polymerase (Catalog 
number: 12344-024, Invitrogen, USA) in accordance with manufacturer’s protocol. Primers for 
Ppargc1α were used, as shown in Table 5.3.. PCR fragments were cut with XhoI and HpaI (New 
England BioLabs, USA), ligated to similarly cut ControlGFP vector with the Quick Ligation Kit 
(Catalog number: M2200L, New England BioLabs, USA) and transformed into Top10 
competent cells. Clones were screened by restriction enzyme digest and sequenced with 
sequencing primers as described in Table 5.3.. A sequenced clone that is perfectly aligned to the 
murine Ppargc1α reference sequence BC066868.1 in both the sense and antisense orientations 
was selected for downstream analysis. This clone expressed Ppargc1α with a constitutively 
active CMV enhancer / β actin promoter and had a reporter IRES-EGFP (Ppargc1αGFP, Figure 
3.7.A.). 
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Table 5.3. Cloning and sequencing primers used to generate the Ppargc1αGFP construct.  
This table summarizes the different cloning and sequencing primers used to generate the 
Ppargc1αGFP construct, as described in section 5.6.1.. 
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Ppargc1α 
Cloning Forward 5’ – AAATTTCTCGAGACCACCATGGCTTGGGACATGTGC – 3’ 
 Reverse 5’ – AAA TTT GTT AAC TTA CCT GCG CAA GCT TCT C – 3’ 
Sequencing Forward 5’ – GCC AAC ACT CAG CTC AGC TAC – 3’ 
  5’ – TTG CAA GAC CGT GGT GCC – 3’ 
  5’ – AGG GAT GGC GAC TTC AGT AA – 3’ 
  5’ – GAG AAG CGG GAG TCT GAA AG – 3’ 
 Reverse 5’ – AAC AAT GGC AGG GTT TGT TC – 3’ 
  5’ – CCC TTT CTT GGT GGA GTG G – 3’ 
  5’ – TCA CTG TCA TCA AAT AGG CCA – 3’ 
  5’ – ACC AAC GTA AAT CAC ACG GC – 3’ 
 
 
 
 
 
 
 
 
 
 
Table 5.3. (Continued) 
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 5.6.2. In utero electroporation. 
 The day of vaginal plug by noon was designated as embryonic day 0.5 (E0.5). At E15.5, 
timed pregnant C57BL/6 wild type mouse dams were deeply anesthetized with Avertin by 
intraperitoneal injection, or with 2% isofluorane (Catalog number: 07-806-3204, Webster Vet, 
USA) by inhalation, and placed on a warm heating pat before, throughout and after the surgery 
during the recovery period. After a small incision was made at the midline of the anesthetized 
dam, a vertical midline laparotomy was carried out along the linea alba of the abdominal wall. 
This was followed by separation of the skin and abdominal wall by blunt dissection techniques 
on the intervening fascia. 690 nL of purified endotoxin-free DNA (1.5 to 2 μg/μL), mixed with 
0.005% Fast Green FCF (Catalog number: F7258-25G, Sigma-Aldrich, USA) to enable easy 
visualization of DNA upon injection, were injected under ultrasound backscatter microscopy 
(Vevo 770, VisualSonics, USA) guidance into the lateral ventricle. Five pulses of 40 volts each 
of 50 ms duration at 1 second intervals were delivered into the progenitors of the ventricular 
zone at the desired orientation with 5 mm diameter CUY650-P5 platinum electrodes (Protech 
International, USA) and a Nepa Gene square wave electroporator (Catalog number: 
CUY21EDIT, Nepa Gene, Japan). DNA was delivered by in utero electroporation to non-
sequential embryos along each horn, excluding the two embryos closest to the birth canal.  
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5.7. Neuronal metabolism analysis. 
 5.7.1. Tissue collection. 
 P14 and 2 month adult Emx1-Cre; Ppargc1αfl/fl and littermate control Ppargc1αfl/fl mice 
were terminated by cervical dislocation. Their brains were quickly removed by manual 
dissection and sectioned immediately at 999 μm thickness with cold PBS coronally with a 
VT1000S vibrating microtome (Leica Microsystems). Approximately 3 to 4 sections were 
obtained per brain. Tissue from the deep layers were collected with tissue punches of 0.35 mm 
diameter (Catalog number: 15070, Ted Pella Inc., USA) into a 1.5 mL eppendorf tube. These 
were immediately frozen with dry ice and stored at -80 oC before further downstream analysis. 8 
tissue punches were collected per hemisphere with a total of 48 punches collected across 6 
hemispheres of 3 sections (Figure 3.10.). 
 
 5.7.2. High performance liquid chromatography and mass spectrometry analysis. 
 Frozen tissue punches were resuspended with 2% acetonitrile in dd H2O, centrifuged to 
collect the samples, and triturated by pipetting up and down slowly for 10 times before freezing 
on dry ice for 2 minutes. Samples were then thawed at r.t. for 3 minutes, further triturated by 
pipetting up and down for 12 times before being centrifugated at 5000 rpm for 10 minutes at 4 oC. 
Supernatant was removed, kept on dry ice and processed immediately for high performance 
liquid chromatography and mass spectrometry analysis by Mr. Kelly Chatman at the Small 
Molecule Mass Spectrometry Facility, FAS Center for System Biology, Harvard University in 
Cambridge, Massachusetts, USA. Detection and quantification of Lactate, Taurine, Creatine, and 
N-Acetyl-Aspartate were achieved by LC/MS/MS analysis performed with an Agilent (Agilent 
Technologies, Santa Clara, CA) 6460 triple-quadrupole LC/MS/MS system employing a novel 
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LC/MS/MS method. The ([M - H+] - / product ion) monitored via electrospray ionization in the 
negative ion mode with multiple reaction monitoring (MRM) were Lactate (89.02/43.1 amu), 
Taurine (130.06/41.1 amu), Creatine (124.0/80.0 amu) and N-Acetyl-Aspartate (174.04/88.0 
amu). Mass spectrometer parameter settings were gas temp (350 °C), gas flow (12 L/min), 
nebulizer pressure (35 psi), sheath gas heater (400 °C), sheath gas flow (12 L/min), and capillary 
(4000V). An external standard curve mixture was prepared and analyzed at various 
concentrations ranging from 10 pg/uL to 1000 pg/uL and utilized for quantification. Reversed 
phase chromatography conditions with a Agilent Eclipse XDB-C18 5 uM 4.6 x 150 mm column 
were as follows: flow rate: 0.4 mLs/min; solvent A: 0.1% formic acid; solvent B: 0.1% formic 
acid in acetonitrile.  The gradient was as follows: t = 0 min, 2% B; t = 5 min, 2% B; t = 10 min, 
100% B; t = 11, 100%B; t = 11.1 min, 2% B; 3 minute equilibration. Concentrations for each 
compound were calculated and expressed in pg/mL. All experimental readings were then 
normalized to relevant creatine levels determined per experiment. Normalized readings were 
processed as a ratio of mutant over control. For P14 samples, n = 5 Emx1-Cre; Ppargc1αfl/fl and 
n = 3 littermate control Ppargc1αfl/fl murine samples were collected over 2 distinct experiments. 
For 2 month old adult samples, n = 7 Emx1-Cre; Ppargc1αfl/fl and n = 5 littermate control 
Ppargc1αfl/fl murine samples were collected over 3 different experiments. A two tailed student’s 
T test was performed for comparative analysis based on the ratios obtained and significant values 
were calculated, as shown in section 3.3.11 and Figure 3.8.. 
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5.8. Microscopy and image analysis. 
 Mounted sections were imaged on a Nikon 90i microscope (Catalog number: MVI 91933, 
Nikon Instruments, USA) with an XCite 120 illuminator (Catalog number: MVI 87541, EXFO, 
Canada) and Q-imaging 5 megapixel cooled CCD digital camera (Nikon Instruments, USA). 
Images were collected either in brightfield or fluorescence and analyzed with Volocity image 
analysis software (Version 6.0.1; Improvision Inc., USA).  
 Images were further processed with Adobe Photoshop/Illustrator software packages (CS5, 
Version 12.0.3, Adobe, USA).  
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Appendix / Chapter 6:  
Fezf2 directs the differentiation of corticofugal neurons from mouse embryonic stem cells.  
 
 
 
 
Author contribution: I started this work during my rotation in the laboratory. After I joined the 
laboratory, I collaborated with Dr. William Hendriks. We shared an equal collaboration in pilot 
molecular characterization of mESC-derived CLN and lentiviral transduction of cells undergoing 
aggregation. Besides this, with the input of Professor Paola Arlotta, I designed, performed and 
interpreted all the experiments detailed in this chapter except for the following: Dr. Bradley J. 
Molyneaux developed the method to label cortical PN intracellularly with subtype-specific 
markers and did the relevant FACS. Dr. Hsu-Hsin Chen developed the method to label nuclei of 
cortical PN with subtype-specific markers with Dr. Molyneaux and did the relevant FACS. She 
also quantified the number of layer specific CLN and generated the overexpressor mESC lines. 
Dr. Chiara Gerhardinger and Dr. Chen prepared the cDNA library from FACS-purified 
Fezf2+/GFP+ cells for deep sequencing. Deep sequencing analysis will be done with Dr. Loyal 
Goff. I also performed the transplantation experiments with the assistance of Zachary Trayes-
Gibson. I thank Dr. Hsu-Hsin Chen for her advice in this project. 
Publication: These data will be published in another article that is distinct from Chapters 2 
through 4.  
 
  249
6.1. Abstract. 
 The molecular signals that govern the development of distinct neuronal subtypes in the 
mammalian cerebral cortex are only beginning to be elucidated. Here, I focus on a specific 
subclass comprising corticospinal motor neurons (CSMN), a clinically relevant neuronal 
population that degenerates in Amyotrophic Lateral Sclerosis (ALS), and are permanently 
damaged in spinal cord injury (SCI).  
 With the identification of a series of neuronal subtype-specific genes that mark CSMN 
and other subcerebral projection neurons (SCPN) in vivo, it was notably discovered that the 
transcription factor Forebrain Embryonic Zinc Finger 2 (Fezf2) is necessary for the birth and 
early differentiation of all SCPN, including CSMN (i.e., Fezf2-/- mice lack SCPN in their cortex), 
and is sufficient to “fate-switch” otherwise fated progenitors and even early postmitotic neurons 
to generate deep layer corticofugal projection neurons (CfuPN), including CSMN. 
 The central role played by Fezf2 in early SCPN differentiation led me to investigate 
whether cell-autonomous developmental signals that direct early SCPN development in the 
embryo could be used to selectively generate these neurons from dorsal telencephalic progenitors 
derived from mouse embryonic stem cells (mESC) or mouse induced pluripotent stem cells 
(miPSC) in vitro. I found that Fezf2 overexpression, either by lentiviral transduction or by newly 
generated inducible mESC lines, represses callosal projection neuron (CPN) specific genes while 
inducing CfuPN specific signals. In addition, Fezf2 induction also results in selective changes in 
axonal connectivity where subcortical and subcerebral projections through the internal capsule to 
targets like the thalamus and cerebral peduncle are favored instead of callosal interhemispheric 
connections. Therefore, Fezf2 preferentially directs the differentiation of CfuPN from mouse 
embryonic stem cells.  
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6.2. Introduction. 
 Terminally differentiated fibroblasts can be reprogrammed into iPSC, which resemble 
ESC. Yamanaka and his group achieved a breakthrough in somatic reprogramming when they 
induced terminally differentiated mouse embryonic or adult fibroblasts to become miPSC by the 
ectopic expression of 4 transcription factors, namely Oct4, Sox2, Klf4 and cMyc (1-3). These 
miPSC are reminiscent of mESC in terms of their morphology, marker gene expression and 
ability to form teratomas that can differentiate into various tissues (1-3). Their work was 
confirmed and extended by the Hochedlinger and Jaenisch laboratories, which showed that these 
miPSC could undergo global epigenetic remodeling into an ES-like state (4, 5). Not only can 
they generate chimaeras that are competent for germline transmission (4), miPSC can also 
produce viable and fertile adult mice through tetraploid complementation, thus passing the most 
stringent test for pluripotency (6, 7). Besides murine fibroblasts, other cell types, such as adult 
mouse hepatocytes and gastric epithelial cells, also have been directly reprogrammed to generate 
iPSC (8). The direct reprogramming of somatic cells by transcription factors therefore made 
possible the efficient production of a large quantity of ESC-like iPSC that can be used in disease 
modeling and chemical screens among other downstream applications.   
 Directed differentiation of ESC can generate dorsal telencephalic precursors and cortical 
neurons. ES cells can be directed to differentiate into different neuronal subtypes, including 
lower motor neurons (9), cerebellar neurons (10, 11), midbrain neurons and hindbrain neurons 
(12). Notably, Watanabe et al. showed that ESC can also be directed to differentiate into 
Emx1+Bf1+Pax6+ dorsal telencephalic progenitors (DTP), when cultured in suspension under 
serum-free conditions and treated with Wnt and Nodal antagonists (Dkk1 and LeftyA) followed 
by Wnt3a treatment (13). Eiraku et al. improved the Watanabe method by using an efficient 
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three-dimensional aggregation culture to drive ESC to further differentiate into self-organized 
apico-basally polarized cortical neuroepithelial aggregates containing a core of DTP surrounded 
by cortical-like neurons (CLN) that are generated in a temporally controlled manner that mimics 
corticogenesis in vivo (14). Another study by Gaspard et al. showed similar results using a 
different protocol in which they directed the differentiation of adherent ESC monolayer cultures 
into Otx1+Pax6+ DTP before differentiating them into CLN under serum- and morphogen-free 
conditions, and in the presence of the Sonic hedgehog inhibitor cyclopamine (15, 16). 
Significantly, these studies verified previous work by Sally Temple and her group, indicating 
that the sequential timing of a generation of cortical PN from ES cells is “pre-programmed” and 
mimics the order of PN type generation from cortical progenitors in the embryo (17). However, 
in spite of this successful, sequential generation of different types of CLN, no one has managed 
to exclusively generate selected PN subtypes, particularly CSMN and other SCPN, in vitro. 
 Notably, prior work has shown that Fezf2 is a key transcription factor that is necessary 
and mostly sufficient for the specification and early differentiation of SCPN, including CSMN in 
vivo (18-21). Fezf2-/- mice display a complete absence of CSMN as well as other SCPN, and 
lacked the corticospinal tract as well as all subcerebral projections (21). Absence of 
SCPN/CSMN is accompanied by the specification of additional CPN (19). Gain-of-function 
analysis showed that Fezf2 overexpression in cortical progenitors fated to form the upper layer 
CPN “fate-switched” them to become neurons that not only express CfuPN-specific genes like 
Ctip2, Sox5, Tle4 and Tbr1, but also extend axons subcortically (i.e., to the thalamus) and 
subcerebrally (i.e., to the cerebral peduncle) (21, 22). Notably, this switch of fate does not 
require neural progenitors of cortical fate (23). Our laboratory has recently demonstrated that 
Fezf2 expression alone is sufficient to direct the differentiation of CfuPN ectopically within the 
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niche of the striatum from striatal progenitors in vivo (23). More remarkably, besides neural 
progenitors, Fezf2 alone is able to instruct lineage reprogramming of early postmitotic upper 
layer CPN to become CfuPN by changing their molecular characteristics as well as axonal 
connectivity from intracortical targets to subcortical and subcerebral targets like the SC (24). 
Therefore, Fezf2 is a critical transcriptional regulator that is sufficient to induce CfuPN, 
including SCPN/CSMN-specification. 
 Since Fezf2 plays a central role in the specification of CSMN and other SCPN in vivo 
(18-24) and mESC-derived DTP and CLN have already taken initial steps committed to a 
cortical neuron fate (13-16), I hypothesize that Fezf2 overexpression in DTP and/or CLN derived 
from mESC or miPSC can selectively direct their differentiation into CfuPN, including 
SCPN/CSMN in vitro. Before testing this hypothesis, I molecularly characterized the various 
DTP and CLN types derived from mESC and miPSC, using combinatorial marker analysis and 
deep sequencing analysis following fluorescence-activated cell sorting (FACS) purification. I 
found that distinct layer specific neurons are generated and a more in-depth expression profile by 
deep sequencing analysis is currently ongoing for future comparative analysis with bona fide 
SCPN at various developmental ages. This molecular characterization is important to gauge our 
present limits of generating cortical PN types in vitro and will serve as a benchmark for future 
improvements to current protocols. To test my hypothesis, I derived DTP and/or CLN from the 
aggregation culture and induced Fezf2 by lentiviral transduction or by using newly generated 
doxycycline inducible mESC lines. I found that Fezf2 overexpression represses CPN specific 
genes like Satb2 while it induces CfuPN specific genes like Mu-crystallin. Expression profiling 
of Fezf2 induced cells by deep sequencing is currently ongoing and is important for comparative 
analysis with bona fide SCPN at various developmental ages as well as CLN generated with 
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current methods. Axonal connectivity analysis of transplanted Fezf2 induced cells revealed that 
Fezf2 expressing cells preferentially develop subcortical and subcerebral projections through the 
internal capsule to the thalamus or even cerebral peduncle but not callosal interhemisphereic 
connections via the corpus callosum. Taken together, I conclude that Fezf2 preferentially directs 
the differentiation of CfuPN from mESC.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  254
6.3. Results. 
 6.3.1. Molecular characterization of mESC/miPSC-derived DTP and CLN from 
monolayer or aggregation culture. 
 mESC can be directed to differentiate into DTP and CLN either by monolayer culture 
under serum- and morphogen-free conditions, and in the presence of the Sonic hedgehog 
inhibitor cyclopamine (15, 16), or by aggregation culture where they self-organize into apico-
basally polarized cortical neuroepithelial aggregates containing a core of DTP surrounded by 
CLN (13, 14). Coculture of mESC with murine stromal cell line MS5 can also generate CLN 
(25). Although they can project to various subcortical structures when transplanted into early 
postnatal pups (14-16, 25), it is still unknown how closely mESC/miPSC-derived CLN resemble 
bona fide cortical PN at the molecular level. Understanding the differences and similarities 
between CLN and bona fide CfuPN/CSMN will not only allow us to gauge our present limits of 
generating cortical PN types in vitro and create a benchmark for future improvements to current 
protocols, but it will more importantly enable us to identify additional cell-autonomous signals 
that can be manipulated to further instruct mESC/miPSC into SCPN/CSMN. 
  6.3.1.A. Monolayer culture. 
 I am fortunate to have established collaboration with Professor Konrad Hochedlinger 
(Department of Stem Cell and Regenerative Biology, Harvard University) who has kindly 
provided me with several lines of miPSC (A1, A2 and A3 lines) that were derived from adult 
male fibroblasts as well as several lines of mESC (A4, A5 and A6 lines). Using these cell lines, I 
have molecularly characterized mESC/miPSC-derived DTP and CLN from the monolayer 
culture. I differentiated mESC (A5, n = 1) and miPSC (A2, n = 1; A3, n = 1) into CLN by plating 
them as a monolayer before differentiating them into DTP and CLN under serum- and 
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morphogen-free conditions for 12 days, and in the presence of the Sonic hedgehog inhibitor 
cyclopamine from day 2 to 10 of differentiation, as shown in Figure 6.1.A. (15, 16). DIV refers 
to day of differentiation. Although marker analysis confirmed prior published results that 
monolayer culture can generate NESTIN+ progenitors by DIV 14 and TUJ1+ neurons by DIV 21, 
I found that specific generation of PAX6+ DTP and CTIP2+ or SATB2+ CLN is inefficient and 
deviates significantly from previously reported percentages (Figures 6.1.B. to 6.1.C., data not 
shown for PAX6). Many cells also continue to express the pluripotency marker OCT3/4 at DIV 
21 (data not shown). These results, as compared to my results from the aggregation culture 
described in section 6.3.1.B., indicate that the latter is a more efficient system to drive neural 
differentiation towards DTP and CLN. Therefore, I chose to focus on the more robust 
aggregation culture to derive DTP/CLN from mESC/miPSC for the rest of my studies.  
  6.3.1.B. Aggregation culture. 
 In addition to the monolayer culture, I have also molecularly characterized 
mESC/miPSC-derived DTP and CLN from the aggregation culture. I differentiated mESC (A5, n 
= 3) and miPSC (A1, n = 1; A2, n = 1; A3, n = 1) into CLN by culturing them in suspension to 
form 3D aggregates under serum-free conditions, and treating them with Wnt and Nodal 
antagonists (Dkk1 and LeftyA) followed by Wnt3a treatment, as shown in Figure 6.2.A. (14). I 
analyzed the identity of mESC/miPSC-derived progenitors and neurons at DIV 11 and 18 by 
immunocytochemistry (ICC) and ISH for pluripotent marker OCT3/4, early neural progenitor 
marker NESTIN, forebrain progenitor marker BF1, dorsal telencephalic marker PAX6, early and 
mature pan-neuronal markers TUJ1 and NeuN, and somatodendritic marker MAP2. I found that 
the aggregation culture is efficient in driving differentiation as few mESC/miPSC remain  
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Figure 6.1. Molecular characterization of mESC/miPSC-derived DTP and CLN from 
monolayer culture. 
(A) Schematic for monolayer culture. DTP and CLN were preferentially generated by DIV 14 
and 21 respectively. DIV refers to day of differentiation. This figure is adapted from (15, 16).  
(B) While many NESTIN+ progenitors were generated by DIV 14, few of them are PAX6+ (data 
not shown). This result differs significantly from previously reported percentages (15, 16).  
(C) Although many TUJ1+ immature neurons were generated at DIV 21, few are CTIP2+ or 
SATB2+. This result varies considerably from previously reported percentages (15, 16).  
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Figure 6.1. (Continued) 
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Figure 6.2. Molecular characterization of mESC/miPSC-derived DTP and CLN from 
aggregation culture. 
(A) Schematic for aggregation culture. DTP and CLN were preferentially generated by DIV 11 
and 18 respectively. DIV refers to day of differentiation. This figure is adapted from (14).  
(B and E) Few mESC/miPSC remained pluripotent (OCT3/4+) by DIV 11 and virtually none 
were pluripotent by DIV 18. 
(C and F) mESC/miPSC differentiated into NESTIN+ progenitors as early as DIV 11 and 
continue to do so till DIV 18. 
(D and G) MAP2+ neurons were generated as early as DIV 11 and were produced till DIV 18. 
Scale bars: 10 μm (B – G).  
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pluripotent (OCT3/4+) by DIV 11 and virtually none are pluripotent by DIV 18 (Figures 6.2.B. 
and 6.2.E.). mESC/miPSC also differentiate into NESTIN+ progenitors and MAP2+ neurons as 
early as DIV 11 (Figures 6.2.C. and 6.2.D.) and persist till DIV 18 (Figures 6.2.F. and 6.2.G.). 
Further analysis also revealed that BF1+/PAX6+ dorsal forebrain progenitors can self-organize 
within an aggregate into distinct proliferative cores surrounded by NeuN+/TUJ1+ neurons from 
DIV 11 to DIV 18 (Figures 6.3.A. to 6.3.L.).  
 In addition, I tested for the expression of the following CfuPN specific markers: SOX5 
(expressed in layer V/VI) (26), CTIP2 (expressed at high levels in layer V and low levels in layer 
VI) (27) and Fezf2 (expressed at high levels in layer V and low levels in layer VI) (18, 20, 21); 
SCPN-specific markers: BHLHB5 (expressed in layers II/III and layer V) (28), MU-
CRYSTALLIN (expressed in layer V) (27) and Clim1 (expressed in layer V) (27); CPN specific 
markers: CUX1 (expressed in layers II/III) (29), SATB2 (expressed in all layers) (30, 31), LHX2 
(expressed in layers II/III) (32, 33) and BRN2 (expressed in layers II/III and V) (34, 35); and 
corticothalamic PN (CThPN) specific markers that are expressed at high levels in layer VI: 
TBR1 (36, 37), TLE4 (38) and ZFPM2/FOG2 (39). Combinatorial marker analysis is not only 
necessary to identify CfuPN/SCPN, but also crucial to define the extent of differentiation into 
specific neuronal subtypes and to investigate the possible acquisition of mixed identity.  
Combinatorial marker analysis demonstrated that mESC/miPSC can robustly differentiate into 
cortical plate-like cells that are TBR1+CTIP2+ from DIV 11 to DV 18 (Figures 6.4.A. to 6.4.I.). 
Further qualitative analysis at DIV 18 revealed that the majority of CLN are single positive for 
cortical layer specific genes such as TLE4 (highly expressed in layer VI CThPN), CTIP2 (highly 
expressed in layer V SCPN) and SATB2 (highly expressed in CPN across all cortical layers) 
(Figures 6.5.B. to 6.5.E.). Occasional double positive cells that are TLE4+CTIP2+,  
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Figure 6.3. mESC/miPSC-derived neural progenitors and postmitotic neurons occupy 
distinct domains within an aggregate.  
(A – F) BF1+ forebrain progenitors can self-organize within an aggregate into distinct 
proliferative cores surrounded by NeuN+ neurons from DIV 11 to DIV 18. Boxes indicate areas 
where high magnification images are taken. High magnification analysis showed that the 
progenitors and neurons are distinct populations.  
(G – L) Similar to what is observed in (A – F), PAX6+ dorsal telecephalic progenitors can self-
organize within an aggregate into proliferative cores surrounded by TUJ1+ immature neurons 
from DIV 11 to DIV 18. Boxes indicate areas where high magnification images are taken. High 
magnification analysis showed that the progenitors and neurons are different populations. Scale 
bars: 10 μm (A – L, including inserts).  
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Figure 6.4. Cortical plate-like neurons are generated from mESC and miPSC at early and 
late stages of differentiation. 
(A) At E13.5, TBR1+CTIP2+TUJ1+ cortical plate-like neurons occupy the more superficial layers, 
above the proliferative zone consisting of the subventricular and ventricular zone that reside 
adjacent to the lateral ventricle (LV).  
(B – I) mESC/miPSC can robustly differentiate into cortical plate-like neurons that are 
TBR1+CTIP2+TUJ1+ from DIV 11 (B – E) to DV 18 (F – I). Scale bars: 100 μm (A), 10 μm (B – 
I).  
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Figure 6.5. Distinct layer-specific CLN are generated from mESC and miPSC at early and 
late stages of differentiation. 
 (A) At E17.5, distinct layer-specific cortical neurons that are predominantly TLE4+ or CTIP2+ or 
SATB2+ are generated and have migrated from the proliferative zone to occupy their destined 
layers in an “inside-out” fashion where later born neurons migrate past earlier born neurons to 
occupy more superficial layers.  
(B – E) Majority of CLN are single positive for cortical layer specific genes such as TLE4 
(highly expressed in layer VI CThPN), CTIP2 (highly expressed in layer V SCPN) and SATB2 
(highly expressed in CPN across all cortical layers). Occasional double positive cells that are 
TLE4+CTIP2+, TLE4+SATB2+ and CTIP2+SATB2+ cells as well as rare triple positive cells that 
are TLE4+CTIP2+SATB2+ are also found (data not shown).  
(F) Quantitative analysis by Dr. Hsu-Hsin Chen ascertained the results in (B – E) and showed 
that among the single positive cells, TLE4+ cells have the highest proportion followed by CTIP2+ 
cells with SATB2+ cells having the lowest proportion. Scale bars: 100 μm (A), 10 μm (B – E).  
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TLE4+SATB2+ and CTIP2+SATB2+ cells as well as rare triple positive cells that are 
TLE4+CTIP2+SATB2+ are also found (data not shown). Quantitative analysis by Dr. Hsu-Hsin 
Chen ascertained these results and showed that among the single positive cells, TLE4+ cells have 
the highest proportion followed by CTIP2+ cells with SATB2+ cells having the lowest proportion 
(Figure 6.5.F.). Thus, the aggregation culture can produce significant numbers of cortical plate-
like cells as well as CLN that can successful segregate layer specific marker genes. Of relevant 
interest, to understand if the aggregation culture can generate layer V SCPN like cells, I have 
isolated the CTIP2+ cells and nuclei by FACS for ongoing expression profiling by deep 
sequencing, as described in section 6.3.2.. Future comparative analysis with bona fide SCPN that 
has been profiled with similar methods by Dr. Bradley J. Molyneaux and Dr. Hsu-Hsin Chen will 
be imperative to understand how similar or different these cells are in terms of their molecular 
identities and to provide the field with a much needed framework to understand and enhance 
present directed differentiation protocols.  
 Moreover, CfuPN/SCPN-specific marker analysis also showed that mESC/miPSC can 
differentiate into ZFPM2+SOX5+ cells that are more similar to layer VI CThPN rather than layer 
V SCPN like ZFPM2-SOX5+ cells (data not shown). CPN specific marker analysis further 
determined that SATB2+ and CUX1+BRN2+ cells are generated by DIV 18 but not earlier at DIV 
11 (data not shown). In all, these data support previous reports that mESC/miPSC-derived CLN 
undergoing aggregation are generated in a temporally controlled manner that mimics 
corticogenesis in vivo.  
 To determine if CLN identity is dependent on maintaining the 3D structure and to 
facilitate combinatorial marker analysis and quantification, I dissociated the aggregates, replated 
the cells as a monolayer at DIV 10, and performed similar marker analysis at DIV 11 and DIV 
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18, as shown in Figure 6.6.A.. My results revealed that CLN maintain their identity as a 
monolayer where TUJ1+ immature neurons are either single or double positive for TBR1 and/or 
CTIP2 at DIV 11 and DIV 18 (Figures 6.6.B. to 6.6.E, data not shown for DIV 18). 
Combinatorial analysis with layer specific markers further showed that the majority of cells are 
TLE4+ cells followed by a substantial number of CTIP2+ cells with SATB2+ cells having the 
lowest proportion at DIV 18 (Figures 6.6.F. to 6.6.I.). Thus, dissociated mESC/miPSC-derived 
CLN do maintain their identity in a monolayer after an initial period of aggregation. This 
characterization is important because lentiviral transduction to overexpress Fezf2 prove to be 
efficient only when cells are in a monolayer and not in aggregates, as described in section 6.3.3.. 
Although replated cells from aggregates behave as a monolayer shortly after dissociation, they 
exhibit a tendency to cluster and form “clumps” in cultures as they differentiate, ultimately 
resulting in a multilayer culture with areas of different cellular densities by DIV 18 (data not 
shown), which makes unbiased quantification of distinct layer specific CLN problematic.  
 In all, my molecular characterization of DTP and CLN derived from either monolayer or 
aggregation cultures showed that the aggregation culture is a more robust system to generate 
these cell types of interest. Qualitative combinatorial marker analysis revealed that the 
aggregation culture can generate cortical plate-like cells that are TBR1+CTIP2+ as well as layer 
specific CLN that singly express markers like TLE4, CTIP2 and SATB2, a result that is further 
supported by quantitative analysis. I also demonstrated that dissociated mESC/miPSC-derived 
CLN can maintain their identity in a monolayer after an initial period of aggregation. Ongoing 
expression profiling of CTIP2+ cells and nuclei from the aggregation culture, as described in 
section 6.3.2., will provide insights on how these cells resemble SCPN in vivo.  
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Figure 6.6. Dissociated mESC/miPSC-derived CLN maintain their identity in a monolayer 
after initial period of aggregation. 
(A) Schematic of dissociation after an initial period of aggregation.  
(B – E) 1 day after dissociation, many TUJ1+ immature neurons continue to be either single or 
double positive for TBR1 and CTIP2. This is in line with what is observed in aggregates, as 
shown in Figure 6.4..  
(F – I) 10 days after dissociation, distinct populations of layer-specific CLN that are single, 
double or triple positive for TLE4, CTIP2, and SATB2 were formed. Proportions of single 
positive cells are in agreement with what is observed in aggregates, as shown in Figure 6.5., 
where majority of cells are TLE4+ cells followed by a substantial number of CTIP2+ cells with 
SATB2+ cells having the lowest proportion at DIV 18. Scale bars: 10 μm (B – I). 
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 6.3.2. Population-specific FACS purification of mESC-derived CLN. 
 This work was done in collaboration with Dr. Bradley J Molyneaux, a post-doctoral 
fellow, and Dr. Hsu-Hsin Chen, an instructor in our laboratory.  
 To understand how mESC-derived CLN compare to bona fide cortical PN subtypes, it is 
crucial to isolate and molecularly profile different CLN populations in addition to performing 
qualitative marker gene analysis. This work is currently limited by the lack of reporter mESC 
lines that can delineate specific CLN classes. However, Dr. Molyneaux recently developed a 
method to label cortical PN intracellularly using a combination of subtype-specific antibodies 
like Ctip2, Tle4 and Satb2, and isolate them by FACS (unpublished data). Together with Dr. 
Chen, he also developed a similar method to mark nuclei extracted from cortical PN 
(unpublished data). Both methods enable us not only to overcome the cellular heterogeneity of 
mESC-derived CLN that confounds gene expression profiling, but also to develop an unbiased 
quantitative approach to determine the proportions of different CLN subtypes in vitro. 
 To quantify and purify the heterogeneous cell populations derived in vitro, I 
enzymatically or chemically dissociated DIV18 mESC-derived neural aggregates into single 
cells, and stained them with subtype-specific antibodies including CTIP2 and SATB2 (n = 3). 
Flow cytometry analysis revealed that the percentages of CTIP2+ and SATB2+ cells are highly 
variable between independent experiments, which are not observed in my ICC results (data not 
shown). This is likely due to inconsistent dissociation of these aggregates into a single cell 
suspension. To optimize the cellular dissociation of these aggregates, I tried various mechanical, 
chemical (Neurocult) and enzymatic (Papain, Accutase, Accumax, TrypLE Express and Trypsin-
EDTA) protocols but could not arrive at a robust reproducible method. To circumvent this 
problem, I extracted nuclei from these aggregates and stained them with similar primary and 
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secondary antibodies before flow cytometry analysis (n = 1). Pilot data showed that CTIP2+ 
(~36%) and SATB2+ (~23%) cell populations are distinguished with this method (data not 
shown). Consistent with ICC results, combinatorial analysis revealed 2 populations that are 
CTIP2highSATB2+ or CTIP2lowSATB2- (data not shown). I have since purified CTIP2+ cells as 
well as nuclei from DIV 18 mESC-derived neural aggregates by FACS, extracted their RNA and 
assessed their quality with a bioanalyzer. Dr. Chen has prepared the cDNA library and the 
samples have been sent for Illumina HiSeq-based deep sequencing. Deep sequencing analysis 
will be done in collaboration with Dr. Loyal Goff, a post-doctoral fellow in the laboratory of 
Professor John Rinn (Department of Stem Cell and Regenerative Biology, Harvard University). 
The molecular profiles of these mESC-derived CLN populations will be compared to those of 
E15.5 and E16.5 cortical PN subtypes that have been purified and profiled by Dr. Molyneaux 
and Dr. Chen (unpublished data).  
  
 6.3.3. Lentiviral transduction of dissociated mESC/miPSC-derived DTP and CLN 
instead of aggregates is efficient and induces neuronal differentiation.  
  6.3.3.A. Lentiviral transduction of miPSC undergoing aggregation is 
inefficient.  
 This work was done in collaboration with Dr. William Hendriks, Head of iPS Genome 
Editing Service at the Harvard Stem Cell Institute. 
 Dr. William Hendriks, together with Dr. Caroline Rouaux in our laboratory, made an 
expression construct that contains the Fezf2 transgene downstream of an eGFP reporter gene and 
a “self-cleaving” T2A peptide sequence. I refer to this construct as LVCMV-Fezf2 (Figure 6.7.A.) 
and the control vector as LVCMV-GFP. To determine whether miPSC undergoing aggregation can  
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Figure 6.7. Lentiviral transduction of mESC/miPSC undergoing aggregation is inefficient.  
(A) Lentiviral constructs and schematic of lentiviral transduction.  
(B – D) Immunostaining for GFP on cross sections of untransduced mock aggregates and 
aggregates transduced with either LV CMV-Fezf2 or LV CMV-GFP collected at DIV 3 revealed the 
segregation of Fezf2+/GFP+ cells to the outermost position of the aggregate.  
(E – G) ISH for Fezf2 confirmed the results in (B – D) where Fezf2+ cells are located at the 
periphery of the aggregate. Scale bars: 100 μm (B – G). 
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be efficiently transduced with lentivirus expressing LVCMV-Fezf2 or LVCMV-GFP, I transduced 
miPSC (A3, n = 3) with either LVCMV-Fezf2 or LVCMV-GFP at DIV 0 and analyzed GFP expression 
at day 3 and day 18 of differentiation. Fluorescent live microscopy analysis showed that 
Fezf2+/GFP+ transduced aggregates expressed eGFP and maintained its expression for at least 18 
days into differentiation (data not shown). However, immunostaining for GFP on cross sections 
of untransduced mock aggregates and aggregates transduced with either LVCMV-Fezf2 or LVCMV-
GFP collected at DIV 3 revealed the segregation of Fezf2+/GFP+ cells to the outermost position in 
the aggregate (Figures 6.7.B. to 6.7.D.). In situ hybridization (ISH) for Fezf2 showed similar 
results where Fezf2 induced cells are present only at the periphery of an aggregate in LVCMV-Fezf2 
transduced cells but not LVCMV-GFP transduced and mock untransduced cells (Figures 6.7.E. to 
6.7.G.). To determine whether the transduction efficiency could be improved, together with Dr. 
Hendriks, I tested different multiplicities of infection (MOI) ranging from 500 to 2,000. We 
found that the GFP+ cells segregate to the outermost surface of the aggregate at day 3 of 
differentiation, regardless of the MOI used (data not shown). Our transduction protocol involved 
transducing miPSC as dissociated, single-cell suspensions and incubating them with virus 
through aggregation for at least 16 hours. To test if we could increase the number of transduced 
cells in the aggregate by using another transduction protocol, we transduced a monolayer of 
miPSC cultured on gelatin-coated dishes before dissociating them for aggregation. We obtained 
high transduction efficiencies (more than 90%) for miPSC transduced as a monolayer and 
formed aggregates that consist of mostly transduced cells (more than 90%) at day 0 of 
differentiation (data not shown). Yet, immunostaining for GFP on cross sections of GFP- and 
Fezf2-transduced aggregates at DIV 3 still show the segregation of GFP+ cells (data not shown). 
This suggests that the transgene may be silenced in transduced cells located at the core of the 
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aggregate but not in cells residing at the periphery. It is also possible that non-transduced cells 
proliferate at a much higher rate than transduced cells and form the core of the aggregates, thus 
segregating the less proliferative, transduced cells to the periphery. We conclude that lentiviral 
transduction of miPSC undergoing aggregation is inefficient and highly variable.  
  6.3.3.B. Lentiviral transduction of dissociated mESC/miPSC-derived DTP 
and CLN as a monolayer is efficient and induces neuronal differentiation.  
 As shown in section 6.3.3.B., lentiviral transduction of mESC/miPSC undergoing neural 
aggregation is inefficient, as transduced cells would segregate to the outermost periphery of the 
aggregate. Since dissociated mESC/miPSC-derived CLN do maintain their identity in a 
monolayer after an initial period of aggregation, in order to improve lentiviral transduction of 
DTP/CLN from neural aggregates, I first differentiated A5 mESC by culturing them in 
suspension to form 3D aggregates for 10 days and chemically dissociated these aggregates 
before replating them as a monolayer on fibronectin/laminin/poly-D-lysine coated coverslips for 
lentiviral transduction on DIV 11, as shown in Figure 6.8.B.. I used lentiviruses expressing 
LVGFP, LVFezf2, LV2AGFP, LVFezf2/Ngn2 or LVFezf2/Mash1 (Figure 6.8.A.), and performed marker gene 
analysis as described in section 6.3.1.B. at DIV 16 and 20. I found a high proportion of cells to 
be transduced (more than 50% by observation), regardless of the type of lentivirus used (Figures 
6.8.C. to 6.8.J., data not shown for DIV 16). This indicates that lentiviral transduction of 
dissociated cells from aggregates is efficient. Molecular analysis also showed that most 
transduced cells become TUJ1+ or NeuN+ neurons (Figures 6.8.C. to 6.8.J., data not shown for 
DIV 16). Thus, lentiviral transduction of mESC-derived DTP/CLN is efficient and does not 
inhibit neural differentiation. Moreover, combining proneural genes like Ngn2 and Mash1 with 
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Figure 6.8. Lentiviral transduction of dissociated mESC/miPSC-derived DTP and CLN as 
a monolayer is efficient and induces neuronal differentiation.  
(A) Lentiviral constructs made. 
(B) Schematic of lentiviral transduction of dissociated mESC/miPSC-derived DTP and CLN 
after an initial period of aggregation.  
(C – J) Lentiviral transduction is efficient as more than 50% of cells by observation were 
transduced, regardless of the lentivirus used. It also does not inhibit neural differentiation as 
lentivirally transduced cells are neuronal in morphology and are TUJ1+ (C – F) and NeuN+ (G – 
J). Scale bars: 10 μm (C – J). 
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Fezf2 also did not seem to significantly enhance neural differentiation (data not shown). Hence, I 
only utilized LVFezf2 and LVGFP constructs for the remaining experiments. 
 
 6.3.4. Fezf2 overexpressor mESC lines efficiently express transgene upon 
doxycycline induction.  
  6.3.4.A. Generation of doxycycline-inducible Fezf2-overexpressor mESC line. 
 This work was done in collaboration with Dr. Hsu-Hsin Chen.  
 Efficient lentiviral transduction of mESC/miPSC-derived DTP/CLN in vitro relies on 
successful dissociation of neural aggregates into a monolayer. Often, inconsistent dissociation 
results in a multilayer culture with clumps of cells, which affects the transduction efficiency at 
different parts of the culture. Moreover, random lentiviral integration may undermine the 
differentiation capability of some infected cells. To address these limitations, Dr. Hsu-Hsin Chen 
generated doxycycline-inducible Fezf2-overexpressor mESC lines (with or without 
Gfp/tdTomato reporter) targeted to the HPRT locus, using a recently developed Inducible 
Cassette Exchange (ICE) system (40) (Figure 6.9.B.). She generated targeting constructs using 
Gateway compatible shuttle vectors (41) (Figures 6.9.A. and 6.9.C.). I utilized these 
overexpressor lines for subsequent experiments: (i) GFP line that only expresses GFP to act as a 
control cell line, (ii) Fezf2IRESGFP line that expresses Fezf2 and a GFP reporter and (iii) 
Fezf2IREStdTomato line that expresses Fezf2 and a tdTomato reporter.  
  6.3.4.B. Fezf2 overexpressor mESC lines efficiently express transgene upon 
doxycycline induction.  
 To test that trangene activation is tightly regulated by doxycycline administration, I 
differentiated the GFP, Fezf2IRESGFP and Fezf2IREStdTomato lines by culturing them in suspension to 
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Figure 6.9. Fezf2 overexpressor mESC lines efficiently express transgene upon doxycycline 
induction.  
(A) Creation of targeting constructs with heterologous loxP sites by Gateway-recombination.  
(B) A schematic of the Inducible Cassette Exchange (ICE) system. Cre-mediated recombination 
in the A2LoxCre mESC line resulted in the insertion of the transgene under a TetO promoter 
targeted to the HPRT locus. Figure A and B are adapted from (40).  
(C) Targeting constructs (with/without GFP/tdTomato reporter). Figure C is adapted from (41).  
(D – G) ICC for GFP showed that the newly generated overexpressor mESC lines efficiently 
express transgene only upon doxycycline (Dox) induction. – Dox indicates no Dox addition 
while + Dox indicates the addition of Dox from DIV 10 to DIV 18. Scale bars: 100 μm (D – G). 
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form 3D aggregates for 10 days before adding doxycycline from DIV 10 to DIV 18. 
Immunostaining on cross-sections of uninduced and induced aggregates for GFP showed that 
transgene expression is only induced upon doxycycline addition and not otherwise (Figures 
6.9.D. to 6.9.G.). Hence, these overexpressor lines can efficiently express transgene upon 
doxycycline induction. Interestingly, some cells in the aggregate—particularly cells organized to 
form the core of an aggregate—do not express the transgene upon doxycycline administration. 
Subsequent marker analysis, as described in sections 6.3.5. and 6.3.6., showed that these cells 
also do not express any marker of interest, which led me to speculate that these cells are 
unhealthy, dying cells that may have silenced the HPRT locus.  
 
 6.3.5. Fezf2 induced cells repress certain CPN specific genes. 
  6.3.5.A. Lentiviral transduction. 
 I hypothesize that Fezf2 overexpression in DTP and/or CLN derived from mESC or 
miPSC can selectively direct their differentiation into CfuPN, including SCPN/CSMN in vitro. If 
this hypothesis is true, I expect Fezf2 induction to repress CPN specific genes. To test this 
hypothesis, I first differentiated A5 mESC by culturing them in suspension to form 3D 
aggregates for 10 days and chemically dissociated these aggregates before replating them as a 
monolayer on fibronectin/laminin/poly-D-lysine coated coverslips for lentiviral transduction on 
DIV 11, as shown in Figure 6.10.A. (n = 3). Doxycycline was added from DIV 12 to DIV 20 for 
a period of 8 days to maintain transgene expression. I used lentiviruses expressing LVFezf2 or 
LVGFP (Figure 6.10.A.), and stained for CPN specific marker SATB2 (30, 31) at DIV 20. 
Strikingly, I discovered that Fezf2 induced cells do not coexpress SATB2, while control GFP 
induced cells do (Figures 6.10.B. to 6.10.G.). This is consistent with previous work in our  
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Figure 6.10. Fezf2 induced cells repress SATB2, a CPN specific marker. 
(A) Lentiviral constructs and a schematic of lentiviral transduction. 
(B – G) Fezf2 induced cells (white arrows) do not coexpress SATB2, a marker that is expressed 
in CPN across all cortical layers. These cells segregate away from mock untransduced cells that 
are SATB2+. In contrast, GFP induced cells coexpress SATB2 and are clustered together with 
SATB2+ cells.  
(H) Overexpressor mESC lines and a schematic illustrating transgene induction by doxycycline 
(Dox) addition.  
(I – N) Similar to results obtained in (B – G), Fezf2 induced cells (white arrows) do not 
coexpress SATB2 while GFP induced cells do. Likewise, Fezf2 induced cells segregate away 
from SATB2+ cells while GFP induced cells cluster together with SATB2+ cells. Scale bars: 50 
μm (B – G and I – N), 10 μm (inserts). 
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laboratory, which demonstrated that Fezf2 overexpression represses CPN specific marker 
SATB2 in cortical progenitors that normally generate upper layer CPN in vivo (22). Hence, Fezf2 
overexpressing cells repress CPN specific marker SATB2. 
 To quantify the different CLN populations upon Fezf2 overexpression with an unbiased 
method, as described in section 6.3.2., I dissociated the infected culture at DIV 20 into a single 
cell suspension, then fixed, permeabilized and stained them intracellularly with subtype-specific 
markers like CTIP2 and SATB2, and analyzed them by flow cytometry analysis (n = 3). Similar 
to what is observed in section 6.3.2., the percentages of CTIP2+ and SATB2+ cells are highly 
variable between independent experiments, which is likely caused by inconsistent dissociation of 
these cells that tend to form clumps by DIV 20 (data not shown). To circumvent this limitation, I 
repeated the experiment on nuclei extracted from transduced cells (n = 1). I found that the 
amount of transduced cells needed for such analysis is much greater than is experimentally 
feasible. Hence, future quantification may need to rely on the biased method of quantifying cells 
of interest within a selected field of interest.  
  6.3.5.B. Overexpressor mESC lines. 
 To ascertain the results shown in section 6.3.5.A., I differentiated the GFP, Fezf2IRESGFP 
and Fezf2IREStdTomato lines by culturing them in suspension to form 3D aggregates for 10 days 
before adding doxycycline from DIV 10 to DIV 18 for a period of 8 days to maintain transgene 
expression, similar to what was performed with lentiviral transduction (Figure 6.10.H.). ICC for 
CPN specific marker SATB2 at DIV 18 revealed similar results where Fezf2 induced cells do not 
coexpress SATB2, while control GFP induced cells do (Figures 6.10.I. to 6.10.N., data not 
shown for Fezf2IREStdTomato line). Therefore, these results further confirm that Fezf2 
overexpressing cells repress CPN specific marker SATB2. ISH for PlxnD1, a marker that is  
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expressed at high levels in CPN of layer IV and Va and at low levels in CPN of upper layers 
II/III (42), also showed that Fezf2 induced cells express PlxnD1 at low levels, as compared to 
GFP control cells that express PlxnD1 at high levels (data not shown). In contrast, ISH for Dkk3, 
a marker that is expressed at high levels in CPN of deep cortical layer VI (42), did not reveal any 
observable differences between Fezf2 and control GFP induced cells (data not shown). Hence, 
these data show that Fezf2 induced cells can repress CPN specific genes like SATB2 and PlxnD1 
but not Dkk3. It is also likely that ISH analysis is not sensitive enough to detect a few fold 
difference in gene expression as quantitative PCR (qPCR) analysis in section 6.3.5.C. revealed a 
reduction in Dkk3 mRNA expression in FACS-purified Fezf2 induced cells. Hence, a 
comprehensive expression profile by deep sequencing and subsequent comparative analysis will 
enable us to better determine the full extent of this repression mediated by Fezf2. 
  6.3.5.C. Expression profiling of FACS-purified Fezf2 induced cells. 
 To understand the full extent of Fezf2 mediated repression of CPN specific genes, I 
differentiated the GFP and Fezf2IRESGFP lines by culturing them in suspension to form 3D 
aggregates for 10 days before adding doxycycline from DIV 10 to DIV 18 for a period of 8 days 
to maintain transgene expression (n = 1 experiment for each clone, n = 2 clones for each line). At 
DIV 12 and DIV 18, I dissociated the aggregates with 0.05% Trypsin and purified the 
Fezf2+/GFP+ cells by FACS (Figure 6.11.A.). qPCR analysis on extracted RNA of purified 
Fezf2+/GFP+ cells that were induced at DIV 9 and isolated at DIV 11 showed that Fezf2 induced 
cells have significant induction of Fezf2 (fold change ~ 177), as compared to control GFP 
induced cells (Figure 6.11.B). Similar analysis for CPN specific genes like Satb2 and Dkk3 
showed that Fezf2 induced cells significantly downregulate the mRNA expression of these genes 
(Satb2: fold change ~ -2.7; Dkk3: fold change ~ 6.0), as compared to control GFP induced cells  
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Figure 6.11. FACS-purified Fezf2 induced cells repress certain CPN specific genes while 
inducing CfuPN specific markers.  
(A) Schematic illustrating the purification of Fezf2+/GFP+ cells from overexpressor mESC lines 
by FACS for expression profiling by deep sequencing analysis.  
(B – F) qPCR analysis on extracted RNA of purified Fezf2+/GFP+ cells that were induced at DIV 
9 and isolated at DIV 11 (48 hours of transgene induction) showed that Fezf2 induced cells has 
significant upregulation of Fezf2 (fold change ~ 177), as compared to control GFP induced cells 
(B). Similar analysis for CPN specific genes like Satb2 and Dkk3 showed that Fezf2 induced 
cells significantly downregulate the mRNA expression of these genes (Satb2: fold change ~ -2.7; 
Dkk3: fold change ~ 6.0), as compared to that of control GFP cells (C – D). In contrast, qPCR 
analysis for CfuPN specific genes like Mu-crystallin and Pcp4 showed that Fezf2 induced cells 
significantly upregulate the mRNA expression of these genes (Mu-crystallin: fold change ~ 5.9; 
Dkk3: fold change ~ 5.8), as compared to control GFP induced cells (E – F). 
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(Figures 6.11.C. and 6.11.D.). In agreement with results shown in sections 6.3.5.A. and 6.3.5.B., 
these data show that Fezf2 overexpression can repress certain CPN specific genes in 
mESC/miPSC-derived neurons. To understand the full extent of Fezf2 repression of CPN 
specific genes, I have since purified DIV 12 and DIV 18 Fezf2+/GFP+ cells (n = 2 clones per 
line). Dr. Chiara Gerhardinger and Dr. Chen have prepared the cDNA library from RNA 
extracted from purified cells. The samples have been sent for Illumina HiSeq-based deep 
sequencing. Deep sequencing analysis will be done in collaboration with Dr. Loyal Goff, a post-
doctoral fellow in the laboratory of Professor John Rinn (Department of Stem Cell and 
Regenerative Biology, Harvard University). The molecular profiles of these Fezf2+/GFP+ cells 
will be compared to that of E15.5 and E16.5 cortical PN subtypes that have been purified and 
profiled by Dr. Molyneaux (unpublished data).  
 
 6.3.6. Fezf2 induced cells upregulate some CfuPN specific genes. 
  6.3.6.A. Lentiviral transduction. 
 I hypothesize that Fezf2 overexpression in DTP and/or CLN derived from mESC or 
miPSC can selectively direct their differentiation into CfuPN, including SCPN/CSMN in vitro. 
To test this hypothesis, I first differentiated A5 mESC by culturing them in suspension to form 
3D aggregates for 10 days and chemically dissociated these aggregates before replating them as a 
monolayer on fibronectin/laminin/poly-D-lysine coated coverslips for lentiviral transduction on 
DIV 11, as shown in Figure 6.10.A. (n = 3). Doxycycline was added from DIV 12 to DIV 20 for 
a period of 8 days to maintain transgene expression. I used lentiviruses expressing LVFezf2 or 
LVGFP (Figure 6.10.A.), and collected the cells for both ICC as well as qPCR analysis at DIV 20. 
Although both Fezf2 and GFP induced cells express TLE4, a CThPN specific marker (38),  I 
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found that Fezf2 induced cells repress the expression of CTIP2, a marker that is expressed at 
high levels in SCPN and low levels in CThPN (27), while control GFP induced cells do not (data 
not shown). The repression of CTIP2 is supported by previous studies done in our laboratory 
where CTIP2 is induced at low proportions in Fezf2 reprogammed neurons, as compared to other 
markers like TLE4 and Mu-crystallin (24). Remarkably, qPCR analysis for Mu-crystallin, a 
marker that is expressed at high levels in SCPN and at lower levels in CThPN (27), and Pcp4, a 
marker that is expressed at high levels in SCPN (27), showed that Fezf2 overexpression in 
lentivirally transduced mESC-derived neurons upregulates the mRNA expression of these genes 
(Mu-crystallin: fold change ~ 12.8; Pcp4: fold change ~ 2.2), as compared to mock untransduced 
as well as control GFP induced cells (Figures 6.12.A. and 6.12.B.). Hence, these data show that 
Fezf2 expressing cells can express or upregulate certain CfuPN specific markers with the 
exception of CTIP2. Comprehensive expression profiling of Fezf2 induced cells will provide 
insights on the full extent of Fezf2 mediated induction of CfuPN selective genes.  
  6.3.6.B. Overexpressor mESC lines. 
 To ascertain the results shown in section 6.3.6.A., I differentiated the GFP, Fezf2IRESGFP 
and Fezf2IREStdTomato lines by culturing them in suspension to form 3D aggregates for 10 days 
before adding doxycycline from DIV 10 to DIV 18 for a period of 8 days to maintain transgene 
expression, similar to what was performed with lentiviral transduction (Figure 6.10.H.). ISH for 
CfuPN specific markers Mu-crystallin and Pcp4 at DIV 18 showed that Fezf2 induced cells 
upregulate mRNA expression of Mu-crystallin, while control GFP induced cells do not (Figure 
6.12.C. to 6.12.D., data not shown for Fezf2IREStdTomato line). In contrast, I did not detect any 
observable difference between Pcp4 mRNA expression between Fezf2 and GFP induced cells 
(data not shown). It is likely that ISH analysis is not sensitive enough to detect a two-or three-  
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Figure 6.12. Fezf2 induced cells upregulate some CfuPN specific genes. 
(A – B) qPCR analysis showed that Fezf2 induced cells upregulate mRNA expression of CfuPN 
specific genes like Mu-crystallin and Pcp4 while control GFP induced cells and mock 
untransduced cells do not. 
(C – D) Similar to results obtained in (A – B), ISH for Mu-crystallin on DIV 18 aggregates 
derived from overexpressor mESC lines (GFP and Fezf2IRESGFP) showed that Fezf2 induced cells 
upregulate Mu-crystallin mRNA expression (arrows), as compared to control GFP induced cells. 
Scale bars: 100 μm (C – D).  
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fold difference in gene expression; therefore, a comprehensive expression profile by deep 
sequencing and subsequent comparative analysis will enable us to better determine the full extent 
of this upregulation mediated by Fezf2.  
  6.3.6.C. Expression profiling of FACS-purified Fezf2 induced cells. 
 To understand the full extent of Fezf2 mediated repression of CPN specific genes, I 
differentiated the GFP and Fezf2IRESGFP lines by culturing them in suspension to form 3D 
aggregates for 10 days before adding doxycycline from DIV 10 to DIV 18 for a period of 8 days 
to maintain transgene expression (n = 1 experiment for each clone, n = 2 clones for each line). At 
DIV 12 and DIV 18, I dissociated the aggregates with 0.05% Trypsin and purified the 
Fezf2+/GFP+ cells by FACS (Figure 6.11.A.). qPCR analysis on extracted RNA of purified 
Fezf2+/GFP+ cells that were induced at DIV 9 and isolated at DIV 11 showed that Fezf2 induced 
cells have significant induction of Fezf2 (fold change ~ 177), as compared to control GFP 
induced cells (Figure 6.11.B). qPCR analysis for CfuPN specific genes like Mu-crystallin and 
Pcp4 showed that Fezf2 induced cells significantly upregulate the mRNA expression of these 
genes (Mu-crystallin: fold change ~ 5.9; Pcp4: fold change ~ 5.8), as compared to control GFP 
induced cells (Figures 6.11.E. and 6.11.F.). Therefore, these data showed that purified Fezf2 
induced cells can significantly upregulate CfuPN/SCPN-specific genes. In agreement with 
results shown in sections 6.3.6.A. and 6.3.6.B., these data show that Fezf2 overexpression can 
induce certain CfuPN/SCPN-specific genes in mESC-derived neurons. To understand the full 
extent of Fezf2 upregulation of CfuPN specific genes, I have since purified DIV 12 and DIV 18 
Fezf2+/GFP+ cells (n = 2 clones per line). Dr. Chiara Gerhardinger and Dr. Chen have prepared 
the cDNA library from RNA extracted from purified cells. The samples have been sent for 
Illumina HiSeq-based deep sequencing. Deep sequencing analysis will be done in collaboration 
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with Dr. Loyal Goff, a post-doctoral fellow in the laboratory of Professor John Rinn (Department 
of Stem Cell and Regenerative Biology, Harvard University). The molecular profiles of these 
Fezf2+/GFP+ cells will be compared to those of E15.5 and E16.5 cortical PN subtypes that have 
been purified and profiled by Dr. Molyneaux (unpublished data).  
 
 6.3.7. Transplanted Fezf2 induced cells project preferentially through the internal 
capsule to subcortical and subcerebral targets and rarely develop callosal interhemispheric 
connections.  
 To determine if Fezf2 induced cells preferentially project to subcortical or subcerebral 
targets, I transduced dissociated A5 mESC-derived DTP/CLN with lentivirus expressing LVFezf2, 
and transplanted enzymatically-dissociated Fezf2 induced neurons into the cortex of P3 Fezf2-/- 
and their littermate wild type control pups. Transgene induction is maintained by administrating 
doxycycline to nursing dams. At 1 to 4 weeks after transplantation, I stained for GFP to detect 
Fezf2+/GFP+ cell soma in the cortex and Fezf2+/GFP+ axonal projections. Strikingly, at 4 weeks 
after transplantation, I found many Fezf2 induced cells to be alive and organized into a clump 
emanating dendrites and axonal projections, many of which were organized into axonal bundles 
of the internal capsule with long distance projections to subcortical targets like the thalamus and 
subcerebral targets like the cerebral peduncle (Figures 6.13.A. to 6.13.E., n = 4 animals). Notably, 
I detected that Fezf2 induced cells rarely project across the corpus callosum to the contralateral 
hemisphere (Figure 6.13.F., n = 4 animals). Examination of Fezf2 induced cells that were 
transplanted near or at the corpus callosum further ascertained this result (n = 3 animals). In 
these cases, I observed few callosal interhemispheric connections by Fezf2 induced cells (Figure 
6.13.F.). This is in contrast to published work where mock or control GFP+ cells develop  
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Figure 6.13. Fezf2 induced cells project preferentially through the internal capsule to 
subcortical and subcerebral targets and rarely develop callosal interhemispheric 
connections.  
(A – F) At 4 weeks after transplantation, immunostaining for GFP revealed that Fezf2 induced 
cells are organized into a clump emanating dendrites (A) and axonal projections, many of which 
are organized into axonal bundles of the internal capsule (B – C) with long distance projections 
to subcortical targets like the thalamus (E) and subcerebral targets like the cerebral peduncle 
(CP) (D). In contrast, transplanted Fezf2 induced cells rarely project via the corpus callosum 
(CC) to the contralateral hemisphere (F). Dotted lines indicate boundaries of described structure. 
Scale bars: 50 μm (C – D).  
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significantly observable axonal extensions via the corpus callosum to the contralateral 
hemisphere (14-16). Transplantations with cells that are lentivirally transduced with control 
lentivirus expressing LVGFP are ongoing and necessary to confirm the above results. In all, and in 
accordance with the results obtained by the molecular analysis shown in sections 6.3.5. and 
6.3.6., these data support that Fezf2 induced cells repress CPN specific genes while upregulating 
CfuPN selective genes. This molecular change mediated by Fezf2 is reflected in similar changes 
to the axonal connectivity where Fezf2 induced cells project preferentially through the internal 
capsule to subcortical and subcerebral targets and rarely develop callosal interhemispheric 
connections.  
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6.4. Discussion. 
 By using combinatorial marker analysis as well as expression profiling, I molecularly 
characterized DTP and CLN derived from mESC and/or miPSC from two established 
protocols—the monolayer culture (15, 16) as well as the aggregation culture (13, 14). 
Combinatorial molecular analysis is not only necessary to identify neuronal subclasses like 
CfuPN/SCPN, but also crucial to defining the extent of differentiation into specific neuronal 
subtypes and to investigating the possible acquisition of mixed identity. I found that the 
aggregation culture is more robust and reproducible in generating DTP and CLN than the 
monolayer culture. I also discovered that the aggregation method can produce significant 
numbers of TBR1+CTIP2+ cortical plate-like cells as well as CLN that can successful segregate 
layer specific marker genes like Tle4, Ctip2 and Satb2. Expression profiling of these distinct 
layer specific CLN is ongoing and is imperative to advance our current knowledge on how 
similar or different these in vitro mESC/miPSC-derived CLN are to bona fide SCPN. It also 
enables the field to develop a defined benchmark upon which future directed differentiation 
experiments can improve.  
 The central role played by transcription factor Fezf2 in early SCPN differentiation (18-
24) led me to investigate whether cell-autonomous developmental signals that direct early SCPN 
development in the embryo can be used to selectively generate these neurons from 
mESC/miPSC-derived DTP and CLN in vitro. Here, I report that Fezf2 can preferentially direct 
the differentiation of CfuPN like neurons from mESC/miPSC-derived DTP and CLN. Fezf2 does 
so by repressing certain CPN specific genes like Satb2 and PlxnD1 while upregulating some 
CfuPN specific genes such as Mu-crystallin and Pcp4. The full extent of Fezf2 mediated 
repression and induction of subtype-specific genes is currently being investigated by expression 
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profiling with deep sequencing followed by comparative analysis with molecular profiles of 
early embryonic bona fide SCPN. The change in the molecular identity of Fezf2 induced cells is 
reflected in the changes to their axonal connectivity where these cells preferentially project their 
axons through the internal capsule to subcortical and subcerebral targets like the thalamus and 
cerebral peduncle, which is in line with Fezf2’s upregulation of CfuPN specific genes. Notably, 
in agreement with Fezf2’s repression of CPN specific genes, these cells rarely connect via the 
corpus callosum to the contralateral hemisphere.  
 mESC and/or miPSC can be directed to generate diverse populations of DTP and CLN, 
yet this diversity is not as well understood as that of bona fide neurons in the cortex. 
Understanding neuronal diversity is important to comprehend the limits of directed 
differentiation and the reproducibility of producing distinct neuronal subclasses in vitro. In the 
cerebral cortex, the huge diversity of progenitors and neurons is tightly controlled and organized 
both temporally and spatially (38). Hence, it becomes possible to classify different populations 
of neurons by their birthdates, laminar positions, molecular identities as well as axonal 
connectivity (38). In contrast, this cannot be achieved in the dish where different cellular 
populations are generated concurrently and are organized randomly. Though cells differentiated 
via the aggregation culture maintain a 3D structure that resembles a “mini-cortex” in vivo, it is 
also different. Notably, the layer specific CLN generated are predominantly of a deep layer 
identity and less of an upper layer II/III CPN identity. Single cell sequencing has been proposed 
to allow gauging of neuron diversity in vivo (43, 44), but its feasibility for in vitro studies 
remains uncertain due to the inherent problems of reproducibility between experiments. I argue 
that population-based analyses may be a better method to obtain knowledge of the neuronal 
diversity generated in vitro. Neuronal subtype identity is often defined not by a single marker, 
  301
but by a combination of distinct genes. Hence, population-based analyses are limited by the 
availability of reliable antibodies, a problem that must be solved before neuronal diversity in the 
dish can be accounted for. 
 I have shown that cell-intrinsic signals like Fezf2 that are developmentally relevant can 
be manipulated to instruct mESC/miPSC-derived DTP and CLN to become more CfuPN-like in 
terms of their molecular identities as well as axonal connectivity. It remains to be tested whether 
other genes, whether in combination with Fezf2 or not, can also be utilized. Current knowledge 
of cell-autonomous signals that control definitive aspects of CfuPN/SCPN continues to restrict 
our manipulation in the dish. Therefore, discovering novel effectors of SCPN development 
continues to be an area of interest.  
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6.5. Materials and Methods. 
 6.5.1. Cell culture. 
 Several lines of miPSC (A1, A2 and A3 lines) that were derived from adult male 
fibroblasts as well as several lines of mESC (A4, A5 and A6 lines) were generated and 
generously given by Professor Konrad Hochedlinger from the Harvard Department of Stem Cell 
and Regenerative Biology, Harvard University in Boston, Massachusetts, USA. mESC and/or 
miPSC were grown on gelatin-coated dishes with irradiated mouse embryonic fibroblasts (MEF) 
in mESC medium (Knockout DMEM, 15% fetal bovine serum, 2 mM Glutamax, 100 U / mL 
Penicillin/Streptomycin, 1X MEM non essential amino acids and 1 X 103 units ESGRO / mL), 
and were passaged every 2 to 3 days with 0.25% Trypsin. Dissociated mESC and/or miPSC were 
preplated on gelatin-coated dishes to preferentially remove MEF before being subcultured to 
initiate differentiation experiments. Monolayer culture was performed according to previously 
described methods outlined in (15, 16) while aggregation culture was done in accordance with 
published protocols described in (13, 14). At desired timepoints, aggregates were washed in PBS 
and fixed in 4% PFA for 1 hour at r.t. before being rinsed in PBS overnight. The next day, 
aggregates were immersed in 30% sucrose and in OCT for 1 hour before being frozen in OCT on 
dry ice and stored at -80 oC. Aggregates were serially sectioned at 20 μm thickness on the 
cryostat before downstream analysis.  
 
 6.5.2. Fluorescent Immunohistochemistry.  
 Fluorescent immunohistochemistry procedures were carried out as described in relevant 
sections of Chapter 2. The following primary antibodies and relevant dilutions were used: mouse 
anti-OCT3/4, 1:250 (Catalog number: BDB611202, BD Transduction Laboratories, USA), 
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mouse anti-NESTIN, 1:200 (Catalog number: 556309, BD Biosciences, USA), rabbit anti-BF1, 
1:1000 (Catalog number: SCFAB, StemCulture Inc, USA), rabbit anti-PAX6, 1:1000 (Catalog 
number: PRB-278P, Covance, USA), mouse anti-TUJ1, 1:1000 (Catalog number: MMS-435P, 
Covance, USA), mouse anti-NeuN, 1:500 (Catalog number: MAB377, Millipore, USA), mouse 
anti-MAP2, 1:500 (Catalog number: M1406-.2ML, Sigma-Aldrich, USA), goat anti-SOX5, 
1:500 (Catalog number: 17329, Santa Cruz Biotechnology, USA), rat anti-CTIP2, 1:1000 
(Catalog number: AB18465, Abcam, USA), goat anti-BHLHB5 (E-17), 1:500 (Catalog number: 
sc-6045, Santa Cruz Biotechnology, USA), mouse anti-MU CRYSTALLIN, 1:100 (Catalog 
number: AB54669, Abcam, USA), rabbit anti-CUX1 (CDP M-222), 1:100 (Catalog number: 
SC13024, Santa Cruz Biotechnology, USA), mouse anti-SATB2, 1:50 (Catalog number: 
AB51502, Abcam, USA), goat anti-LHX2, 1:200 (Catalog number:SC-19344, Santa Cruz 
Biotechnology, USA), goat anti-BRN2, 1:200 (Catalog number: SC-6029, Santa Cruz 
Biotechnology, USA), rabbit anti-TBR1, 1:1000 (a gift from Professor Robert Hevner, 
University of Washington, USA), rabbit anti-ZFPM2/FOG2, 1:500 (Catalog number: SC-10755, 
Santa Cruz Biotechnology, USA).  
 
 6.5.3. In situ hybridization. 
 Nonradioactive colorimetric in situ hybridization was executed as described in relevant 
sections of Chapter 2.   
  
 6.5.4. Lentiviral transduction. 
 Lentivirus production and transduction were carried out in accordance with previously 
published methods (45).  
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 6.5.5. qPCR analysis. 
 TaqMan qPCR analysis was carried out in accordance with the manufacturer’s protocol. 
The following primer sets are used: Mouse Fezf2 (Catalog number: 4448892, ID: 
Mm01320619_m1, Invitrogen, USA), mouse Satb2 (Catalog number: 4331182, ID: 
Mm00507331_m1, Invitrogen, USA), mouse Dkk3 (Catalog number: 4331182, ID: 
Mm00443800_m1, Invitrogen, USA), mouse Mu-crystallin (Catalog number: 4331182, ID: 
Mm00516679_m1, Invitrogen, USA) and mouse Pcp4 (Catalog number: 4331182, ID: 
Mm00500973_m1, Invitrogen, USA) 
 
 6.5.6. Transplantation. 
 Transduced A5 mESC-derived DTP/CLN with lentivirus expressing LVFezf2 were 
dissociated enzymatically with Accutase for 20 to 30 minutes at 37 oC. Dissociated cells were 
resuspended in Optimem and mixed with 0.005% Fast Green FCF (Catalog number: F7258-25G, 
Sigma-Aldrich, USA) to enable easy visualization of cells upon injection. P3 pups were 
anesthetized by hypothermia with ice for at least 3 minutes before 1 μl of cell suspension at an 
approximate density of 5 to 10 X 104 cells / μl (total of 5 to 10 X 104 cells per animal) was 
injected into the cortex by a glass microcapillary over 3 minutes. Transgene was induced and 
maintained by administrating doxycycline (2 mg / mL) to nursing dams. 4 weeks after 
transplantation, the cortex was dissected, fixed and sectioned at 40 μm thickness with cold PBS 
either on a coronal or sagittal plane with a VT1000S vibrating microtome (Leica Microsystems). 
Floating sections were stored in PBS-Azide at 4 oC. 
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 6.5.7. Microscopy and image analysis. 
 Microscopy and image analysis were performed as described in relevant sections of 
Chapter 2.   
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